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ABSTRACT 
 
 
The study of applications based on the use of ultrasound in medicine and biology for 
therapeutic purposes is under strong development at international level and joins the 
notoriously well-established and widespread use of diagnostic applications [1]. In the 
past few years, High Intensity Focused Ultrasound (HIFU) has developed from a 
scientific curiosity to an accepted therapeutic modality. HIFU is a non invasive 
technique for the treatment of various types of cancer, as well as non-malignant 
pathologies, by inducing localized hyperthermia that causes necrosis of the tissue. 
Beside HIFU technology, other innovative therapeutic modalities to treat cancer are 
emerging. Among them, an extremely innovative technique is represented by oxygen 
loaded nanobubbles (OLNs): gas cavities confined by an appropriately functionalized 
coating. This is an oxygenating drugs aimed at re-oxygenation of cancerous tissue. 
Oxygen deficiency, in fact, is the main hallmark of cancerous solid tumors and a major 
factor limiting the effectiveness of radiotherapy. In this work, these two approaches to 
treat tumours are under study from a metrological point of view. In particular, a 
complete characterization of an HIFU fields regarding power, pressure and temperature 
is provided while oxygen load nanobubbles are synthesized, characterized and applied 
in in vitro and in vivo experiments.  
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CHAPTER 1 
 
 
INTRODUCTION AND BACKGROUND 
 
 
Cancer is the general name for a group of more than 100 diseases where cells in a part 
of the body begin to grow abnormally and uncontrollably. In 2007, cancer surpassed 
cardiovascular and cerebrovascular diseases as the leading cause of death. Human 
efforts have made great strides in the treatment of cancer. A century ago the chances of 
someone surviving cancer was negligible. Today two out of every three people 
diagnosed will still be alive at the end of five years. It is evident by the ever-increasing 
number of survivors that cancer diagnosis and treatment continues to improve, although 
the ‘cure’ for cancer has been far more elusive than once hoped [2]. Cancer treatments 
have improved in part due to the increase in understanding of cellular, genetic and 
molecular mechanisms, which provide targets for interventions to prevent, detect, 
eliminate and control the disease [3]. When the disease is local, surgery and radiation 
therapy are commonly used to treat cancer with a radical intent. Technological 
advancements in imaging and non-invasive treatments bring new therapeutic 
possibilities to the field [4]. Among the minimally invasive treatment methods that have 
been developed, High Intensity Focused Ultrasound (HIFU) appears the most 
investigated technology in the new panorama of solid tumor treatment based on 
ultrasound [5-6]. In HIFU medical treatments, ultrasound (US) energy emitted by 
transducer is focused into a small volume to heat and destroy the targeted tissue while 
ideally not damaging tissue outside the focal region. In spite of the multitude of medical 
applications, the effects of ultrasonic waves interactions on living tissues are not 
completely described and the definition of the “acoustic dose” is still dividing the 
scientific community. For this reason, the transducer’s characterization in terms of 
2 
 
acoustic pressure, ultrasound power measurement and monitoring of the temperature 
rise induced by ultrasound beam in tissues is essential. The characterization of the 
ultrasonic field is carried out through the use of hydrophones able to evaluate the spatial 
distribution of the acoustic pressure; however, high intensity and possible cavitation 
phenomena generated by the focused transducers restrict the use of conventional sensors 
(piezoelectric) for the characterization of these sources. Recently, new measurement 
techniques based on optical methods are emerged. One of the most promising 
measurement methods is the fiber optic hydrophone, a tool that allows obtaining an 
accurate measurement of pressure and temperature with a high spatial and temporal 
resolution; moreover, it can be exposed to high intensity and acoustic cavitation. My 
thesis work has been conducted with the aim of characterizing the HIFU sources and to 
measure the main parameters of the acoustic field (power and pressure). After that, a 
fiber optic hydrophone was used to perform measurements of pressure emitted by a 
transducer and for the determination of the temperature increase induced by ultrasound 
field. Heating effects induced by HIFU transducers were observed not only in water, but 
also in different tissue mimicking material (TMM) realized at INRiM: an agar based 
gel, a polyacrilamide gel and for the first time a reversible thermochromic silica gel. 
Subsequently to the measurements carried out in laboratory, temperature rise in the 
focus of an HIFU transducer was evaluated in situ, at Istituto Oncologico Europeo 
(IEO) of Milan.  
Among high intensity focused ultrasound, other innovative applications that use 
ultrasound to treat cancer are under development. In this regard, nanobubbles represent 
a new class of agents with both diagnostic and therapeutic applications. Indeed, 
encapsulated gas nanobubbles are well known as ultrasound contrast agents for medical 
ultrasound imaging [7]. Nonetheless, they not only help to image, but they can also be 
used as drug/gene carriers [8]. The nanobubbles as drug/gene carriers have an average 
size less than that of red blood cells, i.e. they are capable of penetrating even into the 
small blood capillaries and releasing drug and genes under the action of ultrasound 
field. The application of ultrasound and nanobubbles to targeted drug and gene delivery 
has been the subject of intense experimental research [9]. Under exposure of sufficiently 
high-amplitude ultrasound, these targeted nanobubbles would rupture, spewing drugs or 
genes, which are contained in its encapsulating layer, to targeted cells (sonoporation) or 
tissues (sonophoresis). At INRIM, we developed a particular type of nanobubbles: 
oxygen-filled nanobubbles (OLNs), which are gaseous cavity confined by a coating 
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suitably functionalized. OLNs are an innovative oxygenating drugs aimed at treating 
hypoxia-associated pathologies, in particular for re-oxygenation of cancerous tissue. It 
has been known for nearly a century that hypoxic cells are more resistant to 
radiotherapy than aerobic cells, and tumor hypoxia is a major factor leading to the 
resistance of tumors to radiation treatment as well as several cytotoxic agents [9]. In my 
thesis, various formulations of OLNs has been synthesized and characterized. OLNs can 
be prepared in liquid or gel formulations, shelled with chitosan or dextran and cored 
with perfluoropentane (PFP) or decafluoropentane (DFP). In vitro, nanobubbles are 
effective to release oxygen in absence and presence of ultrasound (sonophoresis induced 
by ultrasonic transducers through a membrane of pig skin epidermis). The application of 
ultrasound combined with oxygen-carrier nanobubbles is demonstrated as a method to 
locally increase dissolved oxygen. Moreover, they were not cytotoxic after 
internalization by human keratinocytes. In vivo, nanobubbles increased levels of 
oxygenated hemoglobin (photoacoustic studies) and transcutaneous oxygen pressure 
(TcPO2) after topical treatment of hypoxic mice both in the absence and in the presence 
of ultrasound. 
 
In this chapter, a brief introduction to the main applications of ultrasound in medicine, 
both regarding diagnostic and therapeutic applications is provided. This introduction is 
followed by a description of the physical effects caused by the interaction of ultrasound 
with the propagation medium. Finally, a complete description of the therapeutic 
applications of ultrasound is given with particular interests for high intensity focused 
ultrasound and for therapeutic applications which use micro and nanobubbles. 
 
1.1 ULTRASOUND IN MEDICINE 
 
Ultrasound, a form of mechanical energy that is transmitted through and into biological 
tissues as an acoustic pressure wave at frequencies above the limit of human hearing, is 
used widely in medicine as a therapeutic, operative, and diagnostic tool [10,11]. 
Therapeutic ultrasound use intensities as 1 to 3 W/cm2 and can cause considerable 
heating in living tissues. To take full advantage of this energy absorption, physical 
therapists often use such levels of ultrasound acutely to decrease joint stiffness, to 
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reduce pain and muscle spasms, and to improve muscle mobility [12]. The use of 
ultrasound as a surgical instrument involves even higher levels of intensity (up to 300 
W/cm2), and sharp bursts of energy are used to fragment calculi, to ablate tissues such 
as cancer tissue, cataracts, and even to remove methylmethacrylate cement during 
revision of prosthetic joints [13]. At the opposite end of the ultrasound-intensity 
spectrum, much lower magnitudes of 1 to 50 mW/cm2 are used to drive diagnostic 
devices that noninvasively image vital organs, fetal development, peripheral blood flow, 
and metabolic bone diseases such as osteoporosis and, coincidentally, to evaluate 
fracture callus during healing [14,15]. The intensity level used for imaging, which is 
five orders of magnitude below that used for surgery, is regarded as non-thermal and 
non-destructive [16]. Nevertheless, low-intensity ultrasound is still a mechanical force, 
and it therefore holds the potential to influence bone mass and morphology through 
bone tissue’s strong sensitivity to physical stimuli.  
 
1.2 INTERACTION OF ULTRASOUND WITH 
 TISSUE 
 
An ultrasound wave emitted by transducer outside the body must travel through 
multiple tissue layers, (including skin, subcutaneous fat, muscle), prior to reaching the 
desired treatment site within the target organ. At each tissue interface, part of the energy 
carried by the sound wave will be reflected, whilst the remaining energy is transmitted. 
The transmission coefficient depends primarily on the difference in acoustic impedance, 
Z, defined as the product of density and speed of sound, between the two tissue layers, 
as well as on the thickness of each layer [17]. At interfaces where there is little 
difference in acoustic properties, the transmission coefficient is close to unity. With the 
exception of fat, air and bone, most tissues in the human body have acoustic properties 
similar to those of water. Aqueous media are therefore optimal for transmitting 
ultrasound energy from the transducer into the body, and reflections at tissue interfaces 
are generally weak.  
Furthermore, when ultrasound propagates through a particular tissue layer, the pressure 
fluctuations induced lead to shearing motion of tissue at a microscopic level, which 
results in frictional heating. Part of the mechanical energy carried (in/out) by the 
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incident wave is thus converted into heat by this viscous absorption, which constitutes 
the primary mechanism for ultrasound-induced hyperthermia. In an in homogenous 
medium, small regions with different acoustic properties from their surroundings will 
scatter the incident wave in all directions, causing a loss of acoustic intensity in the 
direction of sound propagation. The loss in incident acoustic energy in a medium is 
characterised by its attenuation coefficient, µ, given by the sum of the absorption 
coefficient µa and the scattering coefficient µs.  
The ultrasound intensity, I, following propagation through a distance x in a medium of 
attenuation coefficient µ is given by: 
 
                                                     (1) 
 
where I0 is the incident ultrasound intensity at the origin (x=0). 
For most tissues, the attenuation coefficient is related to the ultrasound frequency via a 
power law of the form 
   
                                        (2) 
 
where a and b are tissue-specific constants [17]. It is precisely this dependency of 
attenuation on frequency that renders ultrasound particularly well suited to non-invasive 
therapy, but which causes some significant challenges in optimizing HIFU induced 
hyperthermia. Unlike other hyperthermia modalities, such as radiofrequency RF or 
microwaves, the attenuation ultrasound field through water-like media at ultrasound 
frequencies is sufficiently low that adequate amounts of energy can be delivered to the 
depths through tissue required during clinical treatments. Increasing the ultrasound 
excitation, frequency results in a power-law increase of both the absorption and 
attenuation coefficient. The former implies that higher heat deposition is achieved, 
while both result in a decreased penetration depth. Therefore, the optimal choice of 
therapeutic ultrasound frequency is application-specific, and represents a compromise 
between treatment depth and the desired rate of heating.  
 
 
 
baf=α
x
oeII
α−=
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1.5.3 MECHANISM OF EFFECTS ON TISSUE 
 
Ultrasound is a pressure wave meaning that it has regions of high pressure 
(compression) and low pressure (rarefaction) (Figure 1.1). As acoustic waves propagate 
through a medium the particles in the medium are subjected to the compression and 
rarefaction regions of the wave which result in changes to the particle displacement, 
velocity, density, pressure and temperature. The interactions of ultrasound for which 
bioeffects are produced can be grouped into two categories: thermal and mechanical 
effects. Broadly, mechanical effects can best be predicted from knowledge of individual 
pulses, whilst thermal effects can best be predicted from knowledge of energy flow over 
an extended time period. 
 
 
Figure 1.1: ultrasound, propagating through tissue,causes alternating regions of 
increased and reduced pressure related to compression and rarefaction. 
 
1.5.4 THERMAL EFFECTS 
 
Therapeutic applications of ultrasound depend on the direct interaction of the ultrasound 
field with the tissue Thermal mechanism can be used to create either a low level thermal 
rise, in general up to around 45 ° C (local hyperthermia) or, a short, highly localized 
high temperature rise that cooks the tissue up to 60-65 °C (thermal ablation). 
Ultrasound-induced temperature rise is dependent on several factors, including tissue 
properties (e.g., absorption coefficient, density, perfusion rate, etc.), ultrasound 
exposure parameters (e.g., frequency, pressure amplitude, pulse duration, pulse 
repetition frequency (PRF), etc.). The generation of heat in tissues can typically be 
controlled through proper exposure planning [18], the acoustic energy removed from 
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the wave by absorption is deposited in the medium as heat at a rate qv per unit of 
volume 
 
                                                                                                                                      (3) 
 
where I, is the intensity of the wave at the focus in W/cm2, and α is amplitude 
absorption coefficient in dB cm-1MHz-1. Due to this heat deposition the temperature T at 
a point in the field will rise at a rate given by 
                                                                                                              
                                                    (4) 
 
Where Cp is specific heat capacity in J/Kg °K of the medium at a constant pressure in 
Pa. 
Once the temperature of the medium rises above the ambient value, convection, 
conduction and radiation will result in heat being transferred from warmer to cooler 
regions [18]. In addition, an extra process of perfusion occurs in tissue. Perfusion is 
described as the process by which heat is removed from warmer regions by blood 
flowing through capillaries and blood vessels and redistributed to cooler regions. The 
temperature elevation in a region subjected to an acoustic disturbance is a direct result 
of acoustic power absorption in the region of interest. For soft tissues these processes 
can be described by using the Pennes bio-heat transfer equation: 
 
                            νρ qTTCwTKC bbttt +−−∆=∂
∂
∞ )(t
T 2                        (5) 
 
where ρ, is the density, Kt  is the specific heat, and Ct, Cb are the thermal conductivity 
with the subscripts t and b referring to tissue and blood, respectively, T is the 
temperature of the tissue,𝑡∞ is the arterial blood temperature, and t is the time. Here the 
first term on the right-hand side accounts for heat diffusion while the second term 
accounts for blood perfusion losses with wb being the perfusion rate. The term qv is the 
rate of acoustic power deposition per unit volume given by Equation. (1).  
Another important parameter related to thermal effects is thermal lesion. The concept of 
thermal lesion is usually used to determine the extent of the lesioned tissue [19]. The 
thermal dose can be defined as the time (t) required to produce an iso-effect at 
pCρ
I2α
dt
dT a=
I2αq aν =
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temperature T to the time (t 43) which would be required to produce the same effect at 
43 ⁰C. Tissue exposed for more than the equivalent of one hour at 43 ⁰C is considered 
"lesioned" (Figure 1.2). Depending on the cell type, this is roughly equivalent to 3 logs 
of cell kill in a typical cell survival experiment and has been shown to induce tissue 
necrosis in-vivo. The boundaries of the thermal isodose curves delineate the lesion 
shape and size. A threshold for the denaturing of tissue protein (thermal coagulation 
necrosis), is calculated according to the thermal dose (TD) formulation. 
 
                                    ')(43 )(43 dtRtTD
t
U
tt∫ −=                                       (6) 
 
where the empirical constant R = 0.5 t≥ 43 °C and R = 0.25 t < 43°C. The thermal dose 
required to create a thermal lesion is equivalent to the thermal dose of a 240- min 
exposure at 43°C [20]. 
The thermal dose concept has been proposed to quantify the relationship between 
treatment efficacy and the temperature of the target as a function of time. Sapareto and 
Dewey (1984) [19] proposed the following relationship between the tissue thermal dose 
TD43(t) (also known as cumulative equivalent minutes (CEM) at 43 ⁰C) as a function of 
treatment temperatures, T(t), and time t. 
This definition originated from the hyperthermia protocol, when the tissue was heated to 
a temperature of 43–45°C during a long exposure of several hours [20] or the 
temperature rise is above a threshold of 56°C and the exposure time is at least 1s. In 
these cases, irreversible cell death will be induced through coagulation necrosis [21]. 
The coagulation necrosis is characterized by cell death mainly due to protein 
denaturation, which is caused by an infarct such as excessive heat [22].  
However, it has been shown that this model gives good estimations of the thermal lesion 
for the higher temperatures caused by HIFU, which include 10 s at 53 °C, 1 s at 57 °C, 
and 0.1 s at 60 °C. In HIFU treatments, the temperature commonly exceeds 70 °C in 
about 1–4 s. Thus, tissue necrosis occurs almost immediately [20]. 
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Figure 1.2: Relation between exposure time and temperature on tissues 
 
1.2.3  MECHANICAL  EFFECTS 
 
Non-thermal effects encompass a range of processes such as radiation force and 
acoustic streaming. Most relevant to this thesis and to mechanical bioeffects of 
ultrasound in general, is cavitation which is described below. 
 
Acoustic Cavitation: Acoustic cavitation term is used to refer to a range of complex 
phenomena that involve the creation, oscillation, growth and collapse of bubbles within 
a medium [18]. The cavitation behavior can be broadly classified into one of two 
categories: stable cavitation and inertial cavitation (Figure 1.3). The behavior of the 
bubble will depend on the frequency, pressure amplitude, bubble radius and 
environment surrounding the bubble. When an existing bubble is exposed to an 
ultrasonic field the acoustic pressure acts as a driving force that drives the bubble and 
results in the bubble radius varying. The bubble behaves as an oscillator with stiffness 
and inertia. The gas within the bubble provides the stiffness. As the gas is compressed it 
provides a force that resists the compression. The liquid surround the bubble provides 
the inertia and moves with the bubble wall. As a result the bubble has a natural resonant 
frequency fr. For the case of a spherical air bubble of radius R0 in water (assumed to be 
incompressible and inviscid) a simple calculation based on linear oscillations gives: 
 
mHzfrR ⋅≈ 30                                                        (7) 
)10( 0 µ≥R  
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When the bubble is exposed to an ultrasound field at its resonance frequency, it exhibits 
its maximum response. The resonance frequency is dependent on the initial size of the 
bubble. The maximum expansion of a non-inertial cavity typically does not exceed 
twice the equilibrium radius. The response of the bubble can be nonlinear and is 
dependent on variables including the acoustic pressure amplitude, exposure frequency, 
and size of the bubble. The damping of the bubble oscillations occurs through viscous 
dissipation, sound radiation, and thermal conduction mechanisms [23-25]. 
 
 
Fig. 1.3. Stable and inertial cavitation. (A) Schematic representation of an acoustic 
pressure wave. (B) and (C) show, respectively, stable and inertial cavitation of 
microbubbles.  
 
Stable cavitation: At very low acoustic pressures, microbubbles oscillate in a 
symmetrical, linear way. This means that their expansion and compression is inversely 
proportional to the local ultrasound pressure [26]. At higher ultrasound intensities, 
microbubbles behave non-linearly with a lengthening of the expansion phase of the 
microbubbles, as the microbubbles are more resistant to compression than to expansion 
[27-28]. This phenomenon is also known as stable cavitation or non-inertial cavitation. 
During stable cavitation of the microbubble (Figure 1.4 A,B), there is gas influx (during 
expansion) and gas efflux (during compression). In the case of symmetrical oscillations, 
the netto gas influx over one expansion/compression cycle is zero. However, when the 
expansion phase extends, there is a net gas influx into the microbubble. For this reason, 
the microbubble grows until it reaches its resonant size, whereupon it demonstrates 
stable, low amplitude oscillation (Figure 1.3). Such stable oscillations create a liquid 
flow around the microbubbles, the so-called microstreams [29] (Figure 1.4C). When 
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these oscillating microbubbles are in close vicinity of cells, these cells will experience 
shear stress. The shear stress related to micro streaming is relatively high compared to 
the shear stress associated with blood flow (0.1–4 Pa) [30]. US induced elevated shear 
stress levels that may induce a large spectrum of biological effects which are explained 
in figure 1.4. Figure 1.4 (A), (B) and (C) refer to biophysical effects caused by stable 
cavitation, while (D) and (E) depict effects of inertial cavitation. Figure 1.4A: Pushing 
(left) and pulling (right) effects during the expansion and compression phase, 
respectively, of a stably oscillating microbubble, thereby disturbing the membrane 
integrity. Figure 1.4B: Acoustic radiation force causes microbubble displacement and 
compresses the microbubble against the cell membrane resulting in membrane 
disruption. The microbubble may even be pushed through the lipid bilayer to enter the 
cell. Figure 1.4C: stable oscillation of a microbubble creates microstreamings in the 
surrounding fluid, which exert mechanical stress on the cell membrane, causing pore 
formation.  
 
Figure 1.4. Biophysical effects of stably and inertial cavitating microbubbles. (A), (B) 
and (C) refer to biophysical effects caused by stable cavitation, while (D) and (E) 
depict effects of inertial cavitation.  
 
Inertial cavitation: At sufficiently high exposure amplitudes, a bubble may expand to a 
maximum radius greater than twice its initial radius and then collapse rapidly to a small 
fraction of its initial radius [18] (Figure 1.3). This type of cavitation is called inertial 
cavitation. The relatively slow expansion is followed by a rapid collapse phase driven 
by the inertia of the spherically converging liquid. Various parameters determine the 
violence of the collapse of the inertial cavity.  
In a given liquid, for a particular spherical bubble nucleus, the occurrence of inertial 
cavitation depends on the acoustic pressure amplitude, the acoustic frequency and 
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bubble radius. The surface tension forces in smaller bubbles prevent the initial growth 
so the bubbles do not grow enough. On the other hand, large nuclei can grow initially, 
however they do not collapse sufficiently to generate high temperatures. For a given 
bubble radius and frequency, there is a threshold pressure required for inertial 
cavitation. The response of an inertial cavitation to an acoustic field is highly nonlinear, 
such that a small increase in acoustic pressure amplitude can change the bubble 
response from a non-inertial cavitation to an inertial cavitation. 
 
Figure 1.5 illustrates the transition threshold between inertial and non-inertial 
cavitation, based on the calculations of Apfel and Holland (1991) [31]. If within one 
period of the applied waveform, the bubble collapsed and generated a temperature in the 
gas in excess of 5000 K, they assumed inertial cavitation. The calculations show that for 
any frequency there is a minimum peak rarefactional pressure popt that is required to 
generate inertial cavitation. This will only occur for bubbles with an initial radius Ropt. 
For example from figure 1.4, for a 10MHz wave the minimum rarefactional pressure to 
induce inertial cavitation is about 0.84 MPa. 
 
 
Figure. 1.5. Plot of the cavitation threshold in water as a function of initial nucleus 
radius for three frequencies of insonication: 1, 5, and 10 MHz. Nuclei consist of air 
bubbles initially at 300 K that undergo growth in a single cycle of ultrasound and 
collapse adiabatically to a temperature of 5000 K. Surface tension, viscosity, and 
inertia of the host fluid are included in this analytical model by Holland and Apfel 
[37-31]. For 5 MHz, the optimal nucleus radius is 0.3 Am with a corresponding 
cavitation threshold, Popt, of 0.58-MPa peak negative pressure. Note that at a pressure 
PV greater than Popt, a broader size range of nuclei cavitate.  
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The acoustic pressure at which the transition occurs is often called the threshold for 
inertial cavitation. Extremely high temperatures and pressures can be achieved at the 
minimum radius of the inertial bubble collapse [32]. Some models predict maximum 
collapse temperatures exceeding thousands of degrees Kelvin [25, 32]. These high 
temperatures and pressures are localized near the collapsing bubble. They are 
temporally limited to the duration of the collapse. Generally for a given pressure 
amplitude and bubble radius, the maximum collapse pressure in the bubble decreases as 
the frequency of exposure increases [25]. The motion of the bubble wall may become 
supersonic during inertial collapse. During the collapse of the microbubbles, shock 
waves (Figure 1.4D) can be generated in the fluid and jet formation (Figure 1.4E) can 
occur [33]. When a collapsing microbubble is located close to a surface, like a cell 
membrane, an asymmetrical collapse takes place, and results in the formation of a liquid 
jet towards the nearby surface. This microjet punctures the cell membrane, thereby 
creating a pore. Micro jets play a role in the fragmentation of kidney stones with 
lithotripter shock waves [34]. It has been shown that shock waves and microjets create 
very high forces that can generate high stresses on cell membranes, perforate cell 
membranes and even permeabilize blood vessels (Figure 1.4D) [35-37]. It has been 
suggested that liquid microjets might act as micro syringes, delivering drugs to cells 
[31,32]. 
 
1.3. THERAPEUTIC ULTRASOUND 
 
Therapeutic ultrasound is generally described as the use of ultrasound for applications 
other than imaging or diagnostics [38]. For diagnostic applications of ultrasound, 
exposures are chosen primarily for their ability to give images with good spatial and 
temporal resolution, using sufficient pressure amplitude to give an acceptable signal to 
noise ratio. The aim is to obtain the required diagnostic information without causing 
biologically significant cellular effects, the energy deposition in tissues is meant to be 
minimal. In contrast, therapeutic applications require that the exposed target tissue 
undergoes reversible or irreversible change, depending on the goal of the treatment. 
Therapeutic ultrasound energy is usually delivered as continuous wave or tone burst 
(long pulse) exposures. Depending on the application, single element and phased array 
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sources may be used. Frequencies range from 0.8 MHz to 20MHz, with the choice of 
frequency being a compromise between the depth of the tissue to be treated, and the 
requirement for ultrasound absorption within the target to provide heating. For 
therapeutic applications, a number of methods are used to couple the sound into the 
tissue. Where the acoustic window is relatively flat, and the transducer’s emitting 
surface is plane, aqueous gel may be used between the source’s front face and the skin. 
However, for awkward tissue geometries and when, for example concave spherical 
bowl transducers are used, water may provide a better coupling medium. For the high 
power applications, it is important that the couplant is degassed to prevent the 
occurrence of cavitation. In diagnostic ultrasound, biological effects are undesirable and 
hence whereas application of therapeutic ultrasound is based on depositing ultrasound 
energy to specifically create beneficial effects. These effects can be mild and non-
destructive, like those generated for physiotherapy healing [39], or more extreme and 
destructive, such as thermal ablation of tumors [6].  The mechanisms of interaction 
between ultrasound field with cells and tissues for producing therapeutic effects are 
typically divided into thermal and non-thermal mechanisms [40]. The three most 
important ultrasound mechanisms (heat generation, acoustic cavitation, and acoustic 
radiation forces) for creating bioeffects have been briefly covered in previous sections.  
 
1.3.1.  APPLICATIONS OF THERAPEUTIC ULTRASOUND 
 
In 1927 it was recognized that ultrasound could produce lasting change in biological 
systems. This was the start of both ultrasound therapy and safety studies [41]. Tissue 
heating due to ultrasonic energy absorption has been used with therapeutic intent in 
many conditions. Recently it has been realized that good results, in terms of hypertermia 
and ablation, may also be obtained from the non-thermal effects that occur as ultrasound 
travels through tissue. Ultrasound therapies can broadly be divided into low power and 
high power therapies where low power applications include sonophoresis, sonoporation, 
gene therapy, sonothrombolysis, bone healing and wound healing. High power therapies 
encompasses physiotherapy, histotripsy, high intensity focused ultrasound (HIFU) and 
lithotripsy. Apart from physiotherapy uses, ultrasound therapies are currently not 
widespread. The following sections will describe the most frequently applications of 
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ultrasound for therapy with a particular interests for HIFU and for therapeutic 
applications which use micro and nanobubbles.  
 
1.4 THERAPEUTIC ULTRASOUND: HIFU  
 
High intensity focused ultrasound (HIFU) is gaining rapid clinical acceptance as a 
treatment modality enabling non-invasive tissue heating and ablation for numerous 
applications. HIFU treatments are usually carried out in a single session, often as a day 
case procedure, with the patient either fully conscious, lightly sedated or under light 
general anaesthesia. A major advantage of HIFU over other thermal ablation techniques 
is that there is no necessity for the transcutaneous insertion of probes into the target 
tissue. The high powered focused beams employed are generated from sources placed 
outside the body (for treatment of tumours of the liver, kidney, breast, uterus, pancreas) 
or in the rectum (for treatment of the prostate), and are designed to enable rapid heating 
of a target tissue volume, while leaving tissue in the ultrasound propagation path 
relatively unaffected. Given the wide-ranging applicability of HIFU, numerous extra-
corporeal, transrectal and interstitial devices have been designed to optimise 
application-specific treatment delivery. Compared to diagnostic ultrasound, HIFU has 
significantly higher time-averaged intensities in the focal region of the ultrasound 
transducer [42]. Typical diagnostic ultrasound transducers deliver ultrasound with time-
averaged intensities of approximately 0.1–100 mW/cm2 and compression and 
rarefaction pressures of 0.001–0.003 MPa. HIFU transducers deliver ultrasound with 
intensities in the range of 100–10,000 W/cm2 to the focal region, with peak compression 
pressures of up to 30 MPa and peak rarefaction pressures up to 10 MPa [42].  
 
1.4.1 HISTORY OF HIFU 
 
The first suggestion that high intensity ultrasound beams might be used for therapeutic 
purposes came in 1942 [43], but the first report of application of HIFU to humans was 
not until 1960 [44, 45]. This technique did not gain significant clinical acceptance until 
the 1990s, despite successful ophthalmological treatments before this date. Early 
equipment was heavy and unwieldy, and the original applications proposed were in the 
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brain, which involved surgical intervention to remove bone. The development of HIFU 
coincided with the introduction of the drug L-dopa. From a patient’s perspective, L-
dopa proved to be a more acceptable treatment for Parkinson’s disease. The lack of 
imaging sophistication also restricted the growth of HIFU applications at that time. In 
order to capitalise on the precision of the cell killing proffered by HIFU, it is necessary 
to be able to achieve accurate placement of ‘‘lesions’’ within the target volume. Precise 
targeting and good treatment follow-up techniques (with anatomical and functional 
imaging), are only now available with ultrasound or magnetic resonance imaging (MRI) 
techniques, thus paving the way to realizing the full potential of HIFU treatments. Early 
attempts to place ultrasound lesions in the brain through the intact skull bone were 
unsuccessful [43, 46]. Small lesions were found in the brain, but there was profound 
damage to the scalp. Mode conversion and the high acoustic absorption of bone lead to 
a high degree of attenuation in the skull bone. Only once a window had been made in 
the skull, could discrete lesions be placed deep within the brain [47-48]. White matter 
appears to be more susceptible to damage than grey matter [49,50]. Fifty patients with 
Parkinson’s disease were amongst the first people to be treated with HIFU [45]. 
Although it was claimed that the symptoms of Parkinsonism were eliminated, this 
treatment does not appear to have been taken further, probably because of the 
concurrent development of the drug L-dopa mentioned above. The requirement to 
remove a section of skull bone, combined with targeting complexity limited the 
progress of this neurosurgical research. However, phase correction (time reversal) 
techniques may allow the focus to be reconstructed following transmission through 
bone [51, 52]. The feasibility of this has been demonstrated using large area 
hemispherical phased array transducers, which allows reduction of the energy density at 
the skull surface. The first proposal to use focused ultrasound in ophthalmology came 
from Lavine et al. [53] who demonstrated cataract formation when the lens of the eye 
was targeted. Further experimental studies demonstrated that HIFU technique was able 
to decrease intra-ocular pressure [54], and produce lesions in the vitreous, lens, retina 
and choroid [55–56]. High intensity focused ultrasound has been used successfully in 
the treatment of glaucoma. This was first established in experimental models using 
intensities up to 2000Wcm2 at 4.6 MHz. Histology showed focal thinning of the sclera, 
and focal disruption of the ciliary body with the conjunctiva remaining intact. The first 
human treatments, undertaken in 1982, gave encouraging results. Of the 880 patients 
treated, 79.3% had a sustained lowered intra-ocular pressure after 1 year [57]. High 
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intensity focused ultrasound has also been used with success in experiments to seal 
traumatic capsular tears [56], and in laboratory treatment of intra-ocular tumours [58, 
59], retinal detachment and vitreous haemorrhage [55]. Although HIFU has shown 
considerable promise in these ophthalmological applications, laser surgery has enjoyed 
wider success and application, presumably because of its apparently simpler technology 
and application. 
 
 1.4.2   PHYSICS OF HIFU 
 
The aim of most ablative therapies, whether for the treatment of cancer or of benign 
conditions, is the selective destruction of a targeted tissue volume, leaving surrounding 
tissues intact [60-61] (Figure 1.6). The aim of a high intensity focused ultrasound 
(HIFU) treatment is to raise the temperature of a selected, isolated tissue volume above 
55°C. It is known that 55°C held for this time will lead to coagulative necrosis and 
immediate cell death [19, 62]. Instantaneous coagulative necrosis occurs and hence cell 
death with a margin of 6–10 cells between live and dead cells at the edge of the focal 
zone [60-63]. In theory, this is possible with a focused ultrasound beam, since the short 
wavelengths of ultrasound at MHz frequencies in soft tissue allows it to be focused into 
small, clinically relevant, volumes. Ultrasonic energy absorption within the focal 
volume induces high temperatures locally at the focus, with temperatures outside this 
region being kept at levels that are not cytotoxic.  
 
Figure 1.6: Diagrammatic illustration of the principle of HIFU. High-intensity 
ultrasound waves are generated by a transducer outside the body and focused onto a 
small region deep within tissue. HIFU-induced heating causes cell death by thermal 
necrosis within the focal volume, but leaves tissue elsewhere in the propagation path 
unaffected.  
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The volume of destroyed cells is call ‘‘lesion’’. An important feature of HIFU lesions is 
that the damage is spatially confined with no surrounding cellular damage. They are 
often referred to as ‘‘trackless’’. In this sense they are different from those produced by 
other ablative therapies which necessitate the introduction of an applicator into the 
volume [64-65]. A key objective of a HIFU treatment is to delivery the energy required 
to raise the tissue temperature to a cytotoxic level sufficiently fast that the tissue 
vasculature does not have a significant effect on the extent of cell killing, that is, that 
cooling due to blood perfusion or heat diffusion is not important. It has been shown that 
HIFU can lead to vessel wall disruption and also to vascular occlusion [66–67].  
A transducer with a piezoelectric crystal can be used as a source of ultrasound that 
vibrates at a fixed frequency when electrical energy is applied. To provide a focus with 
a given depth and shape, single element transducers are designed using a flat 
piezoelectric element with a lens, a spherically curved element with concavity in the 
propagation direction, or a combination of transducer curvature and a lens. Such 
applicators may provide a fixed focus; however, they are limited in high- power 
applications because of mechanical self-heating of the element.  
In Figure 1.7 is shown simple focusing achieved by a spherical-shaped concave 
radiator. This type of focusing transducer is usually a piezoelectric whose front surface 
is of spherical shape of a given radius of curvature (ROC), rc. The aperture diameter of 
the transducer is D. The geometrical center of the sphere is at C. The dimensions of the 
curved front surface have the following relationship; 
 
 
D/2 = (ROC) sin α 
h = ROC (1 – cos α), 
Where h is the depth of the concave 
surface 
f number = ROC / D 
 
Figure 1.7: Illustration of a focusing acoustic radiator. 
The focus of a single element transducer lies on its central axis near its center of 
curvature. It has been demonstrated by O'Neil (1949) [68] that the greatest intensity 
takes place near but not exactly at C (geometrical focus). The magnitude of focusing, 
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expressed by the ratio of the intensity at C to the average intensity at the radiating 
surface, is equal to (2πh /λ). In other words, decreasing  f number increases the 
sharpness of the focusing [69]. Furthermore, it also decreases the distance between the 
physical focus and the geometrical focus C. The plane that contains C and is normal to 
the axis of the sound field is called the focal plane. The focal length is defined as 
distance F [69]. A cigar-shaped focal volume (an ellipsoid of revolution around the 
central axis) is formed with HIFU. The size depends on the frequency used, with its 
width decreasing with increasing frequency for a given absorbed energy [70]. At 1.7 
MHz, using a 10 cm diameter transducer with a focal length of 14 cm produces focal 
lesion approximately 1.5 mm in diameter and 15 mm long. The precise shape of the 
lesion depends on the tissue acoustic properties, ultrasound intensity and exposure time, 
and the transducer geometry. The most useful frequencies for HIFU treatments in 
human diseases are from 0.8 MHz to 10 MHz, the ultrasound waves have wavelengths 
from 0.1 to 3 mm, which are much shorter than the dimensions of both tumors and 
applicators. Thus, dispersion of the beam is minimal and well-collimated beams are 
directed into tumor size volumes. The optimum frequency for a treatment at any depth 
is a compromise between the need to keep the attenuation in the tissue path overlying 
the target low in order that sufficient energy reaches this volume, and the necessity of 
having adequate absorption at the focus to ensure the required temperature rise [70]. 
Several factors determine whether an effective lesion will be formed. These include the 
thermal properties of the targeted tissue, the acoustic properties of the tissue that the 
beam will pass through, and the presence of blood vessels that, if close to the focus, can 
act as heat sinks reducing the rate of temperature rise. 
Technological changes are under way to make the HIFU devices more users friendly 
and effective. Nowadays there are two methods for the application of ultrasound energy, 
namely, transrectal and extracorporeal devices.  
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1.4.3 HIFU DAMAGE ON TISSUES 
 
Ultrasound beam propagating through tissue loses energy due to ultrasonic attenuation 
caused by both scattering and absorption of the tissue [22]. The absorption of ultrasonic 
energy causes a local temperature rise in tissue if the rate of heating exceeds the rate of 
cooling. The energy levels carried in the HIFU beam are several orders of magnitude 
greater than those of a clinical diagnostic ultrasound beam, within a wide range of 
frequencies from a few hundred kHz to a few tens of MHz [71]. When the intensity of 
the ultrasound beam is increased and focused onto a tight spot the temperature at the 
focus rises rapidly above a certain limit, it leads to effective cell killing even for very 
short exposures [72-21]. Very little damage to overlying or surrounding tissue occurs 
during HIFU lesioning. There are two main mechanisms that are directly involved in the 
tissue damage induced by HIFU exposure. The first is a thermal effect from the 
conversion of mechanical energy into heat in the tissue, and the second is acoustic 
cavitation. 
The predominant mode of ablation with HIFU is heating. Absorption of ultrasound 
results in the conversion of ultrasonic energy to heat. Acoustic cavitation is the second 
mechanism of HIFU induced tissue damage. Cavitation is relatively unpredictable. It 
depends on many independent variables such as frequency, intensity pulse shape and 
length and the degree of presence of particles of gases in the medium [73]. During 
HIFU exposure, it would be difficult to identify distinctly thermal effect from 
mechanical effect. In practice, the two effects occur simultaneously within tissue. 
Hence, the coagulation necrosis induced by HIFU can be considered as the result of 
biological effects from a combination of mechanical stresses and thermal damage on the 
tissue [74]. However there is increasing interest in using cavitation to optimize HIFU 
treatments and this is currently under extensive investigation. Specifically, inducing 
cavitation during exposures can improve the rate of heating through enhanced 
absorption [74-77]. 
 
1.4.4 THE TREATMENT PROCESS 
 
Effective HIFU treatments depend on the successful conduct of a number of different 
stages of the procedure. For cancer, the initial diagnosis is usually made from CT or MR 
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scans. An assessment of the tumour’s visibility to diagnostic ultrasound is then required. 
This involves ascertaining that there is a suitable acoustic window through which the 
treatment can be delivered, that the target boundaries can be clearly identified, and that 
no sensitive normal tissue structures lie in the beam path. The target volume must be 
accurately identified and spatially localised. The second stage in the treatment is to 
determine the correct ultrasound exposure to achieve ablation. This is done in a number 
of ways. Where ultrasound imaging is used for guidance, the most common method is 
to use a combination of focal peak intensity and exposure time that results in a 
hyperechoic region at the target, whereas when MR is the guidance method, this 
combination is varied until the required temperature (and hence thermal dose), as seen 
using MR thermometry, is reached. During the treatment delivery phase, some indicator 
of tissue change is desirable. This enables assessment of treatment progress, and may 
also provide feedback to allow adjustment of exposure parameters in real time. For MR 
guided HIFU, the temperature rise could be determined using spinlattice relaxation time 
(T1), proton resonance frequency (PRF) or proton diffusion (D) related sequences [78]. 
For US guided treatments, the most commonly used indicator of tissue ablation is the 
appearance of a hyperechoic region on the image, but other techniques such as 
elastography and ultrasound thermometry are under investigation [78]. The final 
component of the HIFU procedure is post-treatment assessment of the extent of tissue 
ablation. Contrast enhanced MR and ultrasound imaging allow visualisation of 
vasculature. Successful HIFU ablation leads to occlusion of blood vessels in the target 
volume, and thus reduced contrast uptake following treatment [79]. More details about 
HIFU’s guidance methods are given in 1.4.6 paragraph. 
 
1.4.5 THE TREATMENT DELIVERY 
 
The guiding principle of HIFU is that an ultrasonic beam should be able to destroy a 
sharply defined region of tissue rapidly. Focusing of the ultrasound beam may be 
achieved in a number of ways. The simplest method is to use a single element spherical 
shell of piezo-electric material capable of delivering high power. Whereas quartz was 
the transducer material of choice in the early days of HIFU, recent developments have 
seen the use of piezo-ceramics such as PZT (lead zirconate titanate) and piezocomposite 
materials. The single element focused bowl transducer gives no flexibility in order to 
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define the focal length. Different focal lengths may be achieved by combining a plane 
single element transducer with lenses of different specifications. Lenses are usually 
made from materials having a speed of sound greater than that of water, and thus are of 
concave shape when a convergent beam is sought. Good impedance matching is 
required in order to minimise energy loss at the transducer–lens interface. Maximum 
transmission is obtained when the transducer and lens are separated by a quarter 
wavelength of impedance matching material. Fry [80] achieved energy localization by 
using four plane transducers each fronted by a plano-concave lens. The beams were 
arranged in such a way that their foci overlapped, and the intensity was maximised by 
optimal phasing of the individual beams. This method requires the availability of four 
separate acoustic windows. Emerging phased array technology for high power 
ultrasound applications has led to the design of transducers that allow electronic beam 
steering to facilitate more rapid treatment of clinically relevant volumes [81–82]. The 
acoustic energy may be delivered in a number of ways. A single exposure (typically 2–
10 s of duration) may be made with the transducer held stationary. This results in a 
well-demarcated ‘‘lesion’’ of dimensions determined by the focal region of the 
transducer. Where larger volumes are to be targeted, the transducer could be moved in 
discrete steps, and fired at each position, where the distance between ‘‘shots’’ will 
determine whether lesions are overlapping or separate, depending on the necessity to 
achieve confluent regions of cell killing (Figure 1.8). An alternative exposure strategy is 
to move the active therapy transducer in pre-determined trajectories (e.g. linear tracks or 
spirals) to conform with the required treatment volume. If the correct combination of 
transducer velocity and ultrasound energy is used, these result in confluent volumes of 
cell damage. 
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Figure 1.8 Diagrammatic illustration of HIFU treatment delivery for the ablation of 
large tissue volumes. Multiple lesions are created side-by-side to span the required 
treatment volume, starting on the side distal to the transducer. The lesions can be 
overlapping or separate, depending on the necessity to achieve confluent regions of 
cell killing. 
 
1.4.6   EXTRACORPOREAL DEVICES 
 
Tissue targets lying within the breast, abdomen, brain or limbs are usually treated using 
an extracorporeal HIFU source. Trans-cutaneous treatments of this nature require that 
there is a suitable acoustic window on the skin that provides a propagation path for the 
focused beam that is uninterrupted by intervening gas. In addition, it must be possible to 
couple the ultrasound energy to the skin surface using coupling gel, a water balloon or 
other suitable liquid path. During last 20 years, many prototype extracorporeal devices 
have been used in feasibility studies [83-84]. Extra-corporeal devices fall into two 
types—those for which the treatment is guided by magnetic resonance (MRgFUS) and 
those for which ultrasound imaging is used (USgFUS). There are advantages and 
disadvantages to each imaging modality for use with HIFU that are described below. 
MRgFUS can provide information on functional and physiological parameters of tissue, 
including diffusion, perfusion, flow, and temperature. This latter capability is particular 
useful in HIFU therapy because it can be used to detect tissue damage induced by 
thermal ablation. MRgFUS is the only currently available technique with proven 
capabilities to create quantitative temperature maps during the treatment. Tissue 
temperatures in the therapeutic ultrasound field are available within approximately 5s 
after treatment completion, with a resolution of approximately 1°C [85]. Follow-up 
evaluation of HIFU induced lesions can also be done by MRI. The high correlation of 
lesion formation with temperature provides a means to measure the treatment volume 
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and quantify tissue damage. At present, there are 3 temperature-sensitive parameters for 
MRgFUS. The first one is related to the molecular diffusion coefficient (diffusion 
coefficient) is used for thermometry, it often takes 2 to 3 min to obtain an image, which 
is too slow for real-time monitoring. Two other parameters are commonly used, 
including proton resonance frequency shift (PRFS) and longitudinal relaxation time 
(T1). However, it will be very difficult to monitor the temperature changes of the tissue 
when the patient movement occurs during HIFU, this may limit application of HIFU 
technology. The temporal resolution is limited in MRgFUS due to the slow image 
acquisition frame rate [86]. Hence, MRgFUS is inherently not real time, resulting in 
temporal misinterpretation of temperature profiles and lengthened treatment times. The 
use of MRgFUS provides high spatial resolution in an arbitrary plane. MRgFUS enables 
an accurate assessment of the extent of tumor infiltration and stage as well as the critical 
surrounding structures.  As a result, MRgFUS is an invaluable tool for planning the 
most precise ablation trajectory for a focused US beam. Both MRgFUS and USgFUS-
guided techniques can be used to measure the distance between the skin and the 
superficial or deep surface of the tumor, regardless of whether the involved skin and 
chest wall areas can be directly imaged. However, MRgFUS has been shown to be more 
precise and reproducible than US in determining the exact location and extent of breast 
cancer in a given patient, as well as the amount of intraductal spread. The improvement 
of 3T MRgFUS from the previous 1.5T MRgFUS further increases the ability of 
MRgFUS to define tumor borders [87]. High costs are associated to MRgFUS; it also 
requires a special environment that can hinder patient accessibility; a minimal use of 
metal parts in the HIFU assembly is necessary to prevent distorsion of the MRgFUS 
images and in addiction the MRgFUS is not appropriate for patients with magnetic 
metal implants. The resulting artifacts influence the quality of imaging, and more 
importantly, implants may endanger patients during HIFU therapy. 
 Ultrasound guided system (USgFUS) has not the possibility to create quantitative 
temperature maps during the treatment but many studies have demonstrated that US 
grey-scale change is reliable for monitoring the temperature response to HIFU treatment 
in real-time. While the temporal resolution is limited in MRgFUS, USgFUS guidance 
provides real-time imaging at a relatively low cost, although with a limited field of 
view, spatial resolution, and contrast resolution. Using real-time USgFUS monitoring, 
treatment effects can be assessed by immediate gray-scale changes. By examining this 
feedback, operators can control the thermal dose delivered. Increasing the ultrasonic 
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greyscale level in the target volume is generally considered a signal of effective 
treatment and is caused by coagulative necrosis of the target lesions, cavitation bubbles, 
and other unidentified factors. By examining the appearance of the hyper-echoic area, 
complete necrosis can be assessed and breast skin burn can also be identified. After 
ablation, it is not easy to observe remaining active lesions or the focal point [87]. 
Ultrasound provides a more rapid imaging technique, but as yet real time imaging of the 
ablated volume has proved difficult in the absence of bubbles, although rapid 
elastography methods are being investigated [88]. When gas bubbles are produced by 
acoustic cavitation or boiling, hyperechoic regions appear on the ultrasound image and 
these have been shown to be a good indicator of tissue damage [89]. Low costs are 
associated to USgFUS; moreover, US-guided HIFU does not have contraindications 
such as the artefacts influence on the quality of imaging, and, more importantly a 
special environment is not required, even ferromagnetic devices are allowed during 
HIFU therapy.  
Clinical results have been reported from prototype extracorporeal devices [83, 90] but 
results from two commercially devices are available [91-92]—these are the Exablate 
(from Insightec) (figure 1.9A) and the JC Tumour therapy device (JC-Haifu) (figure 
1.9B). Early reports from these studies have been encouraging [93-94]. Visioli et al. 
(1999) [83] published their preliminary phase I clinical trial results for the treatment of 
soft tissue tumours, including those of liver, using their own clinical prototype (1.7 
MHz, focal peak intensity in situ 1500 Wcm2). Both system have  demonstrated that 
HIFU could be used as an outpatient procedure without anaesthetic or other sedation, 
with liver motion being reduced by patient breath holding. There are a large number of 
reports of the results from clinical trials of the treatment of liver cancer, all using the 
Chongqing HAIFU device [91, 95]. Experimental studies of kidney ablation have been 
reasonably successful [96-98].  Marberger et al. (2005) [99] reviewed the use of HIFU 
for the treatment of renal tumours. They concluded that the kidney provides a more 
challenging target than other organs, but that the results from China [100] give cause for 
optimism that the problems of rib shielding and respiratory motion can be overcome. 
Illing et al. (2005) [101] have also reported encouraging results in renal tumour 
treatment.  The breast is in many ways an obvious target for HIFU as access is relatively 
simple, tissue movement is not a problem, and ultrasonic and MR imaging of the breast 
is well established. Using MR guidance, fibroadenomas and malignant breast tumours 
have been treated [92].  Cancers of the bladder, pancreas and bone have also been 
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targeted by ultrasound guided HIFU [90,96, 102]. The potential for HIFU treatment of 
uterine fibroids has been explored  both experimentally [103] and clinically [104-105].  
It’s clear advantages are its non-invasive nature, the ability to achieve high spatial 
specificity, the potential for retreatment or use of other therapeutic modalities after its 
use, and its low side effect profile. Ultrasound will not penetrate air filled viscera, and 
so cannot be used in, for example, the lung or bowel, although it may be effective on 
their surfaces. The current restrictions to treatments in the brain due to the presence of 
the skull may be overcome using time reversal techniques [106-107]. HIFU treatments 
are lengthy at present, but methods of speeding up treatments are actively being sought, 
using sophisticated ultrasound delivery modes and for example, contrast agent 
microbubbles, to increase the rate of tissue destruction [108]. Early fears that HIFU 
might stimulate metastatic spread of cancer have not proved founded [109-110]. 
 
  
Figure 1.9 Two commercially available extracorporeal devices: Exablate (from 
Insightec) (figure 1.9A) and JC Tumour therapy device (Chongqing HAIFU company) 
(figure 1.9B). 
 
1.4.7  TRANSRECTAL DEVICES 
 
The transrectal devices that have been developed for the treatment of benign and 
malignant prostate disease have probes that can be inserted in the rectum and which 
incorporate both imaging and therapy transducers in one unit [111-112]. Based on this 
technique there are 2 commercially available transrectal devices. They are undergoing 
multicenter evaluation to assess their role in the management of prostate cancer [113]. 
The Sonablate 500 transrectal device (Focus Surgery; Milpitas, California) uses a 4-
MHz curved lead-zirconate-titanate transducer with a dimension of 3.0 x 2.2 cm for 
treatment. The central, circular, 12-mm-diameter portion is used for imaging. The focal 
A B 
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length can be 3.0, 3.5, 4.0, or 4.5 cm. The intensity at the focus is 1680 to 2000 W/cm2, 
depending on the focal length [114]. The second device is the Ablatherm® (Technomed 
International, Lyon, France) system. This device includes a motorized probe-positioning 
system, ultrasound power generator, a cooling system for preservation of the rectal wall, 
and the ultrasound scanner [115]. Treatment (or thermal ablation) treats prostate cancer 
by focusing high-intensity ultrasound waves on the affected area, causing localized 
heating that destroys the cells in the gland without damaging the surrounding tissue. 
Focused ultrasound works in the same way as rays of sunlight that pass through a 
magnifying glass and are concentrated at a single point, causing a significant 
temperature rise around the focal point. Both systems incorporate therapy and imaging 
transducers into a treatment head mounted at the end of a trans-rectal probe. The 
therapy transducer takes the form of a truncated spherical bowl. The clinical aim of both 
devices is usually to ablate the entire prostate, although nerve sparing treatments are 
sometimes required. Prostate ablation is achieved by placing touching lesions side by 
side. In the Ablatherm® device, lesion length is varied by adjustment of the ultrasound 
power to pre-set levels, whereas for the SonablateTM the thicker prostates are ablated 
using two layers of lesions, the deeper layer being created using a longer focal length 
than the more superficial layer. The different focal lengths are achieved by rotating the 
transducer, the two sides having different geometries. SonablateTM users are able to vary 
the acoustic output power of the probe.  
 
1.4.8  INTERSTITIAL DEVICES 
 
There has been some interest in the development of high intensity ultrasound probes for 
interstitial use. In the main, these use plane transducers rather than focusing elements, 
and volume destruction is obtained by rotation of the probe. Prat et al. [116, 117] have 
described a probe designed for the intra-ductal treatment of biliary tumours. A 3mm x 
10mm 10MHz plane transducer is mounted on a stainless steel shaft that is passed 
through a jumbo fiberduodenoscope. The probe can be positioned under fluoroscopic 
guidance. Ultrasound intensity at the transducer face of 14Wcm-2 is used for 10–20 s 
bursts. Circumferential ablation is achieved by rotation of the flexible probe. The 
transducer is rotated by 18° after each ‘‘shot’’. Once 360° of damage has been achieved 
the probe is repositioned under fluoroscopic guidance to create adjacent rings, each 
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8mm in height. This has been used clinically with some encouraging results [118, 119]. 
A similar device has been created for the treatment of esophageal tumors [120]. A 
15mm x 8mm 10MHz piezoceramic plane transducer is mounted on an 80cm long, 
10mm outside diameter flexible shaft. Intensities of 12-16Wcm-2 for exposure times of 
5–20 s gave ablation to a maximum depth of 13mm in ex vivo liver. In the oesophagus 
ex vivo a 10 s exposure at 12Wcm-2 resulted in damage to a depth of 4–5mm. A similar 
MR compatible device has been developed. Makin et al. [121] have also developed a 
probe for percutaneous and laparoscopic treatment of the liver. The probe consists of a 
(32 3.1MHz) element imaging and therapy array with 2.3 mm elevation, 1.53 mm pitch 
and 49 mm aperture. Rotational treatments can be undertaken. The ability of high 
intensity ultrasound beams to occlude the blood supply and coagulate tissue has been 
exploited in the design of a device to allow bloodless partial nephrectomy [122]. A 
3.8MHz, 1.2 cm2 plane transducer mounted on a handheld applicator is used at intensity 
at the transducer face of 26Wcm-2.  
 
1.4.9  CLINICAL APPLICATIONS 
 
While focused ultrasound is in the early stages of development and adoption, it has the 
potential to transform the treatment of a variety of serious medical conditions. Some 
applications of the technology are approved for commercial use and are available in 
medical treatment centers around the world.  Other uses are still undergoing research, 
with opportunities for patients to participate in clinical trials at leading medical research 
institutions [123].  Even more potential uses of the technology are in the early stages of 
technical research.  Today, focused ultrasound can be used in the treatment of various 
conditions in the human body, these conditions include the following:  
 
Prostate Cancer -This is treated via the insertion of a rectal ultrasound probe into the 
rectum. This insertion allows better access to the prostate [125].  
 
Kidney Cancer - HIFU is a non invasive method of treating kidney cancer which leaves 
the patient with no need for dialysis as compared with the other methods like surgery or 
radiotherapy[126].  
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Liver Cancer - Cancer that was normally managed by surgery can now be treated with 
focused ultrasound. Other cancers that can be treated with this ultrasound are bone 
cancer, pancreatic cancer [126].  
 
Atrial Fibrillation - Abnormal rhythms of the heart can be treated by ablating the heart 
tissue that is responsible for causing the arrhythmias [127].  
 
In total there are more than 82,000 patients treated with focused ultrasound.  A majority 
of patients treated have had prostate cancer, followed by uterine fibroids and liver 
cancer.   
 
Figure 1.10. Patients Treated 
 
The future of focused ultrasound  
There are many clinical studies in the field of focused ultrasound with the aim of 
replacing the standard invasive surgical procedures with this non invasive technology. 
Research is being conducted to advance the accurate administration of focused 
ultrasound waves to internal organs using MRI technology. 
 
1.4.10  HIFU LIMITATIONS 
 
Safety is paramount in developing any new technology. It is important to consider the 
safety, side effects, and limitations of the treatment. A clear knowledge of expected and 
hazardous side effects is critical in order to achieve regulatory approval and for a patient 
to give fully informed consent for a procedure. It has been shown to be successful for 
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the treatment of liver tumors in the former [129] and in the selective destruction of 
normal liver, bladder, muscle, and kidney in the latter [130]. Small-animal studies have 
also shown that HIFU does not increase the risk of tumor metastasis [109]. Studies 
involving transrectal HIFU for the treatment of prostate cancer have recorded side effect 
profiles [113]. The most serious complication described is rectal wall injury. Although, 
after improvements in device-design and safety features such as rectal wall cooling, this 
particular complication occurs very rarely at less than 1%. The other side effects are 
disease specific, with urinary incontinence (<5%) and impotence (≈50%) being the most 
common. The general consensus from all studies to date has been that extracorporeal 
and transrectal HIFU are both safe and acceptable to patients. The adverse effects of the 
HIFU process have been reported in previous studies. First, on the basis of clinical 
experiences in China [102] it can be seen that the duration of HIFU treatment is long. 
The procedure takes several hours and the patients must lie on the therapy platform, 
making them uncomfortable and causing unnecessary deposition of energy in the 
surrounding tissues. This procedure may cause adverse events such as skin burns, 
transient pain, and nerve injury. Kennedy et al. (2004) [131] reported that the most 
severe treatment-related adverse events were transient pain and superficial skin burns in 
their study for the HIFU treatment of 11 patients with liver tumors. Second, a few live 
cells may be left in the targeted area after HIFU ablation. Spaces between extremely 
small focal regions of HIFU may result in the survival of a few cells in the focal area 
[132].Third, ablation and blocking of micro vessels smaller than 0.2 mm in diameter is 
achievable with HIFU, but it is less effective with vessels 0.2 mm in diameter and larger 
because rapid blood flow may reduce HIFU energy absorption, preventing it from 
depositing sufficient energy in the target zone within a short time [102]. These adverse 
effects may be due to small throughput and long treatment time. Therefore, HIFU 
energy deposition should be enhanced in a much shorter time. Factors related to HIFU 
energy deposition in HIFU therapy consist of the acoustic intensity of transducers, 
energy absorption characteristics of tissues and the exposure duration. Theoretically, 
high acoustic intensity or prolonging duration of sonication can change small 
throughput. However, there is always a risk of depositing more energy to the overlying 
tissue. The resulting effect is a longer ablation time for patients with an increase in the 
incidence of adverse effects and the technical difficulty of providing treatment. Many 
studies have focused on how the tissue characteristics of acoustic absorption can be 
changed to make energy deposition more efficient [133-134]. In order to enhance the 
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HIFU ablation efficiency, heating, cavitation, and mechanical events in the target 
tissues should be enhanced [135-136]. Several types of materials such as iodized oil, 
porphyrin, and ultrasound contrast agents have been investigated for enhancing energy 
deposition in tissue in the past [137]. In particular, ultrasound contrast agents have been 
intensively studied to enhance the effect of HIFU therapy. 
 
1.5 THERAPEUTIC ULTRASOUND: DRUG 
ENHANCEMENT  USING MICRO-
NANOBUBBLES  
 
Although therapeutic ultrasound was considered a tool for hyperthermia or thermal 
ablation of tumors for over 40 years, more recently new mechanisms for ultrasound-
based or ultrasound-enhanced therapies have been described, and there is now great 
momentum and enthusiasm for the clinical translation of these techniques [138]. 
Ultrasound has been proposed as an innovative method for noninvasive delivering of 
drugs and genes to different tissues. To target and deliver drug and gene, microbubbles 
has been the subject of intense experimental research [139]. Encapsulated gas 
microbubbles are well known as ultrasound contrast agents for medical ultrasound 
imaging. While the use of microbubbles as contrast agents has been around for perhaps 
a couple of decades, the use of microbubbles for therapy is in its infancy [140].  
In diagnostic ultrasound, microbubbles create an acoustic impedance mismatch between 
fluids and tissues to increase reflection of sound. Accordingly, these new contrast 
agents increase the signal from flowing blood and vascularized tissues containing blood. 
Ultrasound contrast agents should have extensive ultrasound applications in radiology 
and cardiology for the detection of perfusion and characterization of tissues [140]. It is 
only recently, however, that the new generation of blood pool agents has become 
available for routine diagnostic applications, and subsequent clinical experience will 
produce guidelines for the use of these agents [140]. The application of microbubbles 
(MBs) in diagnostic as contrast-enhanced ultrasound has become an indispensable part 
of clinical ultrasonography [141], and molecular imaging via ultrasound has recently 
attracted significant attention [142]. MBs help to enhance the specificity and sensitivity 
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of imaging for various types of diseases, especially with tumors [143]. Other advantages 
of using MBs include a lower cost of contrast agents, an opportunity for real-time 
observation and the elimination of the exposure to radiation. However, compared with 
contrast agents for computed tomography (CT) and magnetic resonance imaging (MRI), 
MBs are much larger. Microbubbles used for clinical imaging are typically between 
about 1 and 10 µ in diameter (the upper limit for passage through the lung capillaries); 
Usually, the diameter of a microbubble is approximately equal to the size of a red blood 
cell, resulting in similar rheology in the microvessels and capillaries throughout the 
body following intravenous administration [144]. Recently developed nanoscale 
bubbles (nanobubbles [NBs]) are promising contrast agents for extravascular ultrasonic 
imaging. Nanoscale ultrasound contrast agents with various shells (polymers or 
phospholipids) and cores (gas, liquid, or solid) have been fabricated and exhibit good 
contrast enhancement. Over recent years, the potential use of nanobubble systems 
combined with US has gained growing amounts of attention not only for diagnostic 
applications as contrast agents, but are currently the subject of much research in relation 
to their potential use as therapeutic tools: they can also be used as drug and gene 
carriers. The nanobubbles as drug/gene carriers have an average size less than that of 
red blood cells, i.e. they are capable of penetrating even into the small blood capillaries 
and releasing drug and genes under the action of ultrasound field. The application of 
ultrasound and nanobubbles to targeted drug and gene delivery has been the subject of 
intense experimental research. Under exposure of sufficiently high-amplitude 
ultrasound, these targeted nanobubbles would rupture, spewing drugs or genes, which 
are contained in its encapsulating layer, to targeted cells or tissues. Recently, targeting 
ligands are attached to the surface of the nanobubbles (i.e. targeted-nanobubbles), which 
have been widely used in cardiovascular system and tumor diagnosis and therapy. This 
technique presents a variety of advantages, including: non-invasiveness, local 
applicability and proven safety [145-146]. Nanobubbles with various shells (polymers 
or phospholipids) and cores (gas, liquid, or solid) have been fabricated and exhibit good 
contrast enhancement. However, research on NBs is still in the initial stages.  
In the following paragraphs I will describe the main proprierties of nanobubbles with a 
particular attention to their interactions with ultrasound and their applications in 
therapeutic ultrasound. 
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1.5.1 GENERAL PROPRIETIES OF NANOBUBBLES 
 
Nanobubbles (NBs) are comprised of spherical voids or cavities filled by a gas. 
Generally, for medical applications, nanobubbles are stabilized by a coating material 
such as phospholipids, surfactant, denatured human serum albumin or synthetic 
polymer.   
Since gas is less dense than liquids or solids, nanobubbles comprise a pocket region or 
structure of low density. This property of low density of NBs has a number of 
potentially important medical applications. These include site-specific delivery and 
treatment of thrombosis and pulmonary delivery [147]. One way of exploiting the 
diagnostic and therapeutic applications of nanobubbles is with ultrasound. Ultrasound is 
one of the most common medical imaging methods and is also used therapeutically. 
Sound travels more slowly in gas than it does in liquid. The difference in speed of sound 
in nanobubbles creates an acoustic impedance mismatch between tissue and blood 
surrounding a nanobubble. Nanobubbles are efficient reflectors of ultrasound energy, 
hence their use as contrast agents for medical ultrasound imaging. Nanobubbles also 
lower the threshold for cavitation with ultrasound. Ultrasound energy can be reflected, 
transmitted or absorbed as it passes through a biological medium. In cavitation, 
ultrasound energy is concentrated within a domain around a nanobubble. Nanobubbles 
can be used as therapeutic cavitation nuclei with ultrasound (see next paragraph). The 
frequency of ultrasound is also important. Cavitation is generally more efficient (i.e., 
easier to produce) at lower frequencies of ultrasound. Cavitation can be used 
therapeutically at clinically useful ultrasound frequencies such as 1 MHz.  
The nanobubbles must be sufficiently stable, that after injection into the blood, they will 
circulate for a long enough period of time to reach the target site. The stability of 
nanobubbles in liquid (e.g., a biological fluid such as the blood) depends upon the 
surrounding medium-temperature, pressure, concentration of dissolved gases, the 
composition of the gas in the bubble and the coating material surrounding the 
nanobubble. Elevations in pressure, such as occur in the heart and arteries during systole 
pose a stress on bubbles. An important parameter to consider in the development of 
stable bubble systems is the Laplace pressure, which governs the in vivo dissolution rate 
of nanobubbles. The gas pressure within a bubble is the sum of the equilibrium 
pressure, the Laplace pressure and the blood pressure. The Laplace pressure is the 
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pressure difference between the inside and the outside of a bubble (or a droplet) in the 
bloodstream [148], given as: 
 
                                                                                                                             (8) 
 
where Pinside and Poutside are the pressures inside and outside a bubble respectively, σ is 
the interfacial tension, and r is the bubble radius. A surfactant layer on the bubble 
surface is able to reduce the interfacial tension and decrease the Laplace pressure. As 
the Laplace pressure is reversely related to the size of a bubble, in accordance with the 
equation, smaller bubbles will have higher pressure values than larger bubbles. When 
the inner gas leaves the core, the bubbles shrink and the Laplace pressure increases, 
thereby accelerating the rate of gas dissipation and the resulting bubble shrink age until 
the system ruptures [149]. 
The solubility of the gas in the nanobubble has an important effect on the stability of the 
nanobubble. Simple air bubbles dissolve very rapidly in the blood under the combined 
action of Laplace pressure, arterial pressure, oxygen metabolism and ultrasound energy, 
hence have little utility. Nanobubble formulations can be stabilised by using a gas with 
a very poor aqueous solubility for thebubble core, such as perfluorocarbons (i.e. 
perfluorobutane) or sulphur hexafluoride, thereby reducing the dissolution of the gas 
into the bloodstream. For example, the encapsulation of suitable perfluorocarbons 
(gases that are insoluble in water) has been proposed to increase the duration of various 
bubble systems. Nanobubbles comprised of perfluorocarbon (PFC) gases, which have a 
higher molecular weight, have a longer residence time in the blood. Perfluorochemicals, 
and in particular PFCs, when used as the filling gas or part of it, delay bubble 
dissolution very effectively, due to very low water solubility, thus providing ample time 
for patient examination. The preferred PFCs are those that combine low water solubility 
and high vapour pressure.  In the US, there are currently two perfluoropropane-based 
nanobubble products marketed for diagnostic imaging with ultrasound. One of these 
products, DefinityR, was developed by ImaRx and is currently marketed by Bristol- 
Myers Squibb for diagnostic ultrasound imaging. The other currently marketed product 
is OptisonR, nanobubbles stabilized by human serum albumin. 
As I shown before, nanobubbles remain relatively stable in water for a long time (they 
have a long lifetime), or rise very slowly, gradual shrink, and finally collapse (i.e., 
shrinking collapse), whereas macrobubbles increase in size, rise rapidly, and burst at the 
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water surface. Figure 1.11 shows the key differences among macrobubbles, MBs and 
NBs. MBs tend to gradually decrease in size and subsequently collapse due to long 
stagnation and dissolution of interior gases into the surrounding water, whereas NBs 
remains as such for months and do not burst out at once [150]. It has been revealed that 
the interface of NBs consists of hard hydrogen bonds similar to those found in ice and 
gas hydrates. This in turn leads to reduced diffusivity of NBs that helps to maintain 
adequate kinetic balance of NBs against high internal pressure.  
 
 
 
Fig. 1.11 Schematic diagram showing macro, micro and nanobubbles [151]. 
 
A further key factor to consider in bubble formulation is the shell composition. First of 
all, the composition of the shell can greatly influence bubble half-life, since it affects 
the gas exchange from the core to the external medium. The thickness and the elasticity 
of the shell determine microbubble stability [152]. Exposure to intense US energy can 
lead to rapid bubble destruction by cavitation due to their rapid contraction and 
expansion. This mechanical stress can weaken the bubble shell until bubble rupture 
[153]. Very soft shells can be ruptured by small pressure variations, but very hard shells 
would be not being able to oscillate. The most elastic shells are made of phospholipids 
[152]. The types of hydrocarbon tails of these lipids can also affect the shell properties. 
For example, saturated diacyl chains provide greater rigidity, often accompanied by 
lower gas permeability, compared to shorter chain lipids. As a consequence, 
microbubbles consisting of lipids with longer acylchains exhibit longer shelf-lives [154-
155]. The presence of abundant surface electrostatic charges could disturbthe stability 
of phospholipid monolayer shells causing lateral electrostatic repulsions [156]. One way 
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of increasing the resistance of phospholipid monolayer-based microbubbles is to add 
polymers to the formulation [157-158]. The influence of polymers on bubble structure 
has been widely investigated. Lindner and colleagues studied the elasticity of polymer-
albumin microbubbles by varying the polymercomposition in order to vary the shell 
properties [159]. Polylactides (PLA), low and high molecular weight poly-mers, and 
caprolactone were tested.  
 
1.5.2 TERAPUTIC APPLICATIONS OF NANOBUBBLES 
 
In paragraph 1.2.1.2 the bubble behaviour when subjected to an acoustic field and the 
biofisical effects provoked by cavitation has been described. Here, I will describe 
different methods of combining drugs with nanobubbles and the innovative 
technologies that allows therapeutic local administration of oxygen, drugs or other 
molecules transdermally (sonophoresis) or directly at the cellular level (sonoporation). 
 
1.5.3 DRUG CONTAINING NANOBUBBLES 
 
For drug delivery applications, it is possible to make therapeutic drug-carrying 
nanobubbles by incorporating the drugs into or onto the bubbles. As shown in Figure 
1.12, drugs can be incorporated into acoustically active carriers in a number of different 
ways, ranging from association with the membrane to development of gas/ drug-filled 
microspheres. Drugs can be conjugated to the nanobubble membrane with the use of a 
charge dependent, noncovalent binding. Especially DNA that is a large negatively 
charged molecule is suitable for attachment to a positively charged membrane. Another 
mechanism to load a bubble with drugs is to incorporate the drug in the shell. This 
process is importantly influenced by the nature of the drug, in terms of lipophilicity and 
hydrophilicity. Although it seems difficult to enclose material within the nanobubble 
itself, as it is a gasfilled microsphere, theoretically a drug containing powder may be 
attached to the inside of the bubble wall. Furthermore, drugs can be bound by ligands 
that are embedded in the membrane. With respect to this type of conjugation, a specific 
technique which is based on an avidinebiotin model, used for binding of antibodies in 
other studies, may be of importance for the binding of certain drugs. Finally, even 
nanobubbles with multiple layers can be constructed, in which drugs can be dissolved. 
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The presence of gas in the drug delivery vehicles is to confer acoustic activity. The 
presence of the gas lowers the threshold for cavitation making the drug carriers sensitive 
to ultrasound for local activation, drug release and drug delivery. Additionally, drug 
delivery and release can be visualized with real-time ultrasound. These studies clearly 
suggest that nanobubbles can be used as a vehicle for drugs, and bubble destruction by 
high acoustic pressure ultrasound can be used for local delivery of materials attached to 
or entrapped in the bubble. As mentioned earlier, cavitation is probably the mechanism 
by which destruction of nanobubbles enables extravasation of red blood cells and 
increases cell permeability; however, the exact process is not clear and needs further 
investigation. 
 
 
Figure 1.12 Several mechanisms to attach drugs to nanobubbles. a: Incorporation in 
the bubble; b: incorporation in the bubble membrane; c: attachment to the membrane; 
d: attachment to a ligand; e: incorporation in multilayer nanobubble [160]. 
 
1.5.4   NANOBUBBLES AS GENE DELIVERY SYSTEMS 
 
Gene therapy, a promising therapeutic option for the treatment of genetic or acquired 
diseases, is based on the ability to introduce new genetic material into hosts. A major 
obstacle to gene transfer is the fact that naked nucleic acids are not efficiently taken up 
by cells due to their negatively charged phosphate groups, relatively large sizes and 
hydrophilic nature. Moreover, they are very susceptible to degradation mediated by 
nucleases present in the blood. To overcome these limitations, a number of gene 
delivery vectors have been developed, falling into either viral or non-viral categories. 
Micro- and nanobubbles provide a promising non-viral strategy for the site-specific 
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delivery of genetic material; this is due to their potential to be ‘activated’ in the 
presence of ultrasound (US) and mediate the delivery of DNA to specific cell targets. 
The insonated nanobubbles technique as a gene delivery system has become 
increasingly popular over recent times due to its versatility and ease of the use. The 
effect of US on cell permeability and its capacity to facilitate the entry of naked DNA 
into cells was first described by Fechheimer [161]. These first studies used a US 
frequency in the range of 20–50 kHz. However, when combined with cavitation these 
frequencies are able to induce tissue damage [162-163].To overcome this limitation, the 
delivery of genes using US at the frequencies applied for clinical imaging (1–3 MHz) 
has received a great deal of research attention. However, as these conditions result in 
very inefficient gene delivery, therapeutic ultrasound combined with nano/microbubble 
contrast agents has been investigated for enhancing gene transfection efficiency [164-
165]. This combination method has many of the characteristics required for practical 
gene therapy including low toxicity, the potential for repeated applications, organ 
specificity and broad applicability to acoustically accessible organs. Under proper 
conditions, the combination of ultrasound and nano/microbubbles can create transient 
non-lethal perforations in cell membranes. Numerous studies have now shown that US 
is able to result in the direct transfer of genes into the cell cytosol, although the level of 
gene transfer is generally very low (alternatively, it can be incorporated into the shell of 
a multilayer polymer nanobubble, thereby increasing the quantity of DNA vehiculated 
(Figure 1.13B). A third approach involves incorporating DNA into 
lipoplexes,polyplexes, liposomes or nanoparticles, which are subsequently associated 
with the bubble surface by means of either physical or chemical interactions [166-167] 
(Figure 1.13C).When loading DNA to the external surface of a nanobubblethrough non 
covalent binding (Figure 1.13A), the nanobubbles must bedesigned to possess a positive 
surface charge in order to favourthe electrostatic interactions with the negatively 
charged nucleicacids. The above findings suggest that the combination of nanobubbles 
and ultrasound could be useful for gene delivery (Fig. 1.13(c)) [149]. 
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Figure 1.13. Technological approaches to attaching DNA to the micro-nanobubble 
shell. (A) Deposition on the surface of a monolayer-shelled bubble; (B) incorporation 
in amulti-layer shelled bubble; (C) binding of DNA-loaded nanocarriers onto the 
bubble shell. 
 
1.5.5 TARGETED NANOBUBBLES 
 
Targeted nanobubbles can be developed by incorporating targeting ligands onto the 
surface of the nanobubbles.  As described earlier, nanobubbles can be loaded with genes 
and injected into a vein, followed by localized ultrasound. In this way, nanobubbles are 
a specific and local delivery is controlled by the local application of ultrasound. 
However, as currently used nanobubbles are relatively stable and circulate through the 
whole body, delivery of material could partly result in deposition of the contents of the 
nanobubble in tissue that is not the target tissue, e.g. in the chest wall, or in the lungs, in 
which nanobubbles with higher diameters are filtered. Therefore, it would be greatly 
desirable to have a nanobubble which can be targeted to a specific tissue by using 
ligands and receptors that are incorporated in the bubble shell (Figure 1.14). Using 
certain ultrasound imaging techniques (e.g., cavitation imaging), it is possible to detect 
a single nanobubble [168]. In terms of sensitivity to low concentrations of an imaging 
agent, ultrasound with nanobubbles rivals nuclear medicine and exceeds the capabilities 
of other commonly used imaging techniques such as magnetic resonance imaging and 
computed tomography. This would enable active attachment of nanobubbles to target 
tissue and create further possibilities for diagnostic imaging and therapy like local drug 
delivery to target lesions. The extreme sensitivity of ultrasound, to low concentrations 
of nanobubbles makes it feasible to do molecular imaging with targeted ultrasound 
contrast agents. An important difference, however, between ultrasound compared to 
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nuclear medicine is that the imaging agent is a microscopic entity or nanoscopic as 
opposed to a small molecule (e.g., a radionuclide chelate in nuclear medicine). This 
means that targeted nanobubbles may be larger entities than some nuclear imaging 
probes. Therefore, targets that are accessible via the vasculature are probably of greatest 
interest for the development of targeted nanobubble agents. Targeted nanobubbles have 
been developed into various types of tissue and processes, e.g., endothelialcells, 
thrombi, inflamed tissue and angiogenesis [160]. 
 
 
Figure 1.14. Targeted nanobubble, connected by ligand and receptor. 
  
1.5.6    OXYGEN LOAD NANOBUBBLES 
 
Oxygen is one of the most widely used therapeutic agents. It is a drug in the true sense 
of the word, with specific biochemical and physiologic actions, a distinct range of 
effective doses, and well-defined adverse effects at high doses. Oxygen is widely 
available and commonly prescribed by medical staff in a broad range of conditions to 
relieve or prevent tissue hypoxia. Hypoxia, a condition of inadequate oxygen supply to 
tissues or the body, can lead to severe tissue damage and can be life threatening. Tissue 
hypoxia can develop if there is a decrease in cardiac output (ischemic hypoxia), 
hemoglobin concentration (anemic hypoxia), or oxygen saturation (hypoxic hypoxia), or 
an increase in the metabolic demands of the body [169]. Hypoxia also induces 
physiological, cellular, and biochemical responses, which can effect pharmacological 
metabolism [170-171]. Hypoxia is the most crucial issue in the treatment of a variety of 
diseases, in particular in tumors. Tumors induce angiogenesis to increase their nutrient 
and oxygen supply, enabling their rapid growth [172]. However, the blood vessels in 
tumors are leaky and defective, with large pore cutoff sizes, and the endothelial cells are 
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misaligned or have large fenestrations [173]. Moreover, tumors have poor lymphatic 
drainage compared with normal tissues [173-174]. In general, acute mild hypoxia 
supports adaptation and survival. On the contrary, chronic extreme hypoxia leads to 
tissue loss. To solve this problem, in the recent years intensive research has been 
conducted to develop new carriers able to effectively release high oxygen amounts for 
sustained times [175-176]. Hemoglobin (Hb)-based oxygen carriers, using natural Hb as 
the oxygen transporting component, have been developed as cell-free suspensions, 
encapsulated within vehicles, or complexed with protective enzymes [175-176]. 
Researchers have also synthesized alternative carriers based on perfluorocarbons, which 
can carry molecular oxygen without actually binding to it, thus favoring gas exchange. 
However, they are not water-miscible, and therefore need to be formulated into 
emulsions for in vivo use [175-176]. Perfluorocarbon-based oxygen nanobubbles have 
been developed and reported to dissolve clinically relevant amounts of oxygen when 
administered in dosages that are approximately 1/500 of usual quantities in which 
perfluorocarbon-based oxygen carriers are administered [177]. Few years ago, our 
group developed a new kind of oxygen-filled nanobubbles, shelled with chitosan and 
cored with perfluoropentane, which proved to act as an efficient oxygen delivery system 
in vitro [178]. Oxygen bubble formulations were further optimized in order to reach the 
nanometer size range, and the new nanodevices, either coated with chitosan or dextran, 
were called oxygen-loaded nanobubbles (OLNs) [178-180]. Recently, nanobubbles 
have also been proposed to carry on molecules other than gaseous oxygen, such as 
DNA, thus opening the gates for future gene therapy applications [181].  
 
1.5.7    SONOPORATION 
 
The ability of nanobubbles to act as cavitation nuclei when destroyed can increase cell 
membrane permeability, if cells are located in close proximity to nanobubbles. 
Although ultrasound had been proven to increase cell membrane permeability on its 
own [182], the use of nanobubbles has a significant additive effect.  Several 
explanations are offered for this phenomenon called ‘sonoporation’. First, nanobubbles, 
by acting as cavitation nuclei, can lower the threshold for cavitation (see paragraph 
1.2.1.2). In body tissue or blood, cavitation sets fluid in motion and creates small shock 
waves that give rise to microstreaming along the endothelial cell. Destruction of 
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nanobubbles may cause high-energy microstreams, or microjets, that will cause shear 
stress on the membrane of an endothelial cell and increase its permeability [183]. This 
increase in permeability is probably due to transient holes in the plasma membrane and 
possibly the nuclear membrane (Figure. 1.15A). A second proposed mechanism, the 
generation of reactive oxygen species in endothelial cells under influence of ultrasound, 
was investigated by Basta et al [184]. As the use of nanobubbles together with 
ultrasound lowers the threshold for cavitation, this could possibly result in an increased 
production of free radicals, which are associated with cell killing in vitro and, as a 
consequence, may be also involved in enhancement of permeability of endothelial cell 
layers. A third interesting aspect is the rise in temperature in tissue following the 
application of high pressure ultrasound [185]. Bubble collapse following high energetic 
ultrasound can create high velocity jet streams that may cause a local, transient increase 
in temperature. As a rise in temperature influences the fluidity of phospholipid bilayer 
membranes, cell membrane permeability could possibly be changed directly as a 
consequence of the increased bilayer fluidity (Figure. 1.15B). Fourth, endocytosis or 
phagocytosis, active membrane transport mechanisms, may also be involved in the 
uptake of the bubble, bubble fragments or material entrapped in nanobubbles (Figure. 
1.15C). A fifth mechanism by which the use of nanobubbles could facilitate the 
deposition of drugs or genes in a cell is exchange or fusion of the phospholipid 
nanobubble coating with the phospholipid bilayer of a cell membrane (Figure. 1.15D). 
This could result in delivery of the cargo of the nanobubble directly into the cytoplasm 
of the cell with the possibility of further uptake in endosomes or delivery to the cell 
nucleus. 
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Figure 1.15. Destruction of nanobubbles by ultrasound resulting in increased 
membrane permeability by shear stress, temperature rise and activation of reactive 
oxygen species. Drug delivery by nanobubbles by: a: transient holes induced by shear 
stress; b: increase in membrane fluidity; c: endocytosis of nanobubbles; d: fusion of 
the nanobubble membrane with the cell membrane [186]. 
 
 
1.5.8    SONOPHORESIS 
 
The skin has been investigated as route for drug administration for several decades and 
many drug delivery techniques to facilitate permeation of drugs across the skin have 
been explored. Sonophoresis describes the use of ultrasound to move low and high 
molecular weight drugs through intact living skin and into the soft tissues [187,188]. It 
is one of the most promising novel drug delivery system and has been shown to enhance 
the skin penetration and release rate of a number of drugs that have poor 
absorption/permeation profiles through the skin[189–192]. Sonophoresis is a localised, 
non-invasive, convenient, rapid topical administration method of delivering low 
molecular weight drugs as well as macromolecules into the skin [193]. This is a 
considerable technological advance compared to oral delivery because gastrointestinal 
degradation and first-pass metabolism through the liver are avoided [194]. Despite these 
advantages, the use of transdermal drug delivery (TDD) has been limited by innate 
barrier functions of the skin [195]. The epidermis is the functional barrier of the 
outermost part of the skin and protects the human body as a first-line defense against 
foreign substances such as bacteria and toxins. The skin, which consists of several 
layers including the stratum corneum (SC), epidermis, and dermis, is the primary 
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defense system of the body [196] (Figure. 1.16). The functions of skin include 
maintenance of body temperature, blockage of ultra-violet radiation, and providing a 
defense against harmful external pathogens such as bacteria and toxins. The most 
important layer of the skin that provides substantial protection from pathogens is the SC 
[197]. The SC is composed of corneocytes interspersed in a laminate of compressed 
keratin and intercorneocyte lipid lamellae, functions to conserve water and electrolytes, 
and is selectively permeable to certain substances such as drugs (see Figure 1.17). 
Naturally, the SC has a very low permeability to foreign molecules and is thus the main 
obstacle of TDD. Because of this barrier, available transdermal medicines are small 
molecules (<500 Da) that are active at low blood concentrations of a few ng/ml or less 
[198].  
 
 
Figure 1.16. Cross section of human skin (left). Barrier function of the stratum 
corneum (right).  
 
A number of methods have been proposed to overcome the natural barrier function of 
the skin, such as skin patches [199], iontophoresis [200], use of chemical enhancers 
[201], and ultrasound methods [202]. Recent research in sonophoresis has indicated that 
MHz range ultrasound has little effect on skin permeability even though 2–10 MHz is 
the most used frequency range in medical ultrasound imaging. On the other hand, low 
frequency (e.g.,100 kHz) ultrasound is better suited for the transdermal transport of 
various drugs such as insulin, erythropoietin and interferon [202-204]. Given that heat 
deposition is dominant at high frequency and cavitation effects are prominent at low 
frequency, the main mechanism for sonophoresis delivery is thought to be cavitational, 
and not thermal, effects [205]. The source of cavitation is believed to be small bubbles 
trapped in the skin during topical application of a drug solution and oscillation of these 
bubbles according to the applied ultrasound field. Since bubbles oscillate in asymmetric 
boundary conditions, microstreaming and asymmetric bubble collapse can occur [206]. 
Microstreaming can generate high velocity gradients and hydrodynamic shear stresses 
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[206]. Bubble oscillation around asymmetric boundary conditions by stable cavitation 
leads to a phenomenon called microstreaming, which can generate high velocity 
gradients and hydrodynamic shear stresses [206]. Microstreaming results from the 
unidirectional flow of fluid in response to bubble dynamics in an acoustic field. The 
characteristics of microstreaming are determined by fluid properties such as acoustic 
attention, viscosity, and density, as well as the ultrasound characteristics including 
temporal average intensity, frequency, transducer aperture size, and pressure amplitude. 
The velocity of microstreaming decreases with increasing fluid viscosity and increases 
with increasing acoustic attenuation. Collis et al. [207] studied several patterns of 
microstreaming and showed that many patterns are possible around a nanobubble. Each 
microstreaming pattern also generated different shear stress with distributions of 
compression and stretch in the vicinity of a bubble. The states of uniform shear stress 
and two types of divergence are illustrated in Figure 1.17 
 
 
Figure 1.17. Illustration of the differences between uniform shear and surface 
divergence. (a) Uniform, high shear stress, no divergence and thus no stretch of cell 
surface, (b) high rate of positive divergence (as well as shear stress), cell/cell 
membrane in stretch-activated state, (c) high rate of negative divergence (as well as 
shear stress), and cell/cell membrane compressed together.  
 
Teoretical and experimental studies have shown that microstreaming near a cell 
boundary can affect a cell membrane [208]. Second-order microstreaming flow may 
generate flow fields that develop shear stresses over a cell membrane, resulting in 
tension and stretching on membrane walls that cause channel activation, allowing 
delivery of compounds such as DNA for therapeutic purposes [209]. Asymmetric 
bubble collapse can induce jet streaming into the skin layer so that direct drug transport 
can occur. Therefore, an increase of cavitation is a logical way to increase skin 
permeability in sonophoresis. Adopting a low frequency ultrasound field is one way to 
increase existing bubbles in cavitation. When the frequency is low enough, it is assumed 
to be quasistatic field to sufficiently small bubbles. If small bubbles can rapidly grow 
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and collapse when adequately exposed to quasi-static rarefractional pressure, these 
bubble activities can be related to asymmetric bubble collapse. Figure 1.18 shows 
possible sites in which the cavitation effect may occur. Cavitation nuclei and air pockets 
in TDD can be formed in intracellular and/or intercellular structures. In addition, 
bubbles can be formed on the skin and coupling medium at the skin surface. However, 
small gaseous nuclei are more resistant to oscillation within densely packed tissue. This 
becomes especially apparent during high frequency (P ~ MHz) sonophoresis when skin 
density variations occur rapidly due to relatively short wavelengths in comparison to 
that at low frequency. Therefore, cavitation may preferentially occur within the 
coupling medium between the ultrasound transducer and skin surface and may locally 
increase skin permeability [206]. 
 
Figure 1.18. Schematic sketching of cavitation occurring in a variety of sites such as 
coupling medium, skin surface, and skin tissue. Cavitation occurs preferentially at the 
interface between keratinocytes and lipid bilayers. 
 
Microstreaming is a characteristic of stable cavitation. For inertial cavitation, lower 
frequencies give bubbles more time to grow in the expansion cycle and consequently 
produce a more violent collapse during the compression cycle. The violent collapse of 
cavitation bubbles may generate either shock waves in the bulk of the liquid or a micro-
jet near a boundary, which is referred to as asymmetric bubble collapse. Figure. 1.19 
schematically shows the shock wave and micro-jet produced by inertial cavitation 
events. A spherical bubble collapse yields high-pressure cores that emit shock waves 
with amplitudes exceeding 10 kbar [210]. The disruption of a target exposed to such a 
pressure wave may occur through relative particle displacement, compressive failure, 
tensile stress, or shear strain [211]. When a bubble collapses asymmetrically nea ra 
boundary, it generally produces a well–defined, high velocity micro- jet [212]. Micro-
jet distortion due to bubble collapse depends on the surface encountered by the bubble. 
If the surface is larger than the resonant size of the bubble (radius of 1–150 lm at 
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approximately 5 MHz–20 kHz), the resulting collapse will be in the form of a micro-jet 
(Figure 1.20). 
 
 
 
 
Figure. 1.19. Three possible modes through which inertial cavitation may enhance SC 
permeability. (a) Spherical collapse near the SC surface emits shock waves, (b)  
impact of an acoustic micro-jet on the SC surface, and (c) micro-jets physically 
penetrating into the SC.  
 
As shown in Figure. 1.18 inertial cavitation has the potential to take place in 
keratinocytes, lipid bilayer regions, and crevices of hair follicles filled with coupling 
medium. Shock waves generated by inertial cavitation can cause structural alterations in 
the surrounding keratinocyte-lipid interface regions, resulting in the creation of 
diffusion channels through which drugs may be potentially delivered. Furthermore, 
impact pressure of the micro-jet on the skin surface may enhance SC permeability by 
disrupting SC lipid bilayers [213]. A micro-jet possessing a radius approximately one-
tenth of the maximum bubble diameter impacts the SC surface without penetrating. 
When combined, these factors lead to lipid bilayer disorder and formation of aqueous 
channels in the skin through which drugs can permeate. 
Transdermal delivery is perhaps the most widely recognized application of 
ultrasonically enhanced drug delivery based on the approval of the Sontra Medical 
(Echo Therapeutics, Inc) system for transdermal delivery of topical therapeutics in 2004 
[214]. Numerous studies have been performed to confirm an enhancement of 
permeability by sonophoresis. Since the initial treatment of polyarthritis with 
hydrocortisone ointment by Fellingher and Schmidt in the 1950s, the transdermal 
delivery of therapeutic drugs such as fentanyl, caffeine, heparin, ketoprofen and insulin 
has become a major concern for clinical medicine. The field of sonophoresis is 
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intriguing. The pre-clinical evidence shows anecdotally that it may prove 
useful.However, many of the published studies, in general, lack sufficient scientific 
rigour. 
 
1.6    THERAPEUTIC ULTRASOUND: OTHERS 
APPLICATIONS  
 
Physiotherapy: Unfocused beams of ultrasound for physical therapy were the first 
clinical application, dating to the 1950s, which often has been referred to simply as 
“therapeutic ultrasound” [215]. This modality now typically has a base unit for 
generating an electrical signal and a handheld transducer. The handheld transducer is 
applied with coupling gel and moved in a circular motion over an injured or painful area 
of the anatomy to treat conditions such as bursitis of the shoulder and tendonitis by 
trained physical therapy technicians. The objective is to warm tendons, muscle, and 
other tissue to improve blood flow and accelerate healing. The coupling medium can 
also include various compounds for enhancing the treatment. Ultrasound application can 
assist by promoting transport of the compound into the skin, a method sometimes called 
sonophoresis. Drugs, such as lidocaine and cortisol, have been used extensively in 
sports medicine. The level of clinical benefit to the patient from physical therapy 
ultrasound treatments remains uncertain [215]. However, the risk of harm, such as 
burns, appears to be low when the modality is properly applied. The mechanism of 
action is known to be thermal. A non-focused beam with low-level energy deposition is 
typically used for physiotherapy. Overall, ultrasound for physical therapy has therefore 
provided a modest level of efficacy and patient benefit but also a low level of risk. 
 
Lithotripsy: Lithotripsy has been the most common treatment for kidney stones since 
1980s and continues to be the favored method for uncomplicated, upper urinary tract 
calculi, even with the advent of percutaneous surgical techniques. Ultrasound induced 
shock waves are used to disintegrate kidney and gallbladder stones. Main mechanisms 
studied in lithotripsy are erosion 5 [216], shear [211], and circumferential compression 
[216]. These mechanisms may all be activated to differing degrees by either the 
lithotripter shock pulse or the subsequent collapse of cavitation bubbles excited by the 
pulse. 
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Histotripsy: Histotripsy is a promising extracorporeal ultrasound technology that 
produces nonthermal tissue fractionation by cavitation (converting the targeted tissue 
into an a cellular liquid) [217]. Cavitation occurs when intense ultrasound pulses induce 
extreme pressure changes within the targeted tissue, resulting in the formation of a 
localized, highly dynamic cluster of microbubbles. These bubbles oscillate and violently 
collapse, producing localized stresses that mechanically fractionate and subdivide the 
targeted tissue, resulting in cellular destruction [218]. 
 
Bone healing and wound healing: There is some evidence in the literature that low 
intensity ultrasound can enhance repair rates and reduce healing times [219-220]. Dyson 
and Brookes (1983) [221] showed in their experiments in rat fibulae that when 
ultrasound exposures are carried out during the inflammatory and early proliferative 
phases of bone repair following fracture, healing can be accelerated, with direct 
ossification being observed. Mechanisms that have been proposed are signal 
transduction, gene expression enhancement, blood flow changes, tissue modeling or re-
modeling effects or micro-mechanical stresses. There is experimental and some clinical 
evidence of the beneficial effects of very low ultrasound intensities on bone repair 
[222]. 
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CHAPTER 2 
 
 
MATERIALS AND METHODS 
 
 
2.1.  ULTRASOUND TRANSDUCERS      
      CHARACTERIZATION: AN       
        OVERWIEV 
 
Before describing in detail the measurement techniques, it would be useful to consider 
in general terms which properties of the transducer fields are currently thought to be of 
most relevance to safety and quality control from a clinical point of view. Ideally, the 
full characterization of the ultrasonic field produced by a transducer would require 
knowledge of the distribution of acoustic pressure at every point of the space and at 
every instant in time. Probably one of the most commonly used parameter is the 
acoustic power. There are many methods for measuring the ultrasonic power, but 
currently the widely diffused is the radiation force balance. Despite its importance, 
ultrasonic power is not an exhaustive parameter. It gives a value of the energy output of 
the source, but doesn’t give any information about how this energy is distributed in 
space and in time. Such information can be obtained by local measurements of other 
acoustic parameters such as acoustic pressure or intensity. Acoustic pressure can be 
measured directly with an  hydrophone. Hydrophones, which could be considered as the 
equivalent of microphones for the ultrasonic frequencies, are tools able to generate an 
electrical voltage proportional to the acoustic pressure incident on their sensitive 
elements. Once the hydrophone has been correctly calibrated it is possible to know the 
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time variation of acoustic pressure in a measurement point from the electrical output of 
the device. So, by positioning the hydrophone within an ultrasonic field and acquiring 
its output electrical signal it is possible to reconstruct the shape, the amplitude and the 
pressure of the acoustic field generated by a transducer in the space. It should be noted 
that, in order to have information about the real parameters values in tissue during 
patient’s treatment, the measurement should be conducted directly in tissues or in tissue 
mimicking materials. A large number of devoted tissue-mimicking materials (TMM) 
with specific and well-characterized physical properties have been studied and 
characterize during my work (see paragraph 2.5). Beside acoustic power and pressure, 
another important parameter, in particular for the clinical use, to provide a complete 
characterization of an ultrasonic field is the temperature increase in the focus region of 
the transducer in specified medium. 
In this chapter, materials and methods for the characterization of ultrasonic transducers 
is described, while in the next chapter results obtained are shown. 
 
2.2     ULTRASOUND TRANSDUCERS 
 
Three Ultrasound-transducers are measured and compared:  
- TRANSDUCER 1 (PTB-256, plane-wave transducer): 1.8611 MHz       
   (Fundamental) and 6.2664 MHz (3rd Harmonic);  
- TRANSDUCER 2 (Sonic Concepts SU-102, HIFU transducer):3.5 MHz     
   (Fundamental);  
- TRANSDUCER 3 (Sonic Concepts H-106-MR, HIFU transducer):2.0 MHz    
   (Fundamental) and 6.38 MHz (3rd Harmonic)  
 
The transducer’s electric input for the excitation voltage is equipped with a (female or 
male) BNC connector. An electrical matching network, for HIFU transducers, is 
included into the transducer or is provided within an external box. The matching 
network ensures an electrical impedance close to 50 Ω at the designated working 
frequency (nominal frequency).  
In the following forms the main information about the transducers are reported. 
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TRANSDUCER 1 
Name:                    TRASDU1  
Manufacturer:        PTB  
Type:         Piston-like  
Model:        n.a.  
S.N.:        256  
Nominal frequency:                      6.8611 MHz (fundamental) 6.2664 MHz     
                                                     (3rd harmonic)  
Radius of curvature:     n.a.  
Aperture/active diameter:    2.54 mm  
Thru opening:      n.a.  
Max. pulsed power level:     50 W (@ 6.8611 MHz)  
Matching network (50 Ohm):     NO  
Max. dimensions (Ø / height):    30.0 mm / 87.0 mm  
Other:                                           Environment: submersible in water (0.05    
                                                      m), 5°C t o 45°C  
r:                                          Connector:                                   BNC female on transducer  
 
 
 
Figure 2.1. Transducer 1, PTB 256, piston-like  
 
 
TRANSDUCER 2 
Name:      TRASDU2  
Manufacturer:     Sonic Concept  
Type:      HIFU  
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Model:      SU-102  
S.N.:      007  
Nominal frequency:    3.5 MHz (fundamental)  
Radius of curvature:    55.00 mm  
Aperture/active diameter:   35.00 mm  
Thru opening:     n.a.  
Max. pulsed power level:  150 W (@ 3.5 MHz)  
Matching network (50 Ohm):   Internal  
Max. dimensions (weight / height):  122.0 mm / 27.0 mm  
Other:      Environment: submmersible in water 
      (0.5 m), 0°C t o  60°C  
      Connector: BNC male on transducer 
 
 
 
Figure 2.2. Transducer 2, Sonic concept SU-102, hifu.  
 
TRANSDUCER 3  
 
Name:      TRASDU3  
Manufacturer:     Sonic Concept  
Type:      HIFU  
Model:      H-106-MRA  
S.N.:     003  
Nominal frequency:   2.0 MHz (fundamental) 6.38 MHz     
                                                               (3rd harmonic)  
Radius of curvature:   63.20 mm  
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Aperture/active diameter:  64.0 mm  
Thru opening:     n.a.  
Max. pulsed power level:   400 W (@ 2.0 MHz)  
Matching network (50 Ohm):   External  
Max. dimensions (Ø / height):  82.0 mm / 19.0 mm  
Other:      Environment: submmersible in water    
                                    (0.5 m), 0°C t o 60°C  
                        Connector: SMA male on transducer, SMA females on both ends of matching 
network  
 
The matching network will function correctly only if it is connected directly to the 
transducer, with no added cable length.  
 
 
Figure 2.3. Transducer 3, Sonic concept H-106-MRA, hifu.  
 
2.3  ULTRASONIC FIELD    
         CHARACTERIZATION: POWER  
 
Knowledge of the strength of the ultrasonic fields produced in many technical 
applications is of increasing importance, particularly with respect to quality assurance 
and patient safety in the field of medical ultrasonics. The time-average ultrasonic power 
emitted by a transducer is one of the key values to be taken into account. Furthermore, 
according to both fundamental IEC standards dealing with the acoustic output of 
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medical ultrasonic devices, that of diagnostic devices (IEC 61157) and that of 
therapeutic devices (IEC 61689), the ultrasonic power is to be measured and declare. 
The most common approach to total emitted power measurement, is based on radiation 
force balance method. When an ultrasonic beam encounter a target, the momentum 
transported by the wave is transferred to it.  
The mass variation , for normal incidence, is proportional to the ultrasonic power 
emitted by the source according to the equation: 
 
                                                     
c
WhF =                                                        (1) 
       
Where F is the time averaged force experienced by the target, W is the acoustic power 
emitted by the source transducer, c is the speed of sound in the propagation medium 
used and h is a proportionality factor whose value, as we will see, depends on the kind 
of target used and on the model adopted in order to describe the real ultrasonic field.  
The international standard IEC 61161  acknowledges as the official method for 
determining the ultrasonic power, that based on the measurement of the radiation force 
by the use of a gravimetric balance.  
At INRIM, the measuring system for the determination of US power based on a 
commercial radiation force balance (RFB System) has been developed. However, the 
measurements of high ultrasonic power, emitted by an HIFU transducer, are critical 
using conventional radiation force balances (RFBs) [223], therefore a second system 
based on a submergible load cell (SLC system) for ultrasonic power from 15 W to 200 
W has been developed.  
 
2.3.1    RADIATION FORCE BALANCE (RFB)  
 
The measurement principle of the radiation force balance (RFB) is as follows: the 
ultrasonic beam to be measured is directed on to a target and the ultrasonic field exerts a 
force on the target that is connected to a gravimetric balance. The difference of the force 
on the target with and without ultrasound is measured from the apparent mass 
difference, Δm, of the target determined between the setting where no ultrasound is 
radiated and that where ultrasound is radiated. The force exerted by the ultrasound is so 
expressed as: 
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                                        gmF ⋅∆=                                                                    
(2) 
 
where F is the radiation force and g is the gravity acceleration.  Schematically a RFB 
set-up is composed by a few parts:  
•  a target that has to be perfectly absorbing or reflecting and large   
   enough as to intercept all the ultrasonic beam; 
•  a balance for measuring the radiation force exerted on the target; 
•  a connection system to ensure that the target is correctly joint to the    
    balance pan; 
• a water tank in which both the transducer and the target have to be  
   submerged so that the ultrasonic wave can propagate; 
• a support for the transducer to hold up the transducer ensuring its   
  right positioning and its dipping in the water tank. 
 
THE BALANCE  
The balance used is a “METTLER TOLEDO” model SAG 285. It is an electronic self 
compensating balance and has a resolution of 10 μg in the range 0-81 g and 100 μg in 
the range 81-210 g. Its sensor is covered by a rigid case and it can be remote controlled. 
The balance readings can be read on a digital display or can be acquired trough a 
software for a off line data analysis. Since the balance is really sensitive to vibrations, it 
has been posed on an anti-vibrating table. Furthermore the measurement system is 
covered by a transparent perspex box, whose aim is to insulate the system from the air 
turbulences which can be present in the laboratory. 
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Figure 2.4. The radiation force balance realized at INRiM, with a schematic 
representation of the system showing the main parts of the system.  
THE WATER TANK  
The water tank is a transparent, perspex made, vessel which inner volume is 3.13 l. It is 
put onto the rigid case of the balance sensor, but it is not in contact with the balance 
pan. The walls of the tank can be covered by some polyurethane rubber slab in order to 
avoid any ultrasonic waves reflection from the border. This care is always taken any 
time the reflecting target is used, while can be neglected when an absorbing target is 
adopted.  
THE TARGET SUPPORT 
The target support has a twofold function. It has to connect the target to the balance pan 
and to keep the target suspended into the water. A rigid, carbon fibre made, structure is 
used. It surround the water tank and it is put in contact with the balance pan. The choice 
of using carbon fibre has been taken for its very suitable physical properties as it is a 
very rigid material, so that just a negligible portion of the radiation force is lost due to 
the structure elasticity, and it is at the same time very light. It is really important 
because the balance automatically reduces its resolution when it is solicited with higher 
loads. So it is important that the whole structure is as light as possible in order to have 
the maximum resolution available for executing the measurement. A picture of this part 
of the support can be seen in Fig 2.5 (a). A second part of the target support is placed 
onto the former and allows to dip the target into the water. Two different structures are 
available (Figure 2.5(b) and (c).  
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Figure 2.5. The target support in its three main parts. (a) The rigid structure punt on 
the sensitive element of the balance, (b) the target support used for absorbing target 
and low ultrasonic power is made of two disks connected with three very thin wires, 
(c) the target support used for high power measurements and with the reflecting target: 
the same two disks are joint together by three rigid rods. 
 
THE TRANSDUCER SUPPORT  
The transducer is held up by a support which allows its full movement. The transducer 
can be tilted along two axes in order to make its surface parallel to the target surface, so 
that orthogonal incidence is ensured. By means of two micrometric screws it is possible 
also to move the source transducer parallel to the target so that it could be aligned with 
the target axis. This is of primary importance when a reflecting target is used. Finally, 
the vertical movement of the target is accounted by a remote controlled stepper motor 
(NEWPORT ESP300) which allows a linear movement up to 10 cm with a controlled 
speed and with a spatial resolution of 10 nm. The motion controller allows to change the 
distance between the transducer and the target.  
 
THE TARGETS  
Two kinds of target (Figure 2.6) are available for the ultrasonic power measurement: an 
absorbing target and convex cone reflecting target. 
59 
 
 
Figure 2.6. The two targets used: the polyurethane rubber absorbing target, on the left, 
and the conical metallic reflecting target, on the right. 
 
The absorbing target is a disk, with a diameter of 8 cm, of a two layer polyurethane 
rubber. The target is composed of two layers with different acoustic properties. The 
upper one is a coupling layer, it has an acoustic impedance near to that of water and 
allows a good propagation of the ultrasonic radiation from the water to the absorbing 
layer. The second layer is the real absorber. Hollow microspheres are dispersed into the 
rubber so that the wave scattering is enhanced. The final result is a longer free path of 
the ultrasonic radiation inside the target with a significant increase in the absorption 
capability of the target. For ultrasonic power level higher than 1 W a reflecting target 
is used. It is a hollow convex cone with a base diameter of 8 cm and an height of 4 cm. 
Its lateral surface is made of a thin layer of Nickel, which is pasted over a plastic base. 
It is full of air in its interior, so that the very high acoustic impedance mismatch 
between water and metal-air interface ensure a complete reflection of the incident 
ultrasonic wave.  
 
2.3.2    SUBMERSIBLE LOAD CELL (SLC) 
 
The measurements of high ultrasonic power, emitted by an HIFU transducer, are critical 
using conventional radiation force balances (RFBs) [226]. At high power levels the 
absorbing targets are heated and pose problems of generation of drift in the signal due to 
thermal expansion and furthermore the target could be severely damaged. The reflecting 
target solves heating problems, but the rather large radiation forces and the imperfect 
centring may cause significant transverse components that cause unwanted movements 
of the target and disturbance of the force readout, and the correction factor for strong 
focusing fields is not yet solved.  
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The problems outlined above required the construction of a device with the following 
characteristics: 
(1) Faster dynamic response, in order to be able to use shorter sinusoidal wave      
   trains, for heating problems reduction.  
(2) A solid fastening of the target to the sensing device, which is compliant     
   only on then vertical axis and very rigid in the directions normal to this   
   axis, as is typical of this kind of load cells. 
(3) Positioning on the bottom of the tank, so that the transducer mounting is  
   simplified; especially for HIFU it may be cumbersome providing an   
   adaptor for mounting the transducer on the bottom of the tank. 
 
The device chosen for this purpose is a submersible load cell (SLC), with full scale 
sensitivity of 50 g. The target is fastened to the SLC by means of a screw. This device 
fulfils requirements (1) to (3), but there are some drawbacks: 
(1) The minimum measurable power is of the order of 1W, with a 1 s wave train, U 
= 10%. 
(2)   The cell has to be calibrated in situ by standard calibrated weights to provide 
traceability to the mass quantity. A balance instead may be more conveniently 
calibrated in an accredited laboratory. 
An additional advantage is that there are no effects due to surface tension, as all the 
measuring system is under water.  
 
MEASUREMENT SET-UP 
The device used for the ultrasonic power measurement is based on the RFB method, 
using a submersible load cell. 
The ultrasonic power is determined from the measurement of the force exerted on a 
target by the field generated by an ultrasonic source. The absorbing target (diameter 150 
mm) is connected to the load cell (Honeywell model 31) which measures mass variation 
due to the ultrasonic field when the source is alternately switched on and off. The signal 
produced by the load cell is conditioned by a strain gauge amplifier (Sensotec model 
UV-10) and then measured by a nanovoltmeter (Agilent 34420A). The load cell is 
screwed on the bottom of a tank with a volume of approximately 15 l. The short 
duration of the tone burst (t ≤ 1 s) used for the measurement of the ultrasonic power, 
Pout, allows the use of the absorbing target even for high values (P ≤ 200 W) of 
61 
 
ultrasonic power. The RMS voltage, Uin, of the transducer driving signal is determined, 
simultaneously with the mass variation, by means of a Rohde&Schwarz model URE-3 
voltmeter. The electroacoustic radiation conductance G is calculated according to the 
relation 
 
                                  22 )( −− ⋅∆⋅⋅== ininout UMTugUPG                        (3) 
 
where g is the gravity acceleration evaluated in the INRiM laboratory, u(T ) is the speed 
of sound in water and ΔM is the apparent mass variation induced by the ultrasound field. 
In figure 2.7 the measurement apparatus is shown, with a detail of load cell and target in 
the upper right box. 
 
 
Figure 2.7.  SLC measurement apparatus, with a detail of load cell and target in the 
upper right box. 
 
THE TARGET 
The target is rigidly connected to the sensing element of the load cell with a screw. The 
two parts who make the target are shown in the lower box of figure 2.8, in the upper 
box the assembled target is presented. 
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Figure 2.8.  Target for SLC measurement apparatus. 
 
The target is made of two polyurethane rubber discs and connected by means of a 
mechanical coupler. The lower disc is 14 mm thick and has a diameter of 80 mm, the 
upper one is 10 mm thick and its diameter is 120 mm. The underlying layer (blue 
rubber, stamped in order to form small pyramids) is the part really responsible for the 
ultrasonic field absorption. The upper disc is made only of blue rubber pyramids 
without transparent layer. 
The absorbing element surface is composed of a large number of pyramids; they serve 
to break the ultrasonic wave front favouring the ultrasonic radiation scattering and 
absorption.  
 
MEASUREMENT PROCEDURE/TECHNIQUE 
In analogy with the measurement system based on a commercial balance, for the SLC 
system a calibration (during measurement conditions) is necessary before the ultrasound 
power measurements. Calibration of the cell is obtained by measuring the output 
voltage of the cell when charged with calibrated weights and calculating the linear 
regression curve relating weight and output signal [226]. This procedure allows us to 
calculate the force induced by the ultrasonic field, by measuring the variation of the 
output voltage of the cell during the insonation time. The computer program for the 
management and the control of the parameters influencing the measurement, such as 
water temperature, distance between transducer and target, power amplifier output level 
etc, is basically the same program used for the RFB system. The computer program 
controls the devices that carry out the measurement (generators, transducer movement) 
and acquires the values of signals sent to the transducer, of the force on the target and 
the values of the environmental quantities that influence the calculation of the power. 
The software program has been derived from the one that controls the RFB 
measurements.  
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2.4    ULTRASOUNIC FIELD 
CHARACTERIZATION: PRESSURE 
 
Ultrasonic power is surely a parameter of interest in transducers characterization, but 
the information it gives is not complete. Some other parameters have to be measured if 
a fully satisfying description of the ultrasonic field produced by a transducer is desired. 
Moreover, the only ultrasonic output power doesn’t give enough information about how 
likely potentially harmful physical effects are to be produced and where the ultrasound 
field propagates in biological tissues. For these reasons a set of parameters has been 
defined whose values are able to give information about the shape and the time 
variation of the ultrasonic beam as well as about the spatial and temporal localization of 
the highest acoustic pressure and intensity levels. The reference standard for these 
measurements is the international standard IEC 6127-1 [227]. Since from the purpose of 
the standard it appears that the key instrument of the whole measurement system is the 
hydrophone, the basic field parameter is the acoustic pressure, as it is the quantity that 
can be directly measured by the hydrophone. All the other parameters are calculated 
from the acquired pressure value.  
 
2.4.1    HYDROPHONES 
 
The hydrophone is the device that allows the ultrasonic pressure measurement, it can be 
considered as the equivalent of microphones for the ultrasonic frequencies, are tools 
able to generate an electrical current proportional to the acoustic pressure incident on 
their sensitive elements. Due to the wide range of medical applications of ultrasounds, 
and to the subsequent wide range of ultrasonic fields to be measured, it is not possible to 
have a single instrument suitable for each measurement. At INRIM laboratories, a set of 
hydrophones with different characteristics and different applications fields are available. 
Four main kinds of hydrophones are present: some needle type of different sizes and 
sensitivity, one membrane Hydrophone, a special HIFU addicted needle type and a 
Fiber Optic Probe Hydrophone (FOPH). The main properties of each hydrophone are 
summarized in Table 2.1.  
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Hydrophone Technical characteristics 
Brand Type 
Size 
/ mm 
Sensibility 
/ mV/MPa 
Bandwith 
/MHz 
Pressure 
Range 
/MPa 
Impedance 
PA PVFD needle 0.5 400 1-20 0.05-20 50 Ω 
PA PVFD needle 1.0 800 1-20 0.05-20 50 Ω 
Force PVFD needle 0.5 250 0.5-20 0-100 50 Ω 
Onda 
PVFD 
membrane 
0.5 250 0.5-45 0-100 50 Ω 
Onda 
PVFD needle 
for HIFU 
0.4 70 1-10 10-500 50 Ω 
Onda PVDF needle 0.4 170 1-10 10-100 50 Ω 
RP 
Acoustic 
Fiber optic 0.1 2 1-100 -60-400 50 Ω 
 
Table 2.1. Main characteristics of the hydrophones present at INRiM. 
 
As can be seen from the table, the hydrophones adopted are different for kind and size, 
which determine different sensitivity and consequently different conditions for their use. 
The fiber optic hydrophone is the hydrophone mainly used in this work, for this reason 
in the following paragraph a more detailed description of this instrument is provided. 
 
FIBER OPTIC PROBE HYDROPHONE (FOPH)  
The fiber optic probe hydrophone is a novel instrument for the absolute measurement of 
short time high positive and negative pressures in liquids. The sensitive element for 
measuring pressure is the tip of an optical glass fiber. The pressure signal is detected by 
the changing light reflection at the glass fiber/water interface caused by the 
pressure/density influence on the refractive index of water. The most important 
advantages of FOPH, in comparison to piezoelectric hydrophone are the following:  
 
- Simple and quick calibration without reference standard. Because of the self 
calibration the fiber optic probe hydrophone can be used as a measuring standard 
itself. 
- High spatial resolution (100 µm) 
- Bandwith 0-100 MHz 
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- Theoretical bandwith 0-30 GHz 
- Because of the hydrophone’s small diameter, a directively dependence of the 
sensitivity can only be noticed for frequencies higher than 1MHz 
- Complete and repeteable reproduction of positive and negative pressure 
amplitudes. 
- A damaged glass fiber tip can easily be repaired within a few minutes. 
- Because of the optic principle of measurement, there is an extreme 
insensitiveness to electromagnetic interference. 
- No aging, because neither electrical lines none piezoelectric material have 
contact with water. 
 
Numerous possible application exist in the medical field, in general ultrasonic 
calibration and measurement as well as in the characterization of technical ultrasonic 
equipment, in particular using this instrument is possible to provide measurement in the 
focus and the extended wave field of medical instruments for ultrasound cancer therapy 
(HIFU) and measurement in the focus and the extended wave field of ultrasonic 
instrument for medical diagnosis (RM) [228]. 
 
 
 
Figure 2.9. Main device and photodetector of the Fiber Optic Probe Hydrophone 
FOPH 2000  
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OPERATION PRINCIPLE 
 
 
 
Figure 2.10. Operation principle of the Fiber Optic Probe Hydrophone 
 
Pressure waves in liquids cause changes mass density of the medium which modulate 
the optical refractive index. With the Fiber Optic Probe Hydrophone the change of the 
refractive index can be measured by the light reflection at the tip of a glass fiber 
submerged in a liquid. Laser light (λ=808 nm) is coupled into the rear end of the glass 
fiber and is partly transmitted through and partly reflected at the fiber tip (figure 2.7). 
The ultrasonic field causes a variation of the refractive index, so the intensity of the 
reflected light is modulated. The reflected light is coupled by an optical fiber coupler to 
a fast semiconductor-photodetector and is converted to an electric signal which 
reproduces, after being amplified, the value of acoustic pressure incident on the fiber on 
the oscilloscope screen. With respect to the stationary light reflection signal, the simple 
calibration instruction allows the determination of the relation between pressure and 
photodiode signal. In addition to the properties set out above, optical hydrophones have 
important advantages compared to a conventional hydrophone: the calibration is carried 
out in a simple and fast way; a damaged glass fiber tip can easily be repaired, in 
addition to being a tool completely compatible with MRI. Due to the fact that the 
refractive index of a liquid depends on the pressure and temperature, the hydrophone 
not only can be used as pressure measuring instrument (paragraph 2.4.4), but it can also 
be used as temperature measuring instrument as it will be explained more in detail in 
paragraph 2.4.4. 
Before starting a measurement, the quality of the glass fiber end surface must be 
checked as explained in paragraph 2.4.3. 
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2.4.2     SCANNING TANK SYSTEM 
 
 
Figure 2.11. Schematic diagram of the ultrasound measurement system present at 
INRiM. 
 
A typical measurement system for pressure field characterization (Fig 2.11) is 
composed by different parts that are described below. 
  
HYDROPHONES 
It is useful to have more than one instrument so that different hydrophones could be 
used for application and pressure range in which they are more suitable. If low 
sensitivity hydrophones are used, or if the ultrasonic pressure level to be measured is 
very low, it is possible to use special preamplifier to increase the electrical signal 
generated by the hydrophone (only for traditional needle hydrophones). 
 
WATER TANK  
It is where the measurement takes place. The tank should be large enough to allows a 
good movement range for the hydrophone and the possibility to perform free field 
measurement. As the basin walls can be sources of reflected waves, it could be useful to 
cover them with absorbing lining, especially when continuous waves devices are 
characterized.  
The water tank in which the measurements take place is a Perspex (plexiglass) made 
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tank with 12 mm thick transparent walls. The dimensions of the basin are 1.0 x 0.5 x 0.5 
m. It is usually filled with 200 l of distilled and deionised water. The water tank is 
connected to the MECS (Measurement Environment Conditioning System) water 
conditioner. This system provides microprocessor-controlled heating, degassing, UV 
filtration and de-ionization functions to maintain optimal water cleanliness and to allow 
repeatable measurements. 
 
POSITIONING SYTSTEM 
This part of the system is mainly concerned with the movement of the hydrophone 
within the measurement tank. A four legs frame made by aluminium is mounted around 
the water tank and support the motion system. This is composed by three linear motion 
stages for controlling the hydrophone movement along the three orthogonal axes. Each 
linear actuator is based on a 2.5 mm pitch ball screw that is driven by a step motor 
giving a positional resolution of 6.0 μm per step. As a safety precaution all drivers have 
two limit switches that can be used to prevent the actuator from moving beyond 
particular user definable positions. These switches are usually used to prevent the 
hydrophone from being driven into the walls of the tank, or in obstacles placed within 
the tank such as the transducer under measurement. Each motor is fitted with a rotary 
encoder that provides feedback to the drive controller about how far the drive has 
actually moved.  
When the encoders are activated their output is feedback to the drive controller, so that, 
if there is a difference between the requested distance to be moved by the actuator and 
the real movement, the drive controller calculates the necessary correction and 
automatically moves the drive as appropriate. Each motion actuator has its own 
dedicated drive controller which deals with all aspects of motion control. In addition to 
supplying power to the steppers motors, they also implement the actions required by the 
limit or emergency stop switches, as well as administering position maintenance 
instructions when the system is used with drive encoders. The stepper motor drive 
control unit communicates with the Host PC via RS-232 interface.  
 
TRANSDUCER HOLDER  
The support for the transducer has to allow a rotation of the transducer in order to align 
the ultrasonic field axis with the direction of maximum sensitivity of the hydrophone. 
The transducer to be tested is mounted on a rigid support partially or totally immersed 
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in water and connected to a tilter that allows to rotate the source around two axis. This 
is necessary because, as will be shown in the measurement procedure description, the 
possibility of tilting the transducer is essential for a correct alignment of the field axis 
with the hydrophone 
 
SIGNAL ACQUISITION SYSTEM 
The signal acquisition system consists on a digital oscilloscope (LeCroy Waverunner 
6000A), to acquire the electrical signal from the output of the hydrophone and a PC for 
remote controlling of the position and acquisition systems and for the data analysis. The 
time resolution and the sampling frequency of the instrument have to be high enough to 
allow a good sampling of the electrical signal at the frequencies of the device to be 
characterised.  
 
HOST PC AND MEASUREMENT SOFTWARE  
A personal computer runs the software which is the heart of the measurement system. 
The PC uses a RS-232 communication card to interface with the stepper motor drive 
control unit, it communicates with the digital storage oscilloscope via an Ethernet 
(RJ45) connector ad it is able to control any other instrument (such as a function 
generator for generating arbitrary waveform with transducers, or a digital multimeter for 
temperature control) via a GPIB port. The ultrasonic measurement system (UMS) is 
controlled from the host PC by means of dedicated LabWIEW™ based software that 
controls all aspects of the operation of the system including:  
•   Initialization of communication interfaces via the LECroy VISA passport for 
communication with the DSO;  
•   Motion of the stepper motors actuators;  
•   Waveform acquisition by the oscilloscope and subsequent transfer of data to 
the host PC;  
•    Archival and post processing of acquired data.  
 
The software has been extended and improved during thesis work, in particular, has 
been implemented to what concern: 
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• The hydrophone automatic alignment in the point in which the electrical signal 
at the hydrophone output is maximum. The hydrophone is automatically 
positioned by the software in that point;  
• The run time visualization of the point that is being measured during a planar 
or a linear scan;   
• The automatic calculation of α and β parameters in order to check the quality 
of the glass fiber tip when the fiber optic probe hydrophone is used; 
• The waveform acquisition by the oscilloscope and the subsequent data transfer 
to the PC in presence of a fiber optic hydrophone;  
• Pressure and temperature calculation has been implemented in the main 
program when a fiber optic hydrophone is used;  
 
So by the software the operator can control any part of the measurement procedure. 
Trough the software it is possible to set both the direction of the scan, along one axis or 
over a planar surface, and the spatial resolution of the scan. Then it is possible to set 
some data acquisition parameters such as the number of averages to be done by the 
oscilloscope or to specify the hydrophone used and to load the proper calibration curve 
for the instruments so that the right conversion from voltage to pressure units can be 
done. Finally it is possible to define what acoustic parameters have to be measured by 
the system. During linear and planar scan the software controls the waveforms 
acquisition by the DSO. For each measurement point the corresponding electrical 
waveform acquired by the oscilloscope is stored in a proper file for post-processing 
elaboration.  
 
2.4.3  MEASUREMENT PROCEDURE 
MEASUREMENT SYSTEM PRAPARATION  
The set-up preparation requires the water thank to be filled with distilled and degassed 
water. Before starting the measurement both the transducer and the hydrophone have to 
be immersed in water. On insertion of both the ultrasonic transducer and the 
hydrophone in the water, it can often happen that some air bubbles appears on the active 
faces of both the devices. Such bubbles are removed before the beginning of the 
measurement by means of a soft brush or by gentle water jet. Periodical checks are also 
conducted during the measurement itself in order to remove every accidental bubble 
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which can significantly modify the source emission or the sensitivity of the hydrophone. 
Finally the hydrophones used at our laboratories are recommended to be immersed in 
water some minutes before the measurement in order to obtain good temperature 
equilibrium and a full wetting of the active element surface. 
 
1. Check of the fiber optic probe hydrophone quality  
    These point is done only if the measurement are conducted using a fiber optic probe 
hydrophone, FOPH system, if a conventional hydrophone is used to perform the 
measure, this point is unnecessary. 
1. Select on the oscilloscope: DC, 1MΩ input. Set the bandwidth of the 
measurements to 2MHz. Set the photodetector ON. 
2. Read the DC-photovoltage Vb on the oscilloscope when the laser is 
off (Vb should be in the range of 50 mV to 150 mV) 
3. Switch on the laser , wait at least 5 minutes until the laser is 
stabilized 
4. Make sure that the fiber tip is in the water 
5. Set the main device in operation. Turn the mode knob in the position: 
MEASUREMENTS. 
6. Read the data of the DC- photovoltage Vwater on the oscilloscope. 
Vwater should be in the range of 500 mV to 1000 mV.  
7. Calculate the value of the DC- photovoltage V0 = VW – VB 
8. Switch the input of the oscilloscope to AC 1 MΩ. 
9. Calculate the parameters α and β, which are respectively the internal 
light scattering factor and the quality of the glass fiber tip, by using 
the following formula: 
 
                              )/()( BairBwater VVVV −−=β                              (4) 
 
Where: VB: DC-photovoltage when the laser is off 
              VWater: DC-photovoltage when the laser is on and the   
                         fiber tip is in water                                   
              Vair: DC-photovoltage when the laser is on and the   
                     fiber tip is in air 
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If β < 0.12: the glass fiber end surface is of good quality. It is 
possible to start with the measurement. 
 If β > 0.12: the glass fiber end surface is damage or dirty. The loss 
of stray light is too high end the signal to noise ratio is decreasing. In 
this case a new fiber end surface should be prepared by cleaving the 
fiber. 
                                                                    
                                                                                                      (5) 
  
Where:      VB: DC-photovoltage when the laser is off 
              Voil: DC-photovoltage when the laser is on and the fiber 
tip is in the Index-adjusted liquid. 
 
Values of  α< 0.3 can be tolerated. If α is higher, it is necessary to 
check the fiber optic installation. 
 
Inserting in a program, the parameters VB, VWater, Vair and Voil, the parameters α  and β 
are calculated automatically. If the values of α and β can be tolerated, it is possible to 
perform pressure or temperature measurement.  
 
2. Alignment of the ultrasonic transducer and the hydrophone  
The third step of the measurement procedures is the alignment of the transducer with 
the hydrophone. The goal of the step is to make the ultrasonic beam axis to coincide 
with the axis of the hydrophone. The method usually followed requires a recursive 
procedure based on the hydrophone signal maximization which brings to the alignment 
by subsequent refinements. The alignment procedure starts with the hydrophone at a 
quite long distance from the source. The transducer is then tilted until the electrical 
signal at the hydrophone output is maximized (a). Then the hydrophone is moved 
toward the source. When they are quite near the hydrophone is moved in a plane 
orthogonal to the direction of motion and placed in the position which maximizes its 
output (b). Once again the two objects are put at a long distance and the whole 
procedure is repeated. This process is then repeated several times, until no 
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remaximisation of the signal is required when moving from one distance to the other. 
The number of iterations required can change significantly, but it is usually reduced 
when the distance between the two positions is set as large as possible. Once the two 
instruments are well aligned the preliminary preparation is concluded and the 
measurement itself can begin.  
 
Figure 2.12. Procedure for aligning the transducer and the hydrophone. 
 
3. Spatial scanning of the ultrasonic field.  
Once the source and the receiver have been well aligned and parameters α and β can be 
tolerated if a fiber optic is used, the characterization itself can take place. Before starting 
the measurement, the hydrophone has to be set in the point of main interest (usually the 
point in which the acoustic waveform is maximized). Spatial scans, both linear and 
planar, are conducted in order to find the point of maximum electrical signal at the 
hydrophone output. For this purpose, the program has been realized, as described 
before. Checked the signal maximization, it is possible to go on with the planar scans 
which are needed for the ultrasonic beam characterization. A really complete 
description of the ultrasonic field would require a three dimensional scan with an 
adequate spatial resolution of the measurement point over a volume large enough to 
contain the entire acoustic beam generated by the source. Obviously it cannot be done in 
routine measurements as it would take a too long time. For this reason the real scanning 
procedure tries to give a good compromise between the requirements for as complete as 
possible information and short time consumption. Three planes are of greatest interest, 
it is to say the axial planes and the transversal plane where the signal acquired reaches 
its maximum. The size and spatial resolution of the planar scans have to be chosen 
taking in mind some elements. The optimal distance between adjacent measurement 
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points is that in which the points are at a distance equal to the hydrophone active 
element radius. Taking nearer points would be of little practical utility, but would 
increase significantly the scan duration. Once the spatial resolution of the planar scan 
has been set, the number of points to be measured would be determined only by the size 
of the area that will be scanned. This area has to be large enough to give the searched 
information about the beam shape, but little enough not to take a too long scan time. 
The aim of the planar scans are the determination of the beam area and the evaluation of 
the beam shape. Concerning the length of the scanning, it ideally should be long enough 
to put in evidence the level increase toward the focus and the intensity decrease beyond 
the focus.  
During the scanning procedure, the hydrophone is moved at any point of the 
measurement array, and for each point the digital oscilloscope acquires the electrical 
signal from the hydrophone, or, if it has been set so, the average of a number of signals 
taken in the same condition, which can significantly reduce the random noise 
superimposed to the acoustical origin signal. Each electrical waveform is then stored as 
a file on the host PC.  
 
Therefore any planar or linear scans don’t give information about the pressure field if 
they are not processed by the software and if the electrical signals are not converted in 
pressure waveforms. The relationship between the acoustic pressure stimulus and the 
voltage response is different using a PVDF hydrophone or a fiber optic probe 
hydrophone. In the following paragraph the measurements procedures for the fiber optic 
probe hydrophone and for a PVDF hydrophone are described. 
 
2.4.4.  PRESSURE CALCULATION: FIBER OPTIC PROBE   
 HYDROPHONE 
 
The equation to perform sound pressure measurement with the FOPH hydrophone is the 
following: 
                                                                                                   
 
                                                                                                            [MPa]      (6)        
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Where ΔV is the voltage variation, V0 is the DC- photovoltage and α is the internal light 
scattering factor of the glass fiber tip. 
 
This equation is implemented in a program. During the scanning procedure, the 
hydrophone is moved at any point of the measurement array, and for each point the 
digital oscilloscope acquires the signal from the hydrophone, or, if it has been set so, the 
average of a number of signals taken in the same condition. Each waveform is then 
stored as a file on the host PC.  
The previous equation is given to the manufacturer of the hydrophone, and is based on 
the fact that between the pressure and the electric photodetector signal is determinate by 
the acoustic-optical properties of water and the DC- photodetector voltage which 
depends on the laser power. A change of pressure in water results in a change of density 
and thereby in a change of the refractive index and the reflection factor at the glass 
fiber/water interface. The signal of the hydrophone is the time dependent intensity of 
the laser light reflected at the fiber tip. The photodetector signal and the reflection 
coefficient are related as follows: 
                                                                                                                       
                                                                                                                            (7) 
   
Where:  R0: light reflection at the glass fiber/water interface; 
  ΔR: reflection coefficient variation; 
  α: internal light scattering factor of the fiber optic system 
  V0: reference voltage  V0 = VW – VB; 
  ΔV: voltage variation;  
 
2.4.5.  PRESSURE CALCULATION: PVDF HYDROPHONE 
 
For a PVDF hydrophone, the relationship between the acoustic pressure stimulus and 
the voltage response, in general, could be  not simply linear, but it is frequency 
dependent. The voltage waveform ν(t) from the hydrophone, acquired through the 
digital oscilloscope and stored in the PC, is converted in a pressure signal, p(t), trough a 
deconvolution, using the sensitivity curve of the hydrophone ML(f) corrected for the 
electrical load at the hydrophone output:  
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Mc is the end of the cable open circuit sensitivity, CH is the corrective term accounts for 
the cable capacitance of the hydrophone, CC is the capacitance of the right angle 
connection used to connect the pre-amplifier and CA is the capacitance of the 
amplifier.  
 
The frequency response of the hydrophone, ML(f), is obtained from its calibration 
certificate. The calibration curve for each hydrophone needs to be loaded on PC before 
the post processing elaboration since it is a necessary step to the right conversion. This 
approach has been shown to provide a more accurate voltage-to-pressure conversion 
process and has so been included in the IEC Hydrophone Use standards. Converting 
voltage signals to pressure, it is possible to obtain the results of the acoustic field spatial 
scans in terms of acoustic pressure. From the pressure waveforms, the peak to peak 
acoustic pressure and the pulse pressure integral are also calculated and stored on the 
PC.  
The peak to peak acoustic pressure is defined as: 
           
                                                                    (10) 
 
Where    )](max[ tppc ∆=                              (11)                                                                                     
and     )](min[ tppc ∆=                                 (12) 
 
are respectively the maximum and the minimum value assumed by the acoustic pressure 
during the acquisition period.  
The pulse pressure squared integral, pi, is defined as the time integral of the square of 
the instantaneous acoustic pressure in the pulse, integrated over the whole of the pulse.: 
                                                                                                                                   (13) 
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Such an equation assumes that p(t) is a continuous function of the time, but in the real 
case what is done is digitising the signal, so that, the acoustic pressure is better 
represented by a function of the discrete time . For such a function the equivalent to the 
above integral is the sum: 
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where, f, is the sampling frequency and N is the number of the acquired samples.  
From the pressure maps it is also possible to calculate spatial average parameters that 
give some information about the energy concentrated by the ultrasonic source over the 
whole area of interest. Many parameters can be defined just averaging the pressure 
parameters over all the spatial points above a requested threshold, but what is usually 
required by the main safety standards, is the spatial-average-temporal-average intensity 
(ISATA). It can be calculated from the pulse pressure squared integral as: 
 
         
 counted points ofmumber  Total
(maximum) p 0.25 > p which points allfor  p iii∑=
c
PRRI sata ρ
              (15) 
 
Where PRR is the pulse repetition rate, which is the inverse of the time interval between 
two identical pulses, and cρ is the acoustic impedance of the propagation medium. This 
coefficient is due to the conversion from pressure to intensity and assumes a plane wave 
approximation. 
 
2.5     ULTRASONIC FIELD       
          CHARACTERIZATION: TEMPERATURE 
 
Despite the fact that the HIFU are widely used in the therapeutic applications 
there is poor knowledge regarding the interaction of the ultrasonic beam with the 
tissues and the possible consequent side effects. In order to fully understand the 
effect of therapeutic focused ultrasound in tissue, it is necessary to measure 
temperature rises. While non-invasive measurement using, for example, MRgFUS 
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and ultrasound techniques is preferable clinically and is free from artefact of 
implantable devices, these cannot always provide sufficient spatial, temporal and 
thermal resolution and, in the case of MRgFUS, is costly and not widely available. 
Consequently, an alternative approach is to measure the temperature field through 
sensors placed in tissue simulators. With this aim, a fiber optic hydrophone and 
some thermocouples are used as temperature measurement instruments.  
 
2.5.1    TEMPERATURE MEASUREMENT: FIBER OPTIC  
            PROBE HYDROPHONE  
 
In paragraph 2.4.4, the pressure measurement method using a FOPH is described. 
Due to the fact that the refractive index of water depends on pressure and 
temperature, it can also be used as temperature measuring instrument with high 
spatial and high temporal resolution. To perform temperature measurements is 
necessary to use the following procedure: 
- Prepare the hydrophone (see paragraph 2.4.3) for the measurement and 
connected the fiber holder to the positioning system; 
- Measure the initial water temperature T0 with a conventional thermometer; 
- Select the following setting on the oscilloscope: DC, 1MΩ input. Set the 
photodetector in operation; 
- Set the bandwith of the measurements to 2MHz;  
- Read the DC-photovoltage Vb on the oscilloscope when the laser is off (Vb 
should be in the range of 50 mV to 150 mV); 
- Swich on the laser, wait at least 5 minutes until the laser is stabilized; 
- Read the data on the DC- photovoltage Vwater on the oscilloscope; 
 
The values Vb and Vwater are inserted on the labwiev program, after that the 
measure is possible. The temperature is calculated with the relation: 
 
 
                                                                                                                            (16) 
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where:           T:      water temperature in °C; 
                 T0:     water initial temperature °C; 
                V0:     DC photodetector signal at atmospheric pressure in V 
                 V∆ :  Change of the photodetector signal in V 
                  α:       internal light scattering factor of the fiber optic system. 
The equation is valid in the water temperature range 5°C - 95°C. 
 
2.5.2 TEMPERATURE MEASUREMENT: THERMOCOUPLES  
 
Thermocouples consist of two wires of different metals connected at one end to form a 
junction. The principle is generally attributed to Seebeck (1821), who demonstrated that 
an electromotive force (e.m.f.) is generated when such a junction is placed in an 
environment at a temperature that is different to that at the free ends. Thermocouples are 
often the method of choice for temperature measurement [230-231]. They consist of two 
wires, generally between 12 and 50 mm in diameter, soldered or spot welded together to 
form a junction or multiple junctions. Apart from the practical difficulties of inserting 
the thin wires into tissue, the use of metal thermocouples introduces two main problems. 
First, the thermal conductivity of metals is between 10 and 1000 times greater than soft 
tissue, leading to a ‘thermal conduction error’. Dickinson [231] found that this leads to 
averaging of the temperature over a region much larger than the junction size. This can 
be minimised by using small-diameter, low-thermal conductivity wire [231-232]. 
Second, the density of metal is between 3 and 10 times greater than that of soft tissue 
(e.g. copper is 8900 kgm-3). Consequently, as the ultrasound wave passes, there is 
relative movement of the tissue and the wire. Friction from this movement results in 
‘viscous heating’ in a thin region around the wire, and leads to an artificially high 
temperature measurement [233]. However, the contribution of viscous heating on 
measured temperature rises seems to reduce with decreasing thermocouple diameter and 
increasing beam width of the HIFU field [234].  
For these reasons, thermocouple is not the optimal instrument for temperature 
measurement, often they have been used to calibrate less invasive techniques. 
Thermocouples used during my work are type T, exploited to characterize the fiber 
optic probe hydrophone and inserted in tissue mimicking phantom to evaluate 
temperature increase in the focus of an HIFU transducer.  
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For this type of termocopule, a voltage-to-temperature conversion equation, is used to 
reduce the data from mV to temperature. The thermocouples are calibrated at INRIM 
laboratories and the corresponding equation in the range 0–400°C is a 6th order 
polynomial:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
T = d0 + d1E1 + d2E2 +d3E3+ d4E4 + d5E5 + d6E6 
The constants are as follows: 
               d1 = 2,592800 *10-2 
    d2 = -7,602961*10-7 
    d3 = 4,637791 *10-11 
    d4 = -2.165394 *10-15  
    d5 = 6,048144 *10-20 
    d6 = -7,293422 *10-25 
 
The maximum specified error for the temperature range is no more than ±0.025°C. This 
is a type B uncertainty. 
 
2.5.3 TEMPERATURE MEASUREMENT: IN SITU AT IEO 
 
An HIFU ultrasound guided system (USgFUS) is installed at Istituto Oncologico 
Europero (IEO) of Milan. The USgFUS system produces and focuses high intensity 
ultrasounds by a single-element parabolic transducer, constituted by a PZT piezoelectric 
ceramic material with fixed focal length (160mm) that works at 1 MHz and can reach 
total power outputs between 70 and 400 W. The geometrical focal spot is about 1mm x 
5 mm. However, the dimensions of the ablations induced in tissues highly depend on 
the intensities reached in the focus, which can be around 10 kW/cm2, and sonication 
exposure times, usually around 2-4 seconds for typical treatments. The imaging 
transducer with frequency of 3.5/5.0 MHz is mounted at the centre of the combined 
treatment head to guide the localization of target tissue and to monitor the therapeutic 
effects in real-time. The combined treatment head is placed within a water reservoir that 
is filled with circulating degassed water. In figure 2.13 a photo with a schematic 
description of the JC- Haifu components installed at IEO is given. 
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Figure 2.13. Scheme of USgFUS at IEO. 
A cylindrical polyacrylamide gel phantom (60 mm radius, 40 mm height) was prepared 
at INRIM in order to reproduce soft tissue behaviour (1023±5 g/cm density, 1550±23 
m/s sound velocity, 0.067 dB/cm attenuation coefficient) (see paragraph 2.6.2). Needle 
thermocouples, inserted in the phantom, were used to evaluate temperature increase 
(∆T) at typical clinical settings (power outputs of 80W, 150W, 300W, 400W and 
sonication times of 3 s) inside the focus and at 5 mm out of it. 
 
2.6     ULTRASONIC FIELD       
         CHARACTERIZATION: TISSUE MIMIKING      
         MATERIALS 
 
The characterization of ultrasonic fields generated in water by transducers as provided 
by national and international standards is surely a fundamental tool for the control of 
device performance and for patient safety protection, but the information they give is 
not complete. As a matter of fact, they describe the morphology and intensity of the 
field, but not the effect induced by this field in real tissue. Some parameters have been 
defined, such as mechanical index or thermal index [229], in order to give indications 
about how intense these effects should be, but these parameters should be considered as 
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general indication and do not allow any quantitative estimation of the physical effect 
they refer to. As an example, it is not possible to estimate the real temperature rise 
generated by ultrasound exposure in tissue from the Thermal Index or the real presence 
of cavitation and the intensity of the effect from the Mechanical Index. A new approach 
is required, based on simulation of physical effects and the quantitative measure of them 
through in vitro measurements. HIFU dosimetry studies are usually performed on 
biological tissues, but this approach has two drawbacks: 1) tissues are opaque and 
development of coagulative lesions cannot be visually observed in real-time, and 2) the 
natural heterogeneous structure of tissue may complicate direct comparison with 
numerical models [235].Therefore, the issue is to realize new materials for simulation of 
acoustic properties of real tissue, new parameters which really refer to biophysical 
effects, and a robust methodology for measuring them. Many phantoms have been 
devised to mimic tissue, in particular for imaging applications [236], but the  
exploration of the high temperature and pressure regimes involved in HIFU exposures 
require a TMM with different properties. An ideal phantom for HIFU conditions has 
specific physical and acoustical requirements to match biological tissues. The material 
must have thermal properties similar to human tissues, but they also must simulate 
human tissues for impedance, density, acoustic absorption, non linearity parameters and 
thermal diffusivity.  In addition to the properties listed above, for real-time visual 
observation of HIFU-induced lesions evolution in the phantom, a high degree of optical 
transparency in its pretreated state is desirable. Also, the phantom must change in a 
permanent, localized, and observable way in response to HIFU heating. To address 
these issues, in the last years, many studies has been conducted on optically transparent 
TMM, generally based on Agar or polyacrylamide hydrogel, in some cases with the 
presence of a thermally sensitive indicator protein (Bovine Serum Albumin) that 
becomes optically diffusive when denatured by high temperature [237]. At relatively 
low power (< 60 W), they have strength enough to not alterate under strong radiation 
stress and acoustic streaming induced by HIFU, even if, when temperatures > 60 °C are 
reached, melting processes or, in the case which was present, the denaturation of the 
protein dissolved, cause a non-reversible process thus limiting their reuse. 
An ideal phantom for HIFU conditions has not been realized yet, but to develop 
measurement techniques, validate theoretical models, and characterize specific HIFU 
ablation devices, a large number of devoted tissue-mimicking materials (TMM) with 
specific and well-characterized physical properties, have been reported [238]. In my 
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PhD activity three different TMM have been realized in our laboratories: Agar-based 
TMM, Poliacrylamide TMM and a thermocromic silica gel. By means of these 
materials it has been possible to analyze the different behaviours and the heating effects 
caused by focused ultrasonic transducers in function of the power, frequency and 
irradiation time.  
 
2.6.1   AGAR-BASED TMM        
 
To produce the TMM based on Agarosepolymer, the liquid component (distilled water) 
is mixed to the dry components (Agar, 3% in weight). The solution is hated at 90 °C and 
then cast into a cylindrical mould. Benzalkonium chloride (0.9% in weight) or Silicon 
Carbide(SiC, 1% in weight) can be added to the solution while it is left to cooling, 
respectively to control microbial invasion, and to vary the backscatter 
coefficientproduce the TMM based on Agarosepolymer, the liquid component (distilled 
water) is mixed to the dry components (Agar, 3% in weight). The solution is hated at 90 
°C and then cast into a cylindrical mould. Benzalkonium chloride (0.9% in weight) or 
Silicon Carbide (SiC, 1% in weight) can be added to the solution while it is left to 
cooling, respectively to control microbial invasion, and to vary the backscatter 
coefficient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
Agarose-based techniques are the most widely used of the soft tissue substitute 
preparation techniques described in the literature. The broad use of agarose-based 
substitutes is a result of their well- characterized performance, the ease of fabrication 
(the mixture can be heated in a microwave) and the flexibility that the process provides, 
allowing the incorporation of additional ingredients to achieve a range of acoustic 
properties. Studies on this agar-based TMM showed that a limited variation of 
scattering ingredients during the manufacturing process resulted in TMMs with varying 
attenuation and backscattered proprieties [239]. Agarose is derived from agar, a 
hydrophilic colloid that is extracted by boiling algae. Agar-based tissue mimicking 
material is the only TMM that has been acoustically characterized at high frequencies 
(17 to 23 MHz). At these frequencies, its speed of sound was found to be independent 
of frequency and attenuation coefficient was found to have a linear response to 
frequency [240]. Interestingly, this is the only material that exhibits a linear response to 
attenuation with frequency of approximately f1.01. Moreover, the acoustic property of all 
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TMMs varied with temperature, with the minimum variation observed in the agar-based 
TMM. Material properties have been reported to remain stable for as long as two and a 
half years under optimal storage conditions. However, in routine laboratory use without 
careful handling, longevity is often limited to less than one month because of microbial 
invasion or damage to the delicate structure. 
 
2.6.2    POLYACRYLAMIDE TMM  
 
The second sample used for the measurement system testing is a poliacrylamide gel 
similar to those described in scientific literature [241]. This gel has acoustic properties 
similar to biological tissue and it has been realized in our laboratory through a solution 
of 100ml of distilled water, 10g of acrylamideand 526mg of N, Nbisacrilamide, 1mlof a 
solution 10% in weight of ammonium persulfateand 0.5 ml of N, 
Ntetramethylethylenediamine (TEMED) which initiates polymerisation. The sample is 
prepared by the mixing of all the components except the TEMED. The liquid solution 
prepared is poured in the plexiglass made cylindrical stamp of height equal to4.5cm and 
a diameter of 5 cm. Than the TEMED is added so starting the geling process. This 
concentration allows the polyacrilamide gel to be very clear and transparent, because 
the normally exothermic polymerization reaction does not release enough heat to 
denature the embedded proteins. The use of a transparent material that mimics tissue 
response to HIFU exposure would facilitate dosimetry studies, transducer evaluation, 
and the development of theoretical and numerical models of HIFU treatments. A 
transparent phantom would indeed permit reducing the number of experiments to 
accomplish any of the goals listed above, compared to the procedure required for doing 
the same on biological tissues[242]. 
 
2.6.3 THERMOCROMIC SILICA GEL 
 
The third sample is an innovative tissue simulator containing thermosensitive chemical 
component . By mean of  this material  it has been possible to "visualize" the effect of 
heating induced by HIFU transducers. The material was a silica based hydrogel 
containing cobalt chloride salt. Aqueous solutions of cobalt chloride are pink colored, 
such color is due to the formation of the ion [Co(H2O)6]2+, while when the salt is 
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dissolved in Propanol, a deep blue solution is obtained, that is due to the formation of 
[CoCl4]2- ion. As reported in [243], with an opportune ratio, between water and chloride 
anion, is possible to obtain a thermochromic silica gel because when temperature 
increase/decrease a desorption/adsorption of water occurs, thus the change from pink-
red to violet-deep blue is observed. In order to obtain a thermochromic gel that had a 
transition temperature in the interval of interest, the samples were prepared following 
the composition reported in [243], expressed in terms of molar ratio: 1 of 
tetrametilorthosilicate ; 8.4 of 1-Propoanol; 6.6 of water and 0.1 of CoCl2. The solution 
was stirred for 30 min up to complete homogenization to accomplish the hydrolysis and 
to favor partial policondensation reaction, afterwards, it has been casted in a square 
cuvette in order to record the colour variation with good resolution, using a digital 
camera.  
Thermochromic materials have already been proposed in the past for investigate the 
heating effect caused by no-focused ultrasounds, using film of liquid crystal [244]; 
however the lack of adsorption of the film have limited its investigating properties; 
recently a standard acoustic absorber containing a thermochromic pigment was 
employed to study the heating effect of  ultrasonic device commonly used in 
physiotherapy, but the transition temperature is quite low (< 50°C)  and when it was 
subjected to longer exposure time, a non linearity into the temperature propagation and 
"blurring effects" have been observed.  Thermochromic gel is also an emerging research 
field, because of the interest into sensoring and smart materials applications. Different 
preparations of thermochromic gels has been reported during last five years [245], but 
in most of these cases they can be used as two dimension materials and do not have 
sufficient rigidity to be casted in three dimension TMM; newly, preparation of a 
reversible thermochromic gel based on silica hydrogel with a temperature transition in 
the range of 30-70 °C in function of the molar ratio of the chemical precursors, has been 
reported [243].  
The thermochromic gel proposed represents a smart and cheap tool for an immediate 
characterization of focused ultrasonic fields and evaluation of temperature rise induced 
by HIFU transducers. Using different transducers, operating at different frequencies and 
with different shape of the emitter, it has been possible verify how the effects of 
temperature rise are not exclusively correlated with the power used, but rather 
influenced by the frequency and the geometry of the focused acoustic field and thus 
from the interaction of the beam with the gel. 
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MEASUREMENT SYSTEM FOT THERMOCROMIC SILICA GEL 
The heating effects in a thermochromic silica gel have been evaluated using a type T 
thermocouple inserted in the sample. The thermocouple is positioned in the point of 
maximum temperature, which is supposed to be the focus region of the ultrasound 
beam, or in the pre-focus region, in order to evaluate the temperature in the external 
lines. For these experiments, two HIFU transducers are used: a single-element concave 
transducer MR-106, (transducer 3) with a working frequency of 2 MHz, diameter of 64 
mm and focus at 51.7 mm, (it can also work at its third harmonic, f = 6.3 MHz), and a 
single-element concave transducer SU-102, with a working frequency of 3 MHz, 
diameter of 35 mm and focus at 51.8 mm (transducer 2).The ultrasound source is 
powered by a wave function generator Agilent 33250A through an amplifier (AR 
500A100A).The power used for these experiment was in the range of 20-100W.The 
transducers and the thermochromic TMM are immersed in deionised water. The voltage 
signal, acquired by the thermocouple, is visualized by a nanovoltmeter (Agilent 34420) 
and a custom-made LabWIEV program collects and plots the signal (see figure 2.14). 
 
 
Figure 2.14. Scheme of experimental apparatus 
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2.7     OXYGEN LOAD NANOBUBBLES 
 
Oxygen nanocarriers have been developed at INRIM to treat a variety of hypoxia-
related diseases and in particular hypoxic cancerous tissues. This is an innovative, 
effective, almost non-invasive and low-cost nano-technological device. Different 
formulations of oxygen-loaded nanobubbles (OLNs) were realized to improve the 
available nanotechnology of gas delivery by studying new core/shell nanocarriers. 
OLNs could result effective in oxygen release, without losing the favorable properties 
of the nanobubbles explained in chapter 1 (e.g. nanometer size range, stability, 
sensitivity to ultrasounds, lack of toxicity, low manufacturing costs) and could be 
prepared in formulations suitable for topical treatment of dermal tissues. The main 
feature of these new nanocarriers consisted of employing 2H,3H-decafluoropentane 
(DFP) or Perfluoropentane (PFP) for the oxygen-storing core structure. Notably, DFP 
displays oxygen-solubilizing capabilities as high as OLNB core-associated PFP [246]. 
However, unlike PFP, which has a boiling point of 32 ºC and is gaseous at body 
temperature, DFP is a clear, colorless fluorocarbon with a boiling point of 51ºC, thus 
resulting liquid at 37°C. For that reason, the new nanocarriers were named oxygen-
loaded nanodroplets (OLNDs). Dextran was kept as the main constituent of the 
polysaccharidic shell as for former OLNs, since dextran-based formulations have been 
extensively tested for biocompatibility, and dextran-based hydrogels are currently used 
as matrices in tissue engineering, without showing signs of inflammation in vivo. 
Recent toxicological studies on mechanically processed polysaccharides of different 
molecular weight showed that dextran, along with the products of its mechano-chemical 
processing, can be classified as class 4 (low-toxicity) substance. On the other hand, 
chitosan was also chosen to build the polysaccharidic shell of OLNDs. This 
polysaccharide is a positively charged, partially deacetylated form of chitin, a natural 
substance found abundantly in the exoskeletons of insects and the shells of crustaceans. 
The repeating units of chitosan are β(1-4)-linked glucosamines, thus it contains a large 
number of hydroxyl- and amino-groups providing several possibilities for derivatization 
or grafting of desirable bioactive groups. Chitosan also displays high biocompatibility, 
healing capabilities, anti-cancer activity and anti-microbial properties against some 
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bacteria (e.g. methicillin-resistant Staphylococcus aureus) and fungi (e.g. Candida 
albicans). Due to these characteristics, it has been investigated for use in several 
biomedical applications, including wound dressings and drug carriers. 
Along with OLNDs, complementary control preparations were also evaluated, including 
OLNBs, oxygen-free nanodroplets (OFNDs), oxygen-free nanobubbles (OFNBs), and 
oxygen-saturated solution (OSS). All preparations were made either in liquid (water) or 
gel (hydroxyethylcellulose, HEC) formulations. For selected experiments with cell 
cultures, two additional OLND phosphate-buffered saline (PBS) formulations were also 
prepared by using dextran or fluorescein isothiocyanate (FITC)-conjugated dextran, 
respectively (see figure 2.16). Furthermore, 346 nm UV exposure for 20 min was 
chosen as a sterilizing procedure, which proved to be effective in a long-term manner 
without inducing O3 or significant singlet oxygen generation.  
 
2.7.1 OVERVIEW OF OLNs EXPERIMENTS 
 
Immediately after manufacturing, OLND and control preparations were characterized 
for: morphology, by optical and transmitting electron microscopy (TEM); average 
diameters, particle size distribution, polydispersity index and zeta potential, by dynamic 
light scattering; and oxygen content (before and after UV sterilization), through a 
chemical assay.  
Note that since the zeta potential measures charge repulsion or attraction between 
particles, it is a fundamental parameter to determine nanoparticle physical stability, with 
zeta potentials lower than -30 mV or larger than +30 mV being generally required for 
physical stability of colloid systems [250]. Although nanodroplets and nanobubbles 
displayed zeta potentials slightly larger than -30 mV, our formulations proved to be 
physically stable over time for the steric repulsion of the polymer chains, as assessed by 
monitoring their sizes and zeta potential by dynamic light scattering for 72 h after 
manufacturing. In addition, nanoparticle charge makes them suitable for topical 
treatment, enhancing their interaction with skin and improving their therapeutic effect 
on inflamed cutaneous tissues, either without or with concomitant US treatment.  
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OLND toxicity on human cells was evaluated by testing in vitro cultures of human 
HaCaT keratinocytes, a cell line immortalized from a 62-year old Caucasian male 
donor.  
As a next step, OLND abilities to release oxygen in vitro were comparatively evaluated. 
Following dissolution of the same amount of nanocarrier-containing gel (2% HEC) in a 
hypoxic solution, OLNDs released larger amounts of oxygen for longer times (up to 6 
h) than OLNBs and OSS. Oxygen release was compared also following sonication. In 
fact US is expected to impact on oxygen release kinetics through several mechanisms. 
Firstly, US can induce bubble formation after acoustic droplet vaporization. Under 
particular gas content and bubble radius conditions, bubble oscillations might lead to a 
more violent release mechanism due to cavitation, that is the formation, growth, and 
implosive collapse of bubbles in a liquid (see paragraph 1.2.3). 
Finally, US might elicit sonophoresis, temporarily enhancing skin leakage thus favoring 
transdermal drug release (see paragraph 1.5.4). To monitor the effect of US on the 
ability of OLNDs to trespass the dermal layer, a home-made apparatus consisting of two 
sealed cylindrical chambers separated by a layer of pig ear skin was employed. One 
chamber (the oxygen-donor), containing OLNDs or control solutions, was connected to 
an US-transducer, with the beam directed towards the membrane; the other chamber 
(the oxygen-recipient) was filled with hypoxic solution and monitored by an oxymeter. 
The US transducer (f = 2.5 MHz; P = 5 W) was alternatively switched on and off at 
regular time intervals of 5 min for an overall observational period of 135 min, and 
oxygen concentration was monitored in the recipient chamber every 45 min.  
Once proven in vitro that OLNDs were more effective than former OLNBs and OSS in 
releasing oxygen, without being toxic on human keratinocytes, and that gel formulation 
appeared suitable for treatment of skin membranes, OLND gel formulation was tested 
for oxygen delivery in vivo. To test OLND effects on tissue oxygenation without US 
treatment, the shaved hindlimbs of nine anaesthetized mice were topically treated with 
OLND, OFND or OSS gel formulations. Before, during and after treatment (10 min), 
the subcutaneous levels of oxy- and deoxy-Hb were monitored by photoacoustic 
imaging. Such innovative hybrid technique, which can image both light absorption 
properties and acoustic transmission properties of an object in a two-dimensional slice 
using a computed tomography photoacoustic imager [251], is applicable to the 
quantification of tissue chromophores such as oxy-Hb and deoxy-Hb for the 
measurement of physiological parameters such as blood oxygen saturation and total Hb 
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concentration [252].  OLNDs were finally tested in vivo. The skin oxygenation of the 
shaved hind limbs of nine anaesthetized mice topically treated with OLND, OFND or 
OSS gel formulations was monitored by visualizing the subcutaneous levels of oxy-Hb 
and deoxy-Hb through photoacoustic imaging before, during and after the treatment (10 
min). This innovative hybrid imaging technique, based on the light absorption and the 
acoustic transmission properties of a tissue slice interrogated by a computed 
tomography photoacoustic imager, can quantify the density of tissue chromophores such 
as oxy-Hb and deoxy-Hb and measure some physiological parameters such as blood 
oxygen saturation and total Hb concentration.  
Lastly, the OLND ability to improve tissue oxygenation in vivo after US treatment was 
investigated. The shaved abdomens of five anaesthetized mice were topically treated 
with OLNDs and sonicated for 30 sec (f = 1 MHz). Skin oxygenation was investigated 
through transcutaneous oxymetry before and after the treatment. This technique 
measures the oxygen transcutaneous tension (tcpO2) through a non-invasive method 
which elicits a heating-related vasodilatation, generating fast diffusion of gases from the 
vessels to an electrode located on the skin. When capillary oxy-Hb dissociation occurs, 
the reaction of oxygen reduction generates a current which is directly proportional to 
capillary oxygen arterial pressure. Monitoring tcpO2 is a well-consolidated technique 
extensively used also in clinical practice. Basal tcpO2 values in mice were 
inhomogeneous, possibly as a consequence of the different level of peripheral 
vasoconstriction induced by anesthesia. Nevertheless, after topical administration of 
US-activated OLNDs, hypoxic mice displayed larger oxygenation levels in a time-
sustained manner (up to 1 h). A graphic to summarise all the experiments performed 
with OLNs is given in figure 2.15. 
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Figure 2.15. Overview of the experiments performed with OLNs 
 
2.7.2   DEXTRAN AND CHITOSAN OLNs: MATERIALS 
 
Unless otherwise stated, all materials were from Sigma-Aldrich (St Louis, MO). 
Ethanol (96%) was obtained from Carlo Erba (Milan, Italy); Epikuron 200® (soya 
phosphatidylcholine 95%) was kindly gifted by Degussa (Hamburg, Germany); palmitic 
acid, decafluoropentane (DFP), perfluoropentane (PFP), dextran sodium salt (MW = 
100.000), chitosan (medium MW) and polyvinylpyrrolidone (PVP) were from Fluka 
(Buchs, Switzerland); ultrapure water was obtained using a 1-800 Millipore system 
(Molsheim, France); Ultra-Turrax SG215 homogenizer was from IKA (Staufen, 
Germany); Delsa Nano C analyzer was from Beckman Coulter (Brea, CA); Philips 
CM10 instrument was from Philips (Eindoven, The Netherlands); XDS-3FL microscope 
was from Optika (Ponteranica, Italy); cell culture RPMI 1640 medium was from 
Invitrogen, (Carlsbad, CA); cell culture Panserin 601 medium was from PAN Biotech 
(Aidenbach, Germany); PEN-STREP was from Cambrex Bio Science (Vervies, 
Belgium); LSM710 inverted confocal laser scanning microscope was from Carl Zeiss 
(Oberkochen, Germany); Synergy HT microplate reader was from Bio-Tek Instruments 
(Winooski, VT); Zoletil 100 was from Virbac (Carros Cedex, France); Rompun was 
from Bayer (Leverkusen, Germany); Vevo® LAZR system for photoacoustic imaging 
was from Fujifilm Visualsonics (Amsterdam, the Netherlands); TINA TCM30 oxymeter 
was from Radiometer (Copenhagen, Denmark). HaCaT cells were kindly provided by 
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Dr. F. Silvagno, Dep. of Oncology, University of Torino. BALB/c mice were bred 
under specific pathogen-free conditions by Fujifilm Visualsonics (Amsterdam, The 
Netherlands) or at the Molecular Biotechnology Center (Torino, Italy). 
 
 
 
 Figure 2.16. Schematic structure of OLND and OLNB liquid/gel formulations. 
 
2.7.3      DEXTRAN AND CHITOSAN OLNS: PREPARATIONS 
 
PREPARATION OF LIQUID FORMULATIONS 
Compositions of all formulations are detailed in Tables 3.15 and 3.17. For oxygen-
loaded nanodroplet (OLND) liquid formulations, 1.5 ml DFP along with 0.5 ml PVP 
and 1,8 ml Epikuron® 200 solved in 1% w/v ethanol and 0.3 % w/v palmitic acid 
solution were homogenized in 30 ml water (preparation A) or phosphate buffered saline 
(PBS) (preparations C-D) for 2 min at 24000 rpm by using Ultra-Turrax SG215 
homogenizer. Thereafter, the solution was saturated with O2 for 2 min. Finally, 1.5 ml 
dextran sulfate (preparations A, C) or fluorescein isothiocyanate (FITC)-labeled dextran 
sulfate (preparation D) solution was added drop-wise whilst the mixture was 
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homogenized at 13000 rpm for 2 min. For OLNs prepared with chitorsan as core, a 
2.7% w/v chitosan solution (pH 5.0) was added drop-wise whilst the mixture was 
homogenized at 13000 rpm for 2 minutes.  For oxygen-loaded nanobubble (OLNB) 
water formulation, the protocol developed by Cavalli and colleagues [180] was applied 
by using PFP as a core fluorocarbon. Oxygen-free nanodroplet (OLND) and nanobubble 
(OFNB) water formulations were prepared according to OLND and OLNB protocols 
without adding O2. For oxygen-saturated solution (OSS) water formulation, OLND 
preparation protocol was applied omitting dextran sulfate and DFP addition. For more 
details, see Table 3.14 and 3.16. 
 
PREPARATION OF GEL FORMULATIONS 
To obtain gel formulations, 0.8 mg hydroxyethylcellulose were solved in 20 ml water, 
and subsequently mixed 1:1 with OLND, OFND, OLNB, OFNB, or OSS water 
formulations. 
 
STERILIZATION 
OLNDs, OFNDs, OLNBs, OFNBs, and OSS were sterilized through 346 nm UV 
exposure for 20 min. Thereafter, UV-treated materials were incubated with cell culture 
RPMI 1640 medium in a humidified CO2/air-incubator at 37°C up to 72 h, not 
displaying any signs of microbial contamination when checked by optical microscopy. 
Moreover, UV-sterilized O2-containing solutions underwent further analyses through O3 
measurement and electron paramagnetic resonance (EPR) spectroscopy, showing no O3 
generation and neglectable singlet oxygen levels immediately after UV exposure. 
 
2.7.4     DEXTRAN AND CHITOSAN OLNS: PHYSICAL-   
             CHEMICAL CHARACTERIZATION 
 
MORPHOLOGY 
The morphology of OND and ONB formulations was determined by transmitting 
electron microscopy (TEM) and by optical microscopy. TEM analysis was carried 
out using a Philips CM10 instrument, whereas optical microscopy was carried out 
using using a XDS-3FL microscope. ND and NB formulations were dropped onto a 
Formwar-coated copper grid and air-dried before observation. 
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SIZE, PARTICLE SIZE DISTRIBUTION AND ZETA POTENTIAL 
Average diameters, polydispersity indexes, and zeta potentials of OLNDs and 
OLNBs were determined by dynamic light scattering using Delsa Nano C 
instrument, displaying a (0.6 nm - 7μm) range for measurements of particle size 
distribution. Each value reported is the average of three measurements of ten 
different formulations. The polydispersity index indicates the size distribution within 
a OLND or OLNB population. For zeta potential determination, formulation samples 
were placed into an electrophoretic cell, where an electric field of approximately 30 
V/cm was applied. Each sample was analyzed at least in triplicate. The 
electrophoretic mobility was converted into zeta potential using the Smoluchowski 
equation [250]. 
 
OXYGEN CONTENT 
Oxygen content of OLNDs, OLNBs and OSS was evaluated by adding known 
amounts of sodium sulfite and measuring generated sodium sulfate, according to the 
reaction: 
Na2SO3  + ½ O2          Na2SO4 
 
STABILITY 
The stability of formulations stored at 4°C, 25°C or 37°C was evaluated over time up 
to 72 h by determining morphology, sizes and zeta potential of OLNDs and OLNBs 
by optical microscopy and light scattering. 
 
2.7.5    DEXTRAN AND CHITOSAN OLNs: BIOCOMPATIBILITY     
            ASSESSMENT 
 
HUMAN KERATINOCYTE CELL CULTURES 
HaCaT, a long-term cell line of human keratinocytes immortalized from a 62-year 
old Caucasian male donor,33 was used for assessment of OLND biocompatibility. 
Cells were grown as adherent monolayers in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% foetal bovine serum (FBS), 100 U/ml penicillin, 
100 µg/ml streptomycin (PEN-STREP) and 2 mM L-glutamine in a humidified 
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CO2/air-incubator at 37°C. Before starting the experiments, cells were washed with 
PBS, detached with trypsin/ethylenediaminetetraacetic acid (EDTA) (0.05/0.02% 
v/v), washed with fresh medium and plated at a standard density (106 cells/well in 6-
well plates) in 2 ml FBS-free Panserin 601 medium to prevent serum interference in 
the toxicity assay. 
 
Evaluation of OLND uptake by human keratinocytes 
HaCaT cells were plated in 24-well plates on glass coverslips and incubated in 
Panserin 601 medium for 24 h with/without 200 µl FITC-labeled OLNDs in a 
humidified CO2/air-incubator at 37°C. After 4',6-diamidino-2-phenylindole (DAPI) 
staining to visualize cells nuclei, fluorescence images were acquired by a LSM710 
inverted confocal laser scanning microscope  equipped with a Plan-Neofluar 63×1.4 
oil objective, that allowed a field view of at least 5 cells. Wavelength of 488 nm was 
used to detect OLNDs, and of 460 nm to detect the labeled nuclei. The acquisition 
time was 400 ms. 
 
OLND CYTOTOXICITY 
The potential cytotoxic effects of OLNDs were measured as the release of lactate 
dehydrogenase (LDH) from HaCaT cells into the extracellular medium. Briefly, cells 
were incubated in Panserin 601 medium for 24 h in the presence or absence of 
increasing doses (100-400 µl) of OLNDs, either in normoxic (20% O2) or hypoxic 
(1% O2) conditions, in a humidified CO2/air-incubator at 37°C. Then, 1 ml of cell 
supernatants was collected and centrifuged at 13000g for 2 min. Cells were washed 
with fresh medium, detached with trypsin/ EDTA (0.05/0.02% v/v), washed with 
PBS, resuspended in 1 ml of TRAP (82.3 mM triethanolamine, pH 7.6), and 
sonicated on ice with a 10 s burst. 5 µl of cell lysates and 50 µl of cell supernatants 
were diluted with TRAP and supplemented with 0.5 mM sodium pyruvate and 0.25 
mM NADH (300 μL as a final volume) to start the reaction. The reaction was 
followed measuring the absorbance at 340 nm (37 °C) with Synergy HT microplate 
reader. Both intracellular and extracellular enzyme activities were expressed as μmol 
of oxidized NADH/min/well. Finally, cytotoxicity was calculated as the net ratio 
between extracellular and total (intracellular + extracellular) LDH activities. 
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HUMAN KERATINOCYTE CELL VIABILITY 
Cell viability was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. HaCaT cells were incubated in Panserin 
601 medium for 24 h with/without increasing doses (100-400 µl) of OLNDs, either 
in normoxic (20% O2) or hypoxic (1% O2) conditions, in a humidified CO2/air-
incubator at 37°C. Thereafter, 20 μL of 5 mg/mL MTT in PBS were added to cells 
for 3 additional hours at 37 °C. The plates were then centrifuged, the supernatants 
discarded and the dark blue formazan crystals dissolved using 100 μL of lysis buffer 
containing 20% (w/v) sodium dodecyl sulfate (SDS), 40% N,N-dimethylformamide 
(pH 4.7 in 80% acetic acid). The plates were then read on Synergy HT microplate 
reader at a test wavelength of 550 nm and at a reference wavelength of 650 nm. 
 
2.7.6    DEXTRAN AND CHITOSAN OLNS: IN VITRO   
            EXPERIMENTS 
 
OXYGEN RELEASE WITHOUT US 
The concentration of oxygen released by diffusion from OLND, OLNB and OSS 
liquid or gel formulations into a hypoxic solution was monitored up to 6 h through 
Hach Langhe LDO oxymeter, displaying an accuracy of 0.01 mg/l. Before each 
measurement, the oxymeter was calibrated in air, waiting for stable temperature and 
humidity conditions to be reached. 
 
OXYGEN RELEASE WITH US AND TRESPASSING OF SKIN MEMBRANES  
To study the ability of US-activated OLNs to release O2 through biological 
membranes, a US probe with a high frequency transducer (f = 2.5 MHz; P = 5 W) 
was used, combined with a home-made apparatus with two sealed cylindrical 
chambers (lower chamber: OLND, OFND, OLNB, OFNB or OSS solutions; upper 
chamber: hypoxic solution) separated by a layer of pig ear skin employed as a model 
of biological membrane (see Figure S7 for details). US treatment was performed for 
5 min; thereafter, O2 concentration in the hypoxic chamber was monitored up to 135 
min every 5 min by Hach Langhe LDO oxymeter (accuracy: 0.01 mg/l). Because of 
the local heating caused by US, the O2 sensor was positioned laterally in order to 
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prevent possible damage of the oxymeter, whereas the transducer was held in a fixed 
position, within the donor compartment (see figure 2.17). The acoustic power of the 
transducer was determined through a balance's radiation force with a reflecting 
target, with an uncertainty of 4%. 
 
 
 
Figure 2.17. Home-made apparatus measuring O2 release across a natural 
membrane after OLN sonication.  
 
2.7.7    DEXTRAN AND CHITOSAN OLNS: IN VIVO     
            EXPERIMENTS 
 
MICE 
Before performing the experiments, healthy BALB/c mice were shaved locally 
(abdomens or hindlimbs depending on the study, as described in the following 
paragraphs) and anaesthetized by injecting intramuscularly a mixture of 
tiletamine/zolazepam 20 mg/Kg (Zoletil 100) and 5 mg/Kg xylazine (Rompun). All 
procedures were done in accordance with the EU guidelines and with the approval of 
the Università di Torino animal care committee.  
 
 
 
NDs/NBs/OSS
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PHOTOACOUSTIC IMAGING 
The shaved hindlimbs of nine anaesthetized mice were topically treated with OLND, 
OFND or OSS gel formulations. Before, during and after treatment (10 min), the 
subcutaneous levels of oxy- and de-oxy-hemoglobin were monitored by 
photoacoustic imaging, which was performed with Vevo® LAZR system featuring a 
hybrid ultrasound transducer (central frequency: 21 MHz; spatial resolution: 75 μm). 
 
MEASUREMENT OF TcpO2 WITH US 
The shaved abdomens of five anaesthetized mice were topically treated with OLNDs 
and ultrasonicated for 30 sec using a home-made ultrasound (US) equipment 
(frequency: 1 MHz). Before and after treatment (1 h), the transcutaneous tension of 
oxygen (tcpO2) was measured through TINA TCM30 oxymeter. The TINA TCM30 
oxymeter provides the measure the oxygen partial pressure of the transcutaneous 
capillary blood (tcPO2). All tcpO2 measurements were taken after physiological 
stabilization. 
 
 
 
 
 
 
 
 
 
 
 
 
 
99 
 
 
 
 
CHAPTER 3 
 
 
RESULTS 
 
 
3.1 ULTRASONIC FIELD CHARACTERIZATION: 
POWER  
 
The first step for transducer’s characterization is the measurement of the total, time-
averaged ultrasonic output power, Pout, emitted by transducers, described in paragraph 
2.2, is measured. The acoustic power values were obtained with the system based on 
radiation force balance method using, in these cases, a submersible load cell (SLC). A 
detailed description of the system has been provided in paragraph 2.3.1.  
A continuous-wave, sinusoidal excitation voltage has been applied to the transducer 
(including the impedance matching network) and measured. There are five voltage 
levels, namely “low”, “medium”, “high”, “very high” and “ultra high”. The specified 
RMS voltage values, Us, and the specified frequency values, fs, are given in Table 3.1. 
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N Transducer Type sf / MHz Level / W US / Vrms 
1 
TRANSDUCER 1 
PTB 256 
1.8611 
10 (low) 42.00 
3 20 (medium) 60.0 
4 
6.2664 
10 (low) 41.0 
6 20 (medium) 58.0 
1 
TRANSDUCER 2 
Sonic Concept 
SU-102 
3.5 
20 (medium) 33.0 
3 50 (high) 53.0 
4 75 (very high) 61.0 
5 100 (ultra high) 70.0 
1 
TRANSDUCER 3 
Sonic Concept 
H-106-MR 
2.0 
20 (medium) 41.0 
3 50 (high) 62.0 
4 75 (very high) 78.0 
5 100 (ultra high) 90.0 
6 
6.38 
10 (low) 29.0 
7 20 (medium) 40.0 
8 50 (high) 61.0 
9 75 (very high) 76.0 
 
Table 3.1 RMS voltage values, Us, and the frequency values, fs, for five voltage 
levels. 
 
The electro-acoustic radiation conductance G must be calculated according to 
 
                                                                    
2
in
out
U
PG =                                                       (1) 
 
G is expressed in Siemens, S, or decimal submultiples of this unit. The input voltage Uin  
refers to the transducer input and is to be measured at a point as near as possible to the 
transducer input connector. 
For each transducer, power level and for each frequency, the final measured value of 
ultrasonic conductance is reported in tables 3.2, 3.3 and 3.4. The G values are calculated 
as the mean of the four measures, realized for each measurement condition. The highest 
101 
 
uncertainty among the four obtained for each conductance for each fixed power level 
and frequency is taken as the uncertainty for the mean value. 
 
TRANSDUCER 1  
 
N fS
 
/ MHz P / W G / mS Uin /  V U(G) / % 
1 1.8611 10 5.50 43.61 8.90 
2 1.8611 20 5.53 62.17 8.43 
3 6.2664 10 6.00 41.01 8.91 
4 6.2664  20  5.91  58.44  8.45  
 
Table 3.2. Power level, frequency input voltage and ultrasonic conductance related to 
transducer 1. 
 
Figure 3.1. Transducer 1: ultrasonic conductance at two different power level. 
 
TRANSDUCER 2 
  
N fs
 
/MHz P / W G / mS Uin
 
/ V U(G) / % 
1  3.50  20  16.67  33.79  8.50  
3 3.50  75  18.09  60.79  8.11  
4  3.50  100  18.79  70.16  8.10  
 
Table 3.3. Power level, frequency input voltage and ultrasonic conductance related to 
transducer 2. 
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             Figure 3.2. Transducer 2: ultrasonic conductance at four different power level. 
 
TRANSDUCER 3 
N fs /MHz P / W G / mS Uin / V U(G) / % 
1 2.00 20 12.20 38.42 8.66 
2 2.00 50 12.22 61.73 8.27 
3 2.00 75 12.24 78.77 8.21 
4 2.00 100 12.42 89.45 8.20 
5 6.38 20 13.68 38.89 8.60 
6 6.38 50 13.34 61.92 8.25 
7 6.38 75 13.17 76.07 8.20 
 
Table 3.4. Power level, frequency input voltage and ultrasonic conductance related to 
transducer 3. 
 
Figure 3.3. Transducer 3: ultrasonic conductance at three different power level 
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3.2    ULTRASOUNIC FIELD    
         CHARACTERIZATION: PRESSURE 
 
Subsequently to the measurement of the ultrasound power emitted by the three 
transducers, the acoustic pressure is measured. The ultrasonic measurement has been 
conducted in the scanning tank as described in paragraph 2.4.2.  
To obtain a pressure field characterization, a series of planar scans are performed 
around the focus region and the pre focus region (10 mm from the focus) for each 
transducer.  The aim of these scans has been to define the beam dimension and shape. 
Ultrasound sources are set for operating at 50 W. In figures 3.4, 3.5 and 3.6, a planar 
scan for each transducers, in the focused region and in pre-focused region (10 mm far 
from the focus) are shown. These are representative images from several independent 
experiments. The pressure 3-d diagram of an HIFU fields was performed using an 
optical hydrophone while a needle hydrophone (Onda PVDF needle, see table 2.1) is 
employed when a planar wave transducer is investigated.  
For transducer 1 in the focus, the surfaces scanned have a dimension of 40 x 40 points 
with 1.00 mm resolution. Consequently, the planar scan requires 1600 points. For 
transducers 2 and 3, and transducer 1 at 10 mm from the focus, the surfaces scanned 
have a dimension of 30 x 30 points with 0.20 mm resolution, so that each planar scan 
requires 900 points. The planar scanning is always performed in x-z plane which is 
perpendicular to the propagation direction of the ultrasound beam.  
For each measurement point the oscilloscope has acquired waveforms with a sampling 
frequency of 5 Gigasamples/s for a time period of 1000 ns. In order to reduce the 
random noise, each acquired electrical waveform has been the result of 10 averages. 
Each electrical waveform has been acquired and stored in the host PC for off-line 
conversion into acoustic pressure  and elaboration.  
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Figure 3.4. Three- dimensional representation of acoustic pressure measured in the 
focus (left) and pre-focus region (right) for transducer 1. The x-z plane is 
perpendicular to the propagation direction of the ultrasound beam.  
 
 
 
Figure 3.5. Three- dimensional representation of acoustic pressure measured in the 
focus (left) and pre-focus region (right) for transducer 2. The x-z plane is 
perpendicular to the propagation direction of the ultrasound beam. 
 
Figure 3.6. Three- dimensional representation of acoustic pressure measured in the 
focus (left) and pre-focus region (right) for transducer 3. The x-z plane is 
perpendicular to the propagation direction of the ultrasound beam. 
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The focus is situated at 55 mm for transducer 2 and at 63 mm for transducer 3 (see 
paragraph 2.2). Using transducer 1, piston-like transducer, the surface is scanned at 20 
cm from the source, in the far field region.  
It is easy to see from the graphs 3.4, 3.5 and 3.6 the pressure in the focus is higher for 
HIFU transducer (Transducer 2 and Transducer 3), than for a planar wave transducer 
(Transducer 1). For Transducer 2 and Transducer 3 the pressures in this point are 
respectively 1.6x108 Pa and 2.3x108 Pa, while for transducer 1 the maximum pressure 
reached is 7.5x106 Pa. In the graphs obtained using an HIFU source, it is also possible to 
observe that the pressure level reached in the pre-focused region is still high and, 
especially for the smaller transducer (Transducer 2), it is evident the presence of 
external “lobes” with high acoustic pressure level due to the more tapered shape of this 
transducer. 
 
3.2.1     PRESSURE MEASUREMENT UNCERTAINTY  
 
Here I present an overview of the main contributions to the final uncertainty associated 
to acoustic pressure measurement dividing if a needle hydrophone or a optic 
hydrophone is used.  
 
PRESSURE UNCERTAINTY USING A NEEDLE HYDROPHONE 
The voltage waveform ν(t) acquired by the hydrophone is converted in a pressure 
signal, p(t), using the sensitivity curve of the hydrophone ML(f) according to: 
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The pressure uncertainty, calculated according to the law of propagation, is: 
 
                                                                                    [MPa]                        (3) 
 
Where: 
( )( ) ( )( )fMutvutpu L22))(( +=
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• u(v(t)) is the type A uncertainty on the voltage values. It is calculated from the 
voltage value acquired by the hydrophone during a planar or linear scan when the 
transducer doesn’t emits any waveform. Three independent measurements have 
been carried out and taken into account in the final result. 
•  u(ML(f)) is the composed uncertainty associated to the product of the end of cable 
hydrophone sensitivity and a correction due to all the electrical load. ML(f) is 
calculated by: 
                           
ACH
H
CL CCC
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          and it is given by: 
 
                                                                                                                                        (5) 
 
where:   
  u(MC) is the type B uncertainty associated to the end of cable open    
            circuit sensitivity;                       
                       u(CC) is the type B uncertainty associated to the right angle connection     
                                used to connect the pre-amplifier (Onda AH2020) and the    
                                hydrophone; 
                      u(CA) is the type B uncertainty associated to the capacitance of the     
                               amplifier;      
                       u(CH) is the type B uncertainty associated to the end of cable capacitance    
                                of the hydrophone; 
 
 Table 3.5 shows the uncertainty contribution to the ML(f): 
 
 Contribution Xi xi cxi u (xi) |cxiu (xi)| 
 ML(f) ML(f) 1.48•10-7 V/Pa - 1.66•10-8 V/Pa - 
1 u(MC(f)) Mc(f) 1.69•10-7 V/Pa 0.87 1.90•10-8 V/Pa 1.65•10-8 V/Pa 
2 u(CH) CH 6.32•10-11     F 0.29•10-3 V/FPa 1.58•10-12 F 4.65•10-10 V/Pa 
3 u(CC) CC 1.60•10-12 F -2.05•103 V/FPa    4.00•10-14 F 8.18•10-11 V/Pa 
4 u(CA) CA 7.50•10-12 F -4.09•103 V/FPa 1.88•10-13 F 7.67•10-10 V/Pa 
 Table 3.5. Uncertainty contribution to ML(f) 
( )( ) ( )( ) ( )( ) ( )( )HCACCCCMc CucCucCucMucu HAC 22222222L ) (f)M( +++=
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The uncertainty on the capacity of the hydrophone and of the other electrical loads are 
furnished by the producers (type B) and are usually on the order of less than 3% while 
the main contribution is given by the uncertainty on MC(f), which is usually more than 
10%. This uncertainty is given by the laboratory that has calibrated the hydrophone and 
it can be quite different concerning what kind of hydrophone is used. In table 3.6 the 
main contributions to the uncertainty budget are expressed as relative quantities. 
 
Source of uncertainty Relative uncertainty / % 
v(t) 2.83 
ML(f) 11.25 
                             u(p(t))                                                       11.60 
 
Table 3.6. Uncertainty budget for pressure measurement using a needle hydrophone. 
 
PRESSURE UNCERTAINTY USING A FIBER OPTIC PROBE HYDROPHONE 
In this paragraph I give an overview of all the terms contributing to the final pressure 
uncertainty when a fiber optic hydrophone is used. Using this instrument, the relation to 
obtain pressure measurement is: 
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while the composed uncertainty associated to pressure values is the sum in quadrature 
of three terms: 
                           ( ) ( ) ( )0222))(( VuVuutpu +∆+= α                         [MPa]      (8)        
Where: 
• u(α) is the uncertainty of the internal light scattering factor of the optical  
    hydrophone. α is given in paragraph 2.4.3 and is given by: 
• u(ΔV):   type A uncertainty associated to change of the photodetector                                                                        
    signal in V; 
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• u(V0):  is the type A uncertainty associated to DC photodetector signal at 
      atmospheric pressure in V; 
 
                           ( ) ( ) 1
1
BoilBw −−−
=
VVVV
α                                           (9)                                                                                                                                   
  
while the uncertainty is calculated according to the law of propagation of the 
uncertainty, as 
 
                   (10)        
             
 Where: 
   u (VW):   is the type A uncertainty of the DC-photovoltage when the laser     
                                      is on and  the fiber tip is in water; 
            u (VB):     is the uncertainty type A of the DC-photovoltage when the laser  
                                      is off; 
            u (Voil):    is the uncertainty type A of the DC-photovoltage when the laser     
                                      is on and the fiber tip is in the index-adjusted liquid; 
   
 Table 3.7 shows the uncertainty contribution to the internal light scattering factor     
  α. 
 Contribution Xi xi cxi u(xi) |cxiu(xi)| 
 u(α) α 0.07 - 1.82•10-3 - 
1 u(VW) VW   0.81 V -1.14•10-4 V-1 1.00•10-3 V 1.14•10-4 
2 u(VB) VB 0.10 V -1.54•10-3 V-1 0.50•10-3 V 7.70•10-4 
3 u(VOIL) VOIL 0.16 V 1.65•10-3 V-1 1.00•10-3 V 1.65•10-3 
 
Table 3.7. uncertainty contribution to the internal light scattering factor α. 
 
The uncertainty of temperature values in Table 3.10 is dominated by estimate of the 
internal light scattering factor α with a constant relative contribution to u(α) = 2.44 %. 
Uncertainty on α values are problematic to reduce. For optimal functioning of the fiber 
optic probe hydrophone, the surface at the end of the fiber, which is the sensitive 
( )( ) ( )( ) ( )( )oilBVwV VucVucVucu oilVW 222222)( ++= Bα
109 
 
element of the system, has to be properly cut. This is not always a clear and easy 
operation and, even if α values can be tolerated (if α < 0.3, parameter given to the 
manufacter to be accepted) some damage could be occur on the fiber tip. In figure 3.7 
this phenomena is underlined: two images of the fiber tip are provided and in both cases 
α values are allowed (α = 0.07 in the left figure and α= 0.12 in the right figure) but a 
significantly difference occurs on the fiber tip, the second one is damaged and pressure 
values could be under estimated. The figures are provided using a scanning tunnelling 
microscopy.  
 
 
Figure 3.7.  Two different images of the fiber tip provided using a scanning tunneling 
microscopy 
 
In table 3.8 the uncertainty sources and their contributions to the final pressure 
uncertainty are summarized: 
 
Source of uncertainty Relative uncertainty / % 
α 2.44 
ΔV 2.22 
V0 0.16 
u(p(t))                                                        3.30 
 
Table 3.8. Main contributions to the pressure uncertainty. 
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3.3     ULTRASOUNIC FIELD                     
          CHARACTERIZATION: TEMPERATURE  
 
In the previous paragraphs the transducers characterization, regarding power and 
pressure has been provided. Beside them, in order to fully understand the effect of 
therapeutic focused ultrasound in tissue, accurate measurements of temperature rises are 
necessary. For this reasons a complete characterization of the temperature rise in the 
focus of an HIFU source is provided.  
 
3.3.1    TEMPERATURE CHARACTERIZATION: COMPARISON     
             BETWEEN THERMOCOUPLE AND FIBER OPTIC     
             HYDROPHONE  
 
As a first step, temperature rise near the focus of an HIFU transducer is provided using 
two different instruments: a fiber optic hydrophone and a thermocouple. Optical 
methods, for ultrasound field, is a new approach for temperature measurement that has 
been developed during this work. For this reason, thermocouples have been also applied 
in order to compare the optical hydrophone response when it is subjected to a 
temperature variation. A thermocouple and the optical hydrophone are embedded in a 
tissue mimicking material that simulates the thermal and acoustic properties of soft-
tissue. The TMM chosen is a polyacrilamide gel realized at INRIM. The measurements 
are performed in the scanning tank system described in paragraph 2.4.2. This system 
allows the positioning of the optical fiber tip (which is the sensible part of the fiber) and 
the end of the thermocouple approximately at the focus of the transducer (the 
positioning is based on the prior knowledge of the parameters about the transducer). 
The fine adjustment of the position is then achieved by a temperature scanning in the 
region of interest with a smallest step (0.1 mm) in 3-dimensions. When the 
thermocouple and the fiber optic hydrophone are in the focal region, the temperature 
rise generated by the focused ultrasound reaches the maximum. To study the 
temperature elevation at the focal spot, the phantom is exposed to a power of 50W, 75W 
and 100W for an exposure time of 5 s. In these experiments, Transducer 3 has been 
used. Results are shown in Figure 3.8. 
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Figure 3.8. Temperature rise for three value of ultrasound power obtained using a 
thermocouple (square symbols) and an optical hydrophone (circle symbols). 
 
In figure 3.8 the results obtained using the thermocouples (square symbols) are 
compared with the results achieved with an optic hydrophone (circle symbols) for the 
three power values taken into account. The graphs indicate that the measurements 
obtained with the different systems are not significantly different. The agreement 
between a traditional instrument for temperature measurements (thermocouple) and the 
new system based on an optical hydrophone is satisfactory and differences are within 
the calculated uncertainty (see paragraphs below).  
 
 
3.3.2    TEMPERATURE CHARACTERIZATION:     
            THERMOCOUPLES UNCERTAINTY  
 
The uncertainty on temperature measurement, u(TT), is given by: 
 
                           
(10)        
   
 
calculated as a combination of two components that constitute the uncertainty of the 
data: 
 
( ) ( )T2sT2T )( TuTuTu r +=
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• ur(TT) is the type B uncertainty given to the laboratories which has been calibrated     
     the thermocouple; 
• us(TT) is the type A uncertainty associated with the sample measurements. It is the    
    estimated variance of the mean which characterizes the variability of the values.  
 
In the table below the uncertainty contribution associated to the three different values of 
ultrasonic power are summarized: 
 
  
Relative uncertainty / % 
P = 50 W P = 75 W P = 100 W 
T = 37.10 °C T = 54.02 °C T = 76.00 °C 
ur(TT) 0.90 0.90 0.96 
us(TT) 0.07 0.05 0.04 
u(TT) 0.91 0.90 0.96 
 
Table 3.9. Main contributions to the temperature uncertainty using a thermocouple. 
 
3.3.3 TEMPERATURE CHARACTERIZATION: FIBER OPTIC 
PROBE HYDROPHONE UNCERTAINTY 
 
For a fiber optic hydrophone, the uncertainty is given by: 
    
                                                                                                      (11)        
where: 
 
• us(TF) is the type A uncertainty associated with the sample measurements, it is the 
estimated variance, deviation standard of the mean which characterizes the 
variability of the values.  
 
• uc(TF): is the composed uncertainty associated to the parameters which compare in    
     equation 2.16 for temperature calculation. They are composed according to: 
                           ( ) ( ) ( ) ( )020222Fc )( TuVuVuuTu ++∆+= α               [°C ]                (12)        
( ) ( )F2cF2sF )( TuTuTu +=
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Where:          u(α):    is the composed uncertainty associated to internal light scattering factor  
               of the fiber optic system. It is already given in table 3.7 
                     u(ΔV):  type A uncertainty associated to change of the photodetector                     
                                  signal in V; 
                      u(V0):  type A uncertainty associated to DC photodetector signal at       
                                  atmospheric pressure in V; ; 
                     u(T0):  type B uncertainty associated to water initial temperature °C; 
 
The contributions to the uncertainty uc(TF) of the temperature are summarized in Table 
3.10. 
Source of uncertainty Relative uncertainty / % 
α 2.44 
ΔV 2.22  
Vo 0.16  
To 0.05  
Uc(TF) 3.30  
 
Table 3.10. Contributions to the relative uncertainty of the temperature using a fiber 
optic probe hydrophone.  
 
In the table below the uncertainty contribution associated to the three different values of 
ultrasonic power are summarized: 
 
Source of uncertainty 
Relative uncertainty / % 
P = 50 W P = 75 W P = 100 W 
 T = 37.50 °C T = 54.12 °C T = 71.1 °C 
uc(TF) 0.57 0.34 0.35 
us (TF) 3.30 3.30 3.30 
u (TF) 3.35 3.31 3.32 
Table 3.11. Main contributions to the temperature uncertainty using a FOPH 
hydrophone. 
The uncertainty related to the measurement performed using an optical hydrophone are 
higher than the measurement realized with a thermocouple, but taking into account that 
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this is an instrument for the high pressure measurement, an uncertainty of 3.30% can be 
tolerated.  
 
3.3.4    TEMPERATURE CHARACTERIZATION IN AGAR-BASED    
            TMMs 
 
In the previous paragraph the fiber optic hydrophone has been validated as temperature 
instrument. Now, using this instrument, temperature increase induced by a focused 
ultrasound field (Transducer 3) in another TMM (agar-based gel, described in paragraph 
2.6.2) is evaluated. The experimental set up is the same used in the previous section. By 
means of a micro positioning system, the polyacrilamide TMM under study, including 
the optical fiber, is moved to reach the point of maximum revealed temperature, which 
is supposed to be the focus region of the ultrasound beam.  
Firstly, the temperature elevation generated by an HIFU source (set to work at P=100 
W) in the TMM phantom is spatially mapped in the focal plane. An x–z axes planar scan 
perpendicular to the propagation direction of the ultrasound beam is performed. In 
figure 3.9, a three- and two-dimensional representation of the temperature distribution is 
shown.
 
Figure 3.9. Three- and two-dimensional representation of the temperature spatial 
distribution around the ultrasound beam focus region. The colour map represents 
temperature variation from 20 °C to 70 °C. 
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The temperature reached in the focus is about 70°C. This value, obtained in a agar-
based gel, is similar to those acquired in the same conditions (P = 100 W in the focus) 
using a polyacrilamide TMM. The uncertainty associated to the temperature increase 
has been already evaluated in paragraph 3.3.3, but in this case, only the contribution due 
to uc2(TF) is taken into account. In table 3.10 contributions to the temperature 
uncertainty are summarized.  
Subsequently to a spatial scan of the temperature reached around the focus, temperature 
rises in different TMMs are performed. Four different Agar-based TMMs have been 
prepared, in order to study the changing in temperature increase when the percentage in 
volume of scattering agents (kieselguhr) is varied. Agar TMM have no scattering 
agents, while in Agar 2, 3 and 4 there is an increasing percentage in volume of them, 
respectively 2%, 3% and 4%. The TMMs are described accurately in paragraph 2.6.1. 
Even in this case, data are acquired by means of a fiber optic hydrophone when the gel 
is subjected to a focused ultrasound field produced at four different values of power 
(20W, 50W, 75W, 100W). The exposure time is 5 s every measurement. Temperature 
values are calculated as the mean of five measures realized for each measurement 
condition. In graph 3.10 data obtained are shown.  
 
 
 
Figure 3.10. Temperature increase at different power values, in four Agar-based 
TMM. 
 
From the graph it is possible to observe that increasing the percentage in volume of 
scattering agents, temperature variation during 5 s of exposure is reduced. This can be 
conducted to an increase of absorption and scattering phenomena caused by wave 
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interactions with structures or inhomogeneities of the medium (in this case: scattering 
agents). Error bar associated to temperature values are calculated as a quadrature 
combination of two components: the uncertainty relative to the fiber optic system 
(which components are described in table 3.10) and the uncertainty associated to the 
repeteability of the measuring data. 
 
  3.3.5   TEMPERATURE CHARACTERIZATION IN   
             THERMOCHROMIC TMMs  
 
After TMMs based on agar and polyacrilamide, a third sample has been synthesized. 
This is a thermochromic silica gel, an innovative TMM that allows not only the 
investigation of temperature rise, but also the "visualization" of the heating effects 
induced by an HIFU transducers.  
 
QUALITATIVE EVALUATION OF TEMPERATURE EFFECTS 
First of all, a quantitative evaluation of temperature effects has been provided, in order 
to visualize the heating regions, their shape and to verify the propriety of being 
reversible. In Figure 3.11 a sequence of the thermochromic gel exposed to the HIFU 
transducer 2 operating at 100 W is shown. It is possible to observe that, after the 
immediate formation of a blue region, in the focus, the heating effect propagates very 
rapidly towards the transducer, with the formation of blue “stream-lines” just after 300 
ms (see fig 3.11, frame 8-9). A direct correlation of temperature, with color transition 
acquired, was difficult to performed since the optical conditions (illumination, presence 
of plexiglass windows with different thick) were not stable enough, however, on the 
bottom it is reported as a reference, a color scale graduated, as function of temperature, 
that have been recorded  keeping a gel sample in a thermostatic bath. Indeed, from 
figure 3.11, it is possible to note the reversible propriety of this TMM . 
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Figure 3.11. Sequence of color variation induced by HIFU transducer (Transducer 2, 
100W ). Frame period from top left: 0.5 s. Total insonation time. Last frame is 
reported to show the reversible effect  
When conducting repeated experimental investigations, at high acoustic power (100 W) 
for longer time exposure ( >2 s), the superheating, combined with mechanical effects, 
become dramatic and induces the formation of non reversible cavities, thus limiting the 
use of this material for trials at high power. As an example, in figure 3.12 are shown 
three frames of the gel exposed to 100 W for 5 s. Picture 3.12a: before to start the 
ultrasonic irradiation; 3.11b: immediately after that the ultrasonic irradiation was 
stopped, 3.12c: 60 s later respect to the frame 3.12b. In this last frame it is possible to 
see some small blue spots, which are cavities that probably are formed owing to the 
heating effect and a consequent lowering of cavitation threshold, probably associated 
with boiling phenomena. 
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Figure 3.12. Sequence of color variation induced by HIFU transducer 2 (f =3 MHz, 
P=100W ) for an insonation time of 5s. 11a before the radiation start, 11b just after the 
radiation was stopped, 11c 60 second after the radiation was stopped, in this last 
picture presence of cavities, due to mechanical damage of the TMM are well visible. 
 
On Figure 3.13 it is shown a sequence of the thermochromic gel exposed to Transducer 
3 working at 100 W. This picture shows that, although the acoustic power was similar, 
the different frequency and the different geometry of focusing of the transducer, causes 
a different “heating area”, highlighted by the color variation.  
 
 
Figure 3.13: Temperature rise and subsequent color variation induced by Transducer 3 
(HR-106 operating at 100 W frequency of 2 MHz for 5 sec). It is possible to note that 
the heating propagation effects are less evident maybe because of the different 
focalization’s shape.  
 
From these preliminary observations we can affirm that: -a temperature of about 50 °C 
can be reached immediately even in the pre-focused region and the phenomenon is more 
evident when using a transducer with a more tapered shape; - the area in which is 
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possible to induce the rise of temperature is influenced by the shape of focused acoustic 
field.  
Since, as it was evidenced by the 3-d acoustic pressure diagram reported in Fig. 3.5, the 
emission shape of Transducer 2 is more tapered and very high pressure levels are 
reached also in the pre-focused region, the formation of a larger heated area could be 
unsurprising but, more interestingly, this phenomenon has evidenced that, when 
working at typical power employed in medical application, several side effect, like 
anomalous heating or formation of cavities could occur during a longer exposure time   
( > of 2 s ). 
 
QUANTITATIVE EVALUATION OF TEMPERATURE RISE 
Exploiting the very narrow color variation of the area exposed to focused ultrasound 
and the reversible properties of this material, temperature rise by means of a needle 
thermocouples inserted in different regions (focused and pre-focused) is evaluated. The 
measurement set up is reported in paragraph 2.6.3. All the performed measures, 
reported in table 3.12 and 3.13, are expressed in term of increment of T, since the 
starting temperature of the material was not the same for each measurement.  
 
 
Insonation time / s 
 
Nominal Power / W 
 
Region 
 
∆T / °C 
 
Relative uncertainty / % 
5 20 Focus 19.91 3.08 
5 50 Focus 21.58 2.54 
5 100 Focus 34.91 2.22 
5 50 Pre-focus 30.68 3.05 
5 100 Pre-focus 32.11 2.65 
 
Table  3.12. Increment of temperature measured in focus and pre-focus region using  
Transducer 2. 
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Insonation time / s 
 
Nominal 
Power / 
W 
 
Region 
 
∆T / °C 
 
Relative uncertainty / % 
2.00 20 Focus 28.08 3.10 
2.00 50 Focus 35.35 2.98 
2.00 100 Focus 50.40 2.35 
2.00 50 Pre-focus 32.80 3.08 
2.00 100 Pre-focus 44.61 2.93 
5.00 20 Focus 32.02 2.72 
5.00 50 Focus 39.01 2.40 
5.00 100 Pre-focus 55.42 2.85 
 
Table  3.13. Increment of temperature measured in focus and pre-focus region using 
Transducer 3. 
 
The relative uncertainty to temperature values given in tables 3.12 and 3.13 are 
calculated as a composed uncertainty of two components: the type B uncertainty 
relative to the thermocouple (uR(TT), which is given from the manufacturer and is 
described in paragraph 3.3.1) and the uncertainty associated to the repeatability of the 
measuring data (us(TT), estimated variance of the mean which characterizes the 
variability of the data). 
 
On Figure 3.14 and 3.15 some examples of temperature rise with needle thermocouples 
using the two transducers are shown.  
 
Figure 3.14: Increment of temperature measured in focus region using Transducer 2. 
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In figure 3.14, are shown two representative graphs registered at the same insonation 
time (5 s), varying the output power levels of the transducer (P = 20W in the left figure 
and P = 100W in the right). Increasing the power level, the temperature reached is 
higher. Moreover, the length of time necessary for temperature decreasing is longer for 
an output power of 100 W. After 50 s from the beginning of the insonation the 
temperature into the gel exposed to a power of 100 W is still 36 °C, while for a power 
level of 20 W the temperature reached is 25°C, almost the same of those before the 
insonation. 
 
 
Figure 3.15: Increment of temperature measured in focus region using 
Transducer 3. 
 
From the figure above it is possible to observe that even if the ultrasonic pressure is the 
same  in the two measurements provides (P = 100W), temperature rise become very 
instable increasing the time of insonation, visible on a “plateau” in the graph of 
temperature rise. This is probably due to a chemical alteration of the gel: bubbles near 
the focus region and liquefaction of the gel itself can occur.  
Beside these considerations, several papers have recently reported the artifact effect 
caused by viscous heating phenomena during evaluation of temperature rise induce by 
HIFU in tissues or TMM, measured with thermocouples. A rigorous evaluation of these 
artefact would require the knowledge of thermophysical parameters of the TMM but 
unfortunately I have not the possibility to measure them. Nevertheless, it is reasonable 
suppose that the overestimation of 10-15%, like those that have been reported, take 
place.  
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3.3.6    TEMPERATURE MEASUREMENT IN TMM AT IEO 
 
After gel characterization and temperature rise evaluation performed in laboratory, the 
evaluation of temperature increase in a tissue-mimicking phantom induced by a 
USgFUS system at Istituto oncologico Europeo (IEO) in Milan. As seen in paragraph 
1.4.6, the USgFUS is not able to provide treatment monitoring by thermal map which is 
allowed using MRgFUS. These activities are conducted with the aim to give some 
contribution in such sense, even considering the thermocouple artifacts described in 
paragraph before. 
The measurements were performed on the JcHaifu apparatus. It has a single element 
transducer, with fixed focal length (160 mm), small focal region dimension and output 
frequency (1 MHz). The target lesion is covered and treated by moving the transducer. 
A cylindrical polyacrylamide gel phantom (60 mm radius, 40 mm height) was prepared 
in order to reproduce soft tissue behaviour (1023±5 g/cm density, 1550±23 m/s sound 
velocity, 0.067 ± 0.002 dB/cm attenuation Needle thermocouples, inserted in the 
phantom, were used to evaluate temperature increase (∆T) at typical clinical settings 
(power outputs of 80W, 150W, 200W, 300W and sonication times of 3 s) inside the 
focus. 
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Figure 3.16. Typical rising curves of temperature recovered in focus region of an 
USgFUS apparatus. 
 
Typical rising curves of temperature, with fixed time constant, were recovered, and 
exponential decrease was found when the HIFU field turned off. The maximum ∆T was 
reached inside the focus after 3 s of sonication, and was in the range of 45±5 °C, 75±5 
°C, 85±5 °C and 92±3 °C for 80W, 150W, 200W and 300W power outputs, 
respectively. The absolute maximum temperature of 95 °C was never exceeded. As seen 
in the previous paragraph (and it can be also seen in figure 3.16 at P = 200 and 300 W), 
a damage of the gel occurs at high power emitted from the transducer. For this reason, 
repeatability of measurements was not possible after sonications at the highest power 
outputs (400W). In figure 3.17 the damage of the gel after insonation at P = 400 W for 3 
s are visualized. The formation of an echoic region and the damage of the gel are 
underlined in the picture below. 
 
 
Figure 3.17. Ecogenic formation and chemical alteration of the gel after 3 s of 
insonation at P =100 W. 
 
In the measurements shown, the heated region is concentrated inside the geometrical 
focus, confirming the precision and high focalisation of the HIFU system. The high 
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temperatures reached could induce tissue boiling, however they are concentrated in the 
small focal region for less than 3s. Furthermore, the lower attenuation coefficient of gel 
phantom, the absence of interfaces compared with biological soft tissues, and viscous 
effects of needle thermocouples may have overestimated the ∆T. Thermal effects should 
be further studied in order to assure the validity of the treatment. 
 
3.4       DEXTRANE NANOBUBBLES 
 
In the following paragraph I will provide the results obtained with oxygen load 
nanobubbles, prepared using dextran as outer shell and perfluoropentane (PFP) or 
decafluoropentane as inner core. I will refer to dextran OLND for those prepared with 
DFP and dextran OLNB for those prepared with PFP. 
 
 
3.4.1    CHARACTERIZATION OF DEXTRAN NANOBUBBLES  
             
OLN COMPOSITION 
In table 3.14. the compositions and the percentage weight/volume (w/v %) for OLND, 
OFND, OLNB, OFNB (oxygen free nanobubbles) and OSS (oxygen saturated solution) 
formulations are reported. Preparations A corresponds to OLND, OFND, OLNB, OFNB 
and OSS water liquid formulations, while preparations B corresponds to OLND, OFND, 
OLNB, OFNB and OSS 2% HEC gel formulations. Preparation C is the OLND in PBS 
liquid formulation. Preparation D corresponds to FITC-labeled OLND in PBS liquid 
formulation. 
 
MORPHOLOGY 
Dextran OLND and OLNB are prepared in liquid (water) or gel (HEC) formulations and 
has been checked for morphology by TEM or by optical microscopy. Results are shown 
in figure 3.18 as representative images from ten different preparations for each 
formulation. Panel A. TEM image of OLND water formulation. Magnification: 
15500X. Panel B. Optical microscopy image of OLND water formulation. 
Magnification: 60X. Panel C. Optical microscopy image of OLND HEC formulation. 
Magnification: 60X. Panel D. TEM image of OLNB water formulation. Magnification: 
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15500X. Panel E. Optical microscopy image of OLNB water formulation. 
Magnification: 60X. Panel F. Optical microscopy image of OLNB HEC formulation. 
Magnification: 60X. 
 
Figure 3.18. Dextran OLND and OLNB morphology. 
 
SIZE, PARTICLE SIZE DISTRIBUTION AND ZETA POTENTIAL 
Water formulations were characterized for average diameters (d), polydispersity index, 
and zeta potential by light scattering, and for oxygen content through a chemical assay. 
Results are shown as means ± SD from ten preparations (average diameters, 
polydispersivity index, and zeta potential) or three preparations (oxygen content) for 
each formulation. Results are shown in Table 3.15. 
            
  
fluorocarb
on boiling 
point 
O2 content (g/ml+SD) d 
 (nm+SD) 
polidispersivity 
index 
zeta potential 
(mV+SD)       before UV after UV 
      OLND 51 °C 0.43 ± 0.01 0.42 ± 0.01 596.35 ± 149.09 0.13 25.68 ± 1.00 
      OFND 51 °C / / 239.54 ± 96.20 0.10 25.17 ± 1.00 
      OLNB 32 °C 0.43 ± 0.01 0.42 ± 0.01 486.87 ± 147.62   0.11 27.31 ± 1.00 
      OFNB 32 °C / / 212.31 ± 94.82 0.95 26.54 ± 1.00 
      OSS / 0.41 ± 0.01 0.40 ± 0.01 / / / 
       
Table 3.15. Physical-chemical characterization of OLNDs, OFNDs, OLNBs, OFNBs and OSS. 
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Ingredients 
OLNDs OFNDs OLNBs OFNBs OSS 
Prep. A 
(%w/v) 
Prep. B 
(%w/v) 
Prep. C 
(%w/v) 
Prep. D 
(%w/v) 
Prep A 
(%w/v) 
Prep. B 
(%w/v) 
Prep. 
A 
(%w/v
) 
Prep. 
B 
(%w/
v) 
Prep. A 
(%w/v) 
Prep. B 
(%w/v) 
Prep. A 
(%w/v) 
Prep. B 
(%w/v) 
dextran sulfate 0.14 0.07 0.14 / 0.14 0.07 0.14 0.07 0.14 0.07 / / 
FITC-dextran sulfate / / / 0.137 / / / / / / / / 
DFP 6.89 3.37 6.87 6.87 6.87 3.37 / / / / / / 
PFP / / / / / / 7.01 3.44 7.01 3.44 / / 
palmitic acid 0.02 0.02 0.02 0.02 0.02 0.01 0.02 0.01 0.02 0.01 0.02 0.01 
Epikuron® 200 0.05 0.03 0.05 0.05 0.05 0.03 0.05 0.03 0.05 0.03 0.06 0.03 
Pvp 0.07 0.03 0.07 0.07 0.07 0.03 0.07 0.03 0.07 0.03 0.08 004 
ethanol 3.99 1.96 3.99 3.99 3.99 1.96 3.99 1.96 3.99 1.96 4.40 2.16 
filtered H2O 88.87 92.58 88.83 88.83 88.87 92.58 88.73 92.51 88.73 92.51 95.44 95.80 
NaCl / / 0.03 0.03 / / / / / / / / 
sodium phosphate 
biphasic / / 0.01 0.01 / / / / / / / / 
HEC / 1.96 / / / 1.96 / 1.96 / 1.96 / 1.96 
O2* YES YES YES YES NO NO YES YES NO NO YES YES 
 
Table 3.14. Composition of OLND, OFND, OLNB, OFNB and OSS formulations.  
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Dextran OLND and OLNB water formulation were checked for size distribution by 
light scattering. Results are shown in figure 3.19 as a representative image from ten 
different preparations.  
 
 
Figure 3.19 Dextran OLND and OLNB size distribution. 
 
Either OLNDs or OLNBs displayed spherical shapes, nanometric sizes, with average 
diameters ranging from ∼500 nm (OLNBs) to ∼600 nm (OLNDs) for oxygen-loaded 
carriers and from ∼210 nm (OFNBs) to ∼240 nm (OFNDs) for oxygen-free carriers, and 
negatively charged surfaces as a consequence of the presence of sulfate groups in 
dextran molecule. OLNDs displayed also a good oxygen capacity, storing ∼0.40 g/ml of 
oxygen either before or after UV sterilization. Such oxygen amount was similar to that 
of OLNBs or OSS, thus allowing the use of similar volumes of OLND, OLNB and OSS 
preparations during the subsequent experiments aimed at comparing in vitro and in vivo 
oxygen release abilities.  
Current ONDs and ONBs displayed zeta potentials slightly higher than -30 mV. 
Nevertheless, formulations proved to be stable over time, as emerged from confirming 
analyses of OLD/OLB sizes and zeta potential performed by dynamic light scattering 72 
h after manufacturing. 
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3.4.2   II VITRO DETERMINATION OF OXYGEN RELEASE FROM        
         DEXTRAN OLNs  
 
After nanobubbles characterization, their ability to release oxygen in vitro has been 
extensively studied. Firstly, oxygen-loading capacity has been evaluated without 
ultrasound and then several sonophoresis experiments have been performed. OLNs has 
been manufactured both in liquid and gel formulations. Gel formulation has been 
prepared in order to simulate a real treatment through the skin. 
 
OXYGEN RELEASE WHITHOUT US  
OLND, OLNB and OSS HEC gel formulations were monitored up to 6 h through an 
oxymeter for oxygen delivery by diffusion. The oxymeter displays an accuracy of 0.01 
mg/l. Before each measurement, the oxymeter was calibrated in air, waiting for stable 
temperature and humidity conditions to be reached. Results are shown in figure 3.20 as 
a representative image from three independent experiments.  
 
Figure 3.20. In vitro oxygen release from dextran OLND and OLNB liquid and gel 
formulation.  
 
From graph 3.19 appears that OLNs also had a good oxygen-loading capacity. This was 
due to the presence of fluorocarbons, as DFP and PFP can favor oxygen entrapment. 
Both OLND and OLNB displayed a very good ability to deliver O2 at high 
concentrations and for long times, either in water or gel formulations; nevertheless, 
DFP-containing OLNs appeared more effective than those with PFP, OSS did deliver 
high O2 concentrations, but for shorter times than OLNs, as expected. 
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OXYGEN RELEASE WITH US AND TRESPASSING OF SKIN MEMBRANES  
As described in paragraph 1.5.4. sonophoresis is a process that exponentially increases 
the absorption of topical compounds (transdermal delivery) into the epidermis, dermis 
and skin appendages by ultrasonic energy. To verify the ability of ultrasound (US)-
activated OLNs to release O2 through biological membranes, an homemade 
experimental apparatus has been used. This is composed by an US probe with a high 
frequency transducer (f = 2.5 MHz; P = 5 W), combined with a home-made apparatus 
with two sealed cylindrical chambers separated by a layer of pig ear skin employed as a 
model of biological membrane (see paragraph 2.7.6 for more detail). The US transducer 
(f = 2.5 MHz; P = 5 W) was alternatively switched on and off at regular time intervals 
of 5 min for an overall observational period of 135 min, and oxygen concentration in 
the recipient chamber was monitored by Hach Langhe LDO oxymeter every 45 min. 
Because of the local heating caused by US, the O2 sensor was positioned laterally in 
order to prevent possible damage of the oxymeter, whereas the transducer was held in a 
fixed position. within the donor compartment. The acoustic power of the transducer was 
determined through a balance's radiation force with a reflecting target, with an 
uncertainty of 4%. 
 
 
Figure 3.21. US abilities to induce sonophoresis and oxygen release from dextran 
OLN and control HEC gel formulations. 
 
US improved the ability of both liquid and gel OLND formulations to cross the pig skin 
membrane and to release oxygen into the hypoxic chamber, being such oxygen release 
significantly larger than that from OFNDs, OLNBs, OFNBs, and OSS formulations. 
Even in this case. OLND appears more effective than OLNB. On the contrary, OFNs 
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did not release significant O2 amounts, whereas OSS did deliver high O2 concentrations. 
but for shorter times than OLNs, as expected. The efficacy of OLNs in releasing O2 on 
skin models is particularly crucial in order to verify the hypothesis that OLNs might 
help to restore the physiological level of oxygenation in cancerous tissues in which 
there is an oxygen deficiency. 
 
3.4.3     BIOCOMPATIBILITY ASSESSMENT 
 
Before in vivo applications, the biocompatibility assessment of dextran OLND 
regarding nanobbubbles cytotoxicity and cell viability have been studied. The cells in 
which the measurement are performed are human keratinocytes (106 cells / 2 ml 
Panserin medium). These were untreated (upper panels) or treated with 200 µl FITC-
conjugated OLND PBS formulation (lower panels) for 24 h in normoxia (20% O2). 
After DAPI staining, cells were checked by confocal microscopy. Results are shown as 
representative images from three independent experiments. Left panels: blue caption 
(cell nuclei after DAPI staining). Central panels: green caption (FITC-conjugated 
OLNDs). Right panels: merged caption. Magnification: 63X. 
 
 
Figure 3.22. Dextran OLND internalization by HaCaT cell line. 
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As emerged from analysis by confocal microscopy. FITC-conjugated OLNDs were 
avidly internalized by HaCaT cells.  
 
OLND CYTOTOXICITY 
Human keratinocytes (106 cells / 2 ml Panserin medium)  were left untreated or treated 
with different doses (100-400 µl) of OLND PBS formulation for 24 h in normoxia (20% 
O2; white-squared curve) or hypoxia (1% O2; black-squared curve). After collection of 
cell supernatants and lysates, OLND cytotoxicity was measured through LDH assay. 
Results are shown as means+SEM from three independent experiments. Data were also 
evaluated for significance by ANOVA. Versus normoxic untreated cells: p not 
significant.  
 
HUMAN KERATINOCYTE CELL VIABILITY 
Human keratinocytes (106 cells / 2 ml Panserin medium) were left untreated or treated 
with different volumes (100-400 µl) of OLND PBS formulation for 24 h in normoxia 
(20% O2; white-squared curve) or hypoxia (1% O2; black-squared curve). Thereafter,  
cell viability was measured through MTT assay. Results are shown as means+SEM 
from three independent experiments. Data were also evaluated for significance by 
Student’s t test. Versus normoxic untreated cells: *p< 0.01; **p< 0.001; ***p<0.0001. 
 
 
Figure 3.23. Cytotoxicity and viability of HaCaT cell line after dextran OLND treatment. 
 
Investigation through lactate dehydrogenase (LDH) assay (Figure 3.22) showed that 
different doses of OLNDs, ranging from 100 to 400 µl, did not result toxic for cells, 
both in normoxic (20% O2) and hypoxic (1% O2) conditions, and eventually OLNDs 
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proved to be effective to improve dose-dependently keratinocyte viability, either in 
normoxia or hypoxia. 
 
3.4.4    IN VIVO DETERMINATION OF OXYGEN RELEASE FROM     
           OLNDs 
 
After in vitro experiments. two different measurements to evaluate the OLNs ability to 
release oxygen in vivo has been performed. Oxygen release have been monitored in 
photoacoustic experiments and throught transcutaneous oxygenation.  
 
PHOTOACOUSTIC IMAGING 
Shaved hind limbs of anaesthetized mice were monitored by photoacoustics for oxy-and 
deoxy-Hb levels before (0 min. upper row), during (0-10 min. central row) and after (10 
min. lower row) topical treatment with OSS (first column), OLND (second column) and 
OFND (third column) gel formulations. White/red pixels: oxy-Hb; blue pixels: deoxy-
Hb. Data are shown in figure 3.24 as representative images from three independent 
experiments (three mice per experiment) with similar results. 
 
 
 
Figure 3.24. Topical treatment with dextran OLND gel formulation effectively enhances 
oxy-Hb levels in vivo. 
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Photoacoustic monitoring revealed that oxy-Hb levels significantly increased for the 
entire observational period in the animals treated with OLNDs while, as expected. OSS 
induced a high but only transient peak in oxy-Hb, whereas OFNDs did not affect oxy-
/deoxy-Hb balances at all. 
 
MEASUREMENT OF TcpO2 WITH US 
Shaved abdomens of anaesthetized mice were topically treated with OLND gel 
formulation and ultrasonicated for 15 sec (f = 1 MHz), Before and after treatment. tcpO2 
was monitored through TINA TCM30 oxymeter. Panel A. Short-term time-course (0-15 
min) tcpO2 monitoring of three mice before and after treatment with OLND gel 
formulation. Data are shown as means±SD. Results were also analyzed for statistical 
significance by Student’s t test. Versus untreated mice: p<0.02. Long-term end-point (1 
h) tcpO2 measurement of five mice before and after treatment with OLND gel 
formulation. Data are shown individually per each mouse (m 1-5).  
 
 
Figure 3.25. Topical treatment with US-activated dextran OLNDs effectively enhances 
tcpO2 in vivo. 
 
After topical administration of US-activated OLNDs, hypoxic mice displayed larger 
oxygenation levels in a time-sustained manner, OLNs significantly increased 
transcutaneous capillary oxygenation in topically treated mice. 
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STATISTICAL ANALYSIS 
Every characterization of ten preparations for each formulation was performed in 
triplicate, and results are shown as means + SD (light scattering and oxygen 
measurement) or as a representative image (TEM and optical microscopy). Data from 
cell studies are shown as means + SEM (LDH and MTT) or as a representative image 
(confocal microscopy) from three independent experiments analyzed in duplicate. 
Results from in vitro oxygen release studies are shown as a representative image 
(release without US) or as means ± SD (release with US) from three independent 
experiments. Results from in vivo oxygen release studies are shown as a representative 
image (release without US) or as means ± SD (release with US) from 5-9 mice. SD or 
SEM were used for descriptive or inferential information. respectively. Data were 
analyzed for significance by Student’s t test or by a one-way Analysis of Variance 
(ANOVA). 
 
3.5        CHITOSAN NANOBUBBLES 
 
In the following paragraph I will provide the results obtained with oxygen load 
nanobubbles prepared using chitosan as outer shell and perfluoropentane (PFP) or 
decafluoropentane as inner core. Even in this case, I will refer to chitosan OLND for 
those prepared with DFP and dextran OLNB for those prepared with PFP. Like dextran 
nanobubbles, also these preparations have been characterized. The ability to release 
oxygen with and without ultrasound has been studied and in vivo experiments has been 
performed. 
 
3.5.1     CHARACTERIZATION OF CHITOSAN NANOBUBBLES  
 
OLN COMPOSITION 
In table 3.16, the composition and the percentage weight/volume (w/v %) for 
CHITOSAN OLND, OFND, OLNB, OFNB and OSS formulations are reported. 
Preparations A corresponds to OLND, OFND, OLNB, OFNB and OSS water liquid 
formulations, while preparations B corresponds to OLND, OFND, OLNB, OFNB and 
OSS 2% HEC gel formulations. Preparation C is the OLND in PBS liquid formulation. 
Preparation D correspond to FITC-labeled OLND in PBS liquid formulation. 
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MORPHOLOGY 
The morphology of chitosan nanobubble, both OLND and OLNB formulations was 
assessed  by transmitting electron microscopy (TEM) (Philips CM10) and by optical 
microscopy (XDS-3FL). OLNs were dropped onto a Formwar-coated copper grid and 
air-dried before observation. Results are shown in figure 3.25. 
 
 
 
Figure 3.26. Chitosan OLND and OLNB were checked for morphology by TEM or by 
optical microscopy. Results are shown as representative images from ten different 
preparations for each formulation. Panel A. TEM image of OLNDs. Magnification: 
15500X. Panel B. Optical microscopy image of OLNDs. Magnification: 630X. Panel 
C. TEM image of OLNBs. Magnification: 52000X. Panel D. Optical microscopy 
image of OLNBs. Magnification: 630X. 
136 
 
Ingredients 
OLNDs OFNDs OLNBs OFNBs OSS 
  Prep. 
A (%w/v) 
Prep. 
 B (%w/v) 
Prep. 
 A (%w/v) 
Prep. 
 B (%w/v) 
Prep. 
 A (%w/v) 
Prep. 
 B (%w/v) 
Prep. 
 A (%w/v) 
Prep. 
 B (%w/v) 
Prep. 
 A (%w/v) 
Prep. 
 B (%w/v) 
  
  chitosan (medium 
MW) 0.14 0.07 0.14 0.07 0.14 0.07 0.14 0.07 / / 
  DFP 6.87 3.37 6.87 3.377 / / / / / / 
  PFP / / / / 7.01 3.44 7.01 3.44 / / 
  palmitic acid 0.02 0.02 0.02 0.01 0.02 0.01 0.02 0.01 0.02 0.01 
  Epikuron® 200  0.051 0.025 0.051 0.03 0.05 0.03 0.05 0.03 0.06 0.03 
  pvp 0.070 0.034 0.070 0.03 0.07 0.03 0.07 0.03 0.08 0.04 
  ethanol 3.98 1.96 3.98 1.96 3.98 1.96 3.99 1.96 4.40 2.16 
  filtered H2O 88.87 92.58 88.87 92.58 88.73 92.51 88.73 92.51 95.44 95.80 
  HEC / 1.960 / 1.96 / 1.96 / 1.96 / 1.96 
  O2* YES YES NO NO YES YES NO NO YES YES 
  * O2 is merely indicated for its presence/absence in the solution (YES/NO), as it was added in excess to reach saturation; the specific O2 content was further 
measured during characterization. as shown in Table 2 
             
Table 3.16. Composition of OLND, OFND, OLNB, OFNB and OSS formulations.
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SIZE, PARTICLE SIZE DISTRIBUTION AND ZETA POTENTIAL 
Average diameters, polydispersity indexes, and zeta potentials of nanodroplets and 
nanobubbles were determined by dynamic light scattering using Delsa Nano C 
instrument, which portrays the particle size distribution of samples in the diameter range 
0.6 nm - 7μm. Each reported value is the average of 10 independent measurements of 3 
different formulations. The polydispersity index assesses the size distribution within a 
nanodroplet or nanobubble population. For the zeta potential determination, formulation 
samples were placed into an electrophoretic cell, where an electric field of 
approximately 30 V/cm was applied. The electrophoretic mobility was converted into 
zeta potential using the Smoluchowski equation. Each sample was analyzed  in 
triplicate. Results are shown in Table 3.17. 
 
       
 
   
Fluorocarb
on boiling 
point  
      O2 content 
(g/ml+SD)     diameters 
(nm+SD) 
    Polidispersivity 
index 
zeta potential 
(mV+SD)      before 
UV 
    after 
UV 
    OLND chitosan DFP 51 °C      0.46 ± 0.01 0.45±0.01   726.55 ± 123.07 
    OFND chitosan DFP 51 °C / /     332.70 ± 101.10 
    OLNB chitosan PFP 32 °C     0.45 ± 0.01 0.44 ± 0.01    745.20 ± 117.89 
    OFNB chitosan PFP 32 °C / /     320.40 ± 100.90 
   OSS / / /     0.41 ± 0.01 0.40 ± 0.01 / 
 
 
Table 3.17. Physical-chemical characterization of OLNDs, OFNDs, OLNBs, OFNBs 
and OSS. 
 
 
Figure 3.27. Chitosan OLND and OLNB size distribution. 
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OLND and OLNB water formulations were checked for size distribution by light 
scattering. Results are shown as representative image from ten different preparations for 
each preparation. Panel A. OLND size distribution. Panel B. OLNB size distribution. 
  
Either chitosan OLND and OLNB (nanodroplets and nanobubbles) displayed spherical 
shapes and nanometric sizes, with average diameters ranging from ∼720 nm (OLNDs) 
to ∼740 nm (OLNBs) for oxygen-loaded carriers and from ∼320 nm (OFNBs) to ∼330 
nm (OFNDs) for oxygen-free carriers. Moreover, nanodroplets and nanobubbles 
displayed cationic zeta potentials ranging from ∼ +35 mV for oxygen-loaded carriers to 
∼ +40 mV for oxygen-free carriers. These values implicate that OLNDs are physically 
stable as a consequence of the electrostatic repulsion of the polymer chains. Indeed, the 
zeta potential measures charge repulsion or attraction between particles and is a 
fundamental parameter to determine nanoparticle physical stability, with zeta potentials 
lower than -30 mV or higher than +30 mV being generally required for physical 
stability of colloid systems. Consistently, further 72 h-monitoring of sizes and zeta 
potentials of OLNDs confirmed their physical stability over time (not shown). The 
cationic surfaces were a clear consequence of the presence of chitosan, which is 
positively charged in the shell. Interestingly, it has been proposed that surface-charged 
nanoparticles are exquisitely suitable for topical treatment, as surface charges enhance 
nanoparticle interaction with skin and improve their therapeutic effect on inflamed 
cutaneous tissues, either without or with concomitant US treatment. In particular, 
cationic nanoparticles are generally recommended for topical treatment due to the 
anionic nature of the skin. 
 
3.5.2 IN VITRO DETERMINATION OF OXYGEN RELEASE FROM OLNS 
          
OXYGEN RELEASE WITHOUT US 
O2  release by diffusion from OLND, OLNB and OSS liquid or gel formulations was 
estimated by monitoring O2 concentration up to 7 h through Hach Langhe LDO 
oxymeter, displaying an accuracy of 0.01 mg/l. The oxymeter was calibrated in air, 
waiting for stable temperature and humidity conditions to be reached before each 
measurement. 
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Figure 3.28. Chitosan OLND and OLNB oxygen release without US. 
 
Results obtained for oxygen release without US using chitosan nanobubbles are quite 
similar to those obtained for dextran OLNs. Even in this case, OLNs also had a good 
oxygen-loading capacity. Both OLND and OLNB displayed a very good ability to 
deliver O2 at high concentrations and for long times, either in water or gel formulations; 
nevertheless, DFP-containing OLNs appeared more effective than those with PFP. OSS 
did deliver high O2 concentrations, but for shorter times than OLNs, as expected. 
 
OXYGEN RELEASE WITH US AND TRESPASSING OF SKIN MEMBRANES  
In figure 3.29 is shown the US abilities to induce sonophoresis and oxygen release from 
OLND and control HEC gel formulations. Sonophoresis is evaluated by using a home-
made apparatus with two sealed cylindrical chambers (lower chamber: OLNDs, 
OFNDs, OLNBs, OFNBs or OSS; upper chamber: hypoxic solution) separated by a 
layer of pig ear skin. The oxygen-donor chamber (filled with OLND or control 
solutions) was connected to an US-transducer, whereas the oxygen-recipient chamber 
(filled with hypoxic solution) was connected to an oxymeter (see  paragraph 2.7.6). 
In our system, US might promote a cascade of events strongly impacting on the oxygen 
release kinetics. At first, US can induce bubble formation after acoustic droplet 
vaporization. Thereafter, bubble oscillations might lead to a stronger release mechanism 
due to cavitation. Finally, US might elicit sonoporation, temporarily enhancing skin 
leakage thus favoring transdermal drug release.  
US improved the ability of both liquid and gel OLND formulations to cross the pig skin 
membrane and to release oxygen into the hypoxic chamber, being such oxygen release 
significantly larger than that from OFNDs, OLNBs, OFNBs, and OSS formulations. US 
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treatment (f = 2.5 MHz; P = 5 W) was performed for 5 min; thereafter, oxygen 
concentration in the hypoxic chamber was monitored every 5 min up to 135 min by 
Hach Langhe LDO oxymeter. Results are shown as means ± SD from three independent 
experiments. Data were also evaluated for significance by ANOVA. Versus OLND 
formulation: p < 0.04. Panel C. Sonophoresis and oxygen release from US-activated gel 
(2% HEC) formulations. Results are shown as means ± SD from three independent 
experiments. Data were also evaluated for significance by ANOVA. Versus OLND 
formulation: p < 0.02. 
 
Figure 3.29. US-activated OLND oxygen release and sonophoresis through skin 
membranes in vitro. 
 
US improved the ability of both liquid and gel OLND formulations to cross the pig skin 
membrane and to release oxygen into the hypoxic chamber, being such oxygen release 
significantly larger than that from OFNDs, OLNBs, OFNBs, and OSS formulations. 
 
3.5.3    BIOCOMPATIBILITY ASSESSMENT 
 
OLND toxicity was evaluated by testing in vitro cultures of human HaCaT 
keratinocytes, a cell line immortalized from a 62-year old Caucasian male donor. 
Human keratinocytes (106 cells/2 ml DMEM medium supplemented with 10% FCS)  
were left untreated or treated with different doses (100-400 µl) of OLNDs for 24 h in 
normoxia (20% O2; white-squared curve) or hypoxia (1% O2; black-squared curve). 
Thereafter, OLND cytotoxicity was measured through LDH assay (Panel A), and 
HaCaT cell viability by MTT assay (Panel B). Results are shown as means ± SEM from 
three independent experiments. Data were also evaluated for significance by Student’s t 
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test. Panel A. Versus normoxic untreated cells: p not significant. Panel B. Versus 
normoxic untreated cells: * p < 0.05; ** p < 0.01; *** p < 0.005. 
 
 
Figure 3.30. Lack of chitosan OLND toxicity on human keratinocytes.  
 
As shown in Figure 3.30 (Panel 3.29A: LDH assay; Panel 3.29B: MTT assay), 
increasing volumes of OLND suspensions (100-400 µl/ 2 ml cell culture medium) were 
not toxic in normoxic conditions (20% O2) and eventually improved keratinocyte 
viability in hypoxic conditions (1% O2).  
 
3.5.4     IN VIVO DETERMINATION OF OXYGEN RELEASE FROM OLNS 
 
PHOTOACOUSTIC IMAGING 
Shaved hind limbs of anaesthetized mice were monitored by photoacoustics for oxy-Hb 
and deoxy-Hb levels before (0 min, upper row), during (0-10 min, central row) and after 
(10 min, lower row) topical treatment with OSS (first column), OLND (second column) 
and OFND (fifth column) gel formulations. White/red pixels: oxy-Hb; blue pixels: 
deoxy-Hb. Data in figure 3.31 are shown as representative images from three 
independent experiments (three mice per experiment) with similar results. 
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Figure 3.31. Topical treatment with OLND gel formulation partially enhances oxy-Hb 
levels in vivo. 
 
As shown in Figure 3.31, in vivo experiments did not reproduce the promising results 
obtained in vitro. OLNDs did appear more effective than OSS, which induced a high 
but only transient peak in oxy-Hb, and OFNDs, which did not affect oxy-/deoxy-Hb 
balances at all. However, OLND-induced oxygenation gradually decreased throughout 
the overall observational period, and at the final time-point oxy-Hb levels were similar 
to those observed before starting treatment.  
 
MEASUREMENT OF TcpO2 WITH US 
Shaved abdomens of anaesthetized mice were topically treated with OLND gel 
formulation and ultrasonicated for 30 sec using a home-made US equipment (f = 1 
MHz; P = 5 W). Before and after treatment, tcpO2 was monitored every 5 min for 15 
min through TINA TCM30 oxymeter. Data are shown as means ± SD of three mice. 
Results were also analyzed for statistical significance by Student’s t test. Versus 
untreated mice: p < 0.03. 
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Figure 3.32. Topical treatment with US-activated OLNDs effectively enhances tcpO2 
in vivo.  
 
As shown in figure 3.32, US promoted  transdermal oxygen delivery in a time-sustained 
manner. Sonication appears therefore essential to induce oxygen release from OLNDs 
in vivo. 
 
3.6 A COMBINED APPROACH: HIFU AND OLN 
 
In this paragraph, a combined approach, regarding HIFU and OLN is provided. In 
particular, temperature increase induced by a focused ultrasound field (Transducer 3) in 
two different TMMs is studied. Two agar-based TMMs (described in paragraph 2.6.1) 
have been prepared. Before the gelling process is completed, 20 ml of dextran OLND 
are added to one of them. By means of a micro positioning system, the TMMs under 
study, including the optical fiber, are moved to reach the point of maximum revealed 
temperature, which is supposed to be the focus region of the ultrasound beam. 
Temperature data are acquired by means of a fiber optic hydrophone when the gel is 
subjected to a focused ultrasound field produced at three different values of power 
(50W, 75W, 100W). The exposure time is 5 s every measurement. Temperature values 
are calculated as the mean of five measures realized for each measurement condition. In 
graph 3.33 data obtained are shown. 
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Figure 3.33. Temperature increment in an agar-based TMM (black bars) and in a 
TMM in which 20 ml of OLND are added to the solution (red bars).  
 
As it is possible to see from the figure above, the temperature rise induced by an HIFU 
source in the TMM phantom without OLN (black bars) are lower than the temperature 
reached in a TMM in which 20 ml of OLN are added (red bars) in all the considered 
cases. The percentage of temperature increment using a TMM containing OLN is about 
26% at 50 W, 22% at 75 W and 34% at 100 W. These experimental evidence are 
probably due to the fact that OLN may act as nuclei for cavitation inducing formation of 
shock waves and local temperature increase. 
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CHAPTER 4 
 
 
CONCLUSIONS 
 
 
This PhD thesis summarizes the results of three years activity devoted to the study 
of two different approaches for cancer treatment based on the use of ultrasound 
for therapeutic purpose. These two techniques regard the characterization of high 
intensity focused ultrasound (HIFU) and the synthesis, characterization and 
applications (both in vitro and in vivo) of oxygen loaded nanobubbles.    
 
To whom concern the characterization of an HIFU field, the necessity of 
guidelines for a safe application of ultrasounds on patients is emerged and 
simulations of ultrasound field interactions with tissues are become fundamental. 
The activities conducted in this PhD aim to give some contribution in such a 
sense. The characterization of an ultrasound source has been provided measuring 
the total emitted power and a spatial description of the pressure field. Beside 
them, an accurate study of the temperature rise in the focus of an HIFU transducer 
has been performed using thermocouples and a fiber optic probe hydrophone. The 
latter instrument is an innovative hydrophone with a wide range of applications 
because it is free of errors due to viscous artifacts that afflict thermocouples and, 
most important advantage, is a completely compatible technique with magnetic 
resonance (MR) systems. Temperature measurements are necessary to understand 
the interaction between ultrasound beam and tissues and an accurate evaluation of 
temperature rise in the focus of an HIFU transducer has been performed in 
different tissue mimicking materials (TMM).  TMM samples of agar and 
poliacrylamide gels have been realized and tested to study the heating effects 
induced by HIFU irradiation. Preliminary test on the accuracy of a fiber optic 
hydrophone conducted with a thermocouple reveal that temperature measurement 
are in good agree using this instrument. Thus, measurements  on temperature rise  
induced by HIFU transducer using this sensors have been conducted, in particular, 
modifying the chemical composition of the gel in order to tuning its acoustic 
properties. It has been found that increasing the percentage of scattering and 
absorbing agents (kieselguhr) the temperature reached in the focus is lower, 
revealing that part of the energy of the ultrasonic beam has been absorbed by 
146 
 
wave interactions with inhomogeneities of the medium. After that, some studies 
on polyacrilamide gel have been performed in situ, using the USgFUS available at 
Istituto Oncologico Europeo (IEO) in Milan. Typical rising curves of temperature 
at different power outputs have been recovered. These are preliminary results 
obtained using an USgFUS system, further measurements in situ using a 
MRgFUS are planned. Due to the fact that the presence of permanent magnets 
within the structure of MR exclude the use of ferromagnetic devices 
(thermocouples), these coming measurement will be conducted using a fiber optic 
probe hydrophone. Successively, a new material has been developed and 
characterized as possible TMM to investigate the temperature rise induced by 
HIFU transducers: a reversible thermocromic silica gel. Preliminary 
measurements on temperature rise have been conducted with this material and it 
has been possible to analyze the heating effects caused by focused ultrasonic 
sources in function of power, frequency and irradiation time. All the begun 
activities would bring to a contribution in the development of a new concept of 
“dose” for ultrasonic treatment and in defining new instruments, methods and 
techniques for quality control assessment of medical ultrasonic devices and for a 
better guarantee for the safety of the patients treated with new generation devices. 
 
The other research activity followed during my PhD has concerned the realization 
and characterization of oxygen load nanobubbles. While the use of nanobubbles 
as contrast agents has been around for a couple of decades, the development of 
nanobubbles for therapeutic purpose is still in its infancy. However, there is 
considerable interest in facilitating the transfer of drug, gene and other therapeutic 
compounds into diseased tissues and organs using ultrasound. In this regard, 
nanobubbles filled by oxygen represent an useful tool for the re-oxygenation of 
cancerous tissues. These tissues are characterized by oxygen deficiency, that is the 
main hallmark of cancerous solid tumors and a major factor limiting the 
effectiveness of radiotherapy. Thankfully, hypoxic regions are often located 
superficially; oxygen, properly encapsulated in suitable formulations of 
nanobubble solutions provided through ultrasonic transdermal sonophoresis, 
might help to counteract hypoxia effects. Oxygen-loaded nanobubbles (OLNs) 
that have been developed are constituted by a shell of biocompatible material 
(chitosan or dextran) and an oxygen-storing core, made of decafluoropentane 
(DFP) or perfluoropentane (PFP). OLNs have been manufactured both in liquid 
and gel formulations with the latter being more suitable for skin spreading. The 
behaviors of the different nanobbules preparation have been fully studied and 
compared looking for a further application to treat hypoxia-associated pathologies 
of superficial tissues. The two OLNs formulations has been characterized from a 
physical-chemical point of view, showing an average diameters lower than 1 μM, 
spherical shapes, and a good capacity of maintain their structure and small 
dimension over time.  OLN sizes and stability are crucial properties in view of 
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their potential for in vivo administration. In addition to the proprieties listed 
above, it has been found that nanobubbles are surface-charged. This is an 
exquisitely propriety suitable for topical treatment, as surface charges enhance 
nanoparticle interaction with skin. However, transdermal oxygen delivery is 
normally limited by low skin permeability due to the stratum corneum, the 
outermost layer of the skin. To overcome this problem, ultrasound have been used 
to elicit sonophoresis, temporarily enhancing skin leakage thus favoring oxygen 
delivery. The first step to demonstrate the OLNs ability to across a skin membrane  
have been  evaluated in vitro. The ability of OLNs to trespass the dermal layer has 
been monitored using a home-made apparatus developed during my work. Both 
liquid and gel OLNs behaviors has been studied. Once proven in vitro that OLNs 
were more effective than simple oxygen saturated solution (OSS) in releasing 
oxygen, without being toxic on human keratinocytes, and that gel formulation 
appeared suitable for treatment of skin membranes, OLND gel formulation was 
tested for oxygen delivery in vivo. In vivo, OLNs significantly increased 
transcutaneous capillary oxygenation in topically treated mice and, finally, 
oxygen release from OLNs have been studied in photoacoustic experiments. The 
skin oxygenation of anaesthetized mice topically treated with OLN, OFN 
(oxygen-free nanobubbles) or OSS gel formulations, was monitored by 
visualizing the subcutaneous levels of oxyhemoglobin (oxy-Hb) and 
deoxyhemoglobin (deoxy-Hb) through photoacoustic imaging. All these 
experiments have confirmed that topical administration of exogenous O2, properly 
encapsulated in nanobubble formulations, might be a new suitable and efficient 
approach to treat hypoxic tissues, cancerous or affected by other disease. Future 
preclinical and clinical studies will be certainly investigated, as OLN application 
appears of great interest for transdermal oxygen delivery. 
 
The activities conducted during my PhD, concerning HIFU field characterization 
and the development of oxygen nanocarriers, can be considered preliminary (but 
necessary) results for further experiments that merge these two techniques in a 
new and non invasive therapeutic modality. Indeed, the application of focused 
ultrasound might promote transdermal oxygen delivery and destroy cancerous 
tissues while, in the same time, nanobubbles in gel formulation might counteract 
hypoxia effects in several pathologies of different etiology (cancer, autoimmunity, 
infection etc) by improving oxygen delivery to hypoxic tissues. 
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